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TRIPTYCENE ANALOGS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
SUMMARY OF THE INVENTION 
This invention provides analogs of triptycene which are 
useful as anticancer drugs, as well as for other uses. The 
This application claims priority to U,S, provisional appli- 5 potency of these compounds is in a similar magnitude as 
daunomycin, a currently used anticancer drug. Each corn- 
pound of the invention produces one or more desired effects 
(blocking nucleoside transport, inhibiting nucleic acid or 
protein syntheses, decreasing the proliferation and viability 
10 of cancer cells, inducing DNA fragmentation or retaining 
their effectiveness against multidrug-resistant tumor cells). 
logs having the following formula: 
cation Ser. No. 601238,856, filed on Oct. 6, 2000, which is 
hereby incorporated by reference to the extent not inconsis- 
tent with the disclosure herewith. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with Government support under 
Grant NO. NAGW-1197 awarded by NASA and Grant NO. 
86842 awarded by the National Institute of Health. The 
BACKGROUND OF THE INVENTION 
As precursors of reactive quinone methides, many natural 
and synthetic quinones function as bioreductive alkylating 
agents and have antitumor activity. (See for example, Thom- 20 
son R H, Naturally occuring quinones 111: recent advances. 
New York Chapman and Hall 1987; Moore H W, Science 
1977, 197: 527-32; Lin A J, et al, J Med Chem 1972, 15: 
More specifically, the invention provides triptycene ana- 
R3 Government has certain rights in the invention. 15 
1247-52; Lin AJ ,  et al, J Med Chem 1973,16: 1268-71; Lin 
A J, et al, J Med Chem 1974, 17: 558-61; Lin A J, et al, J zs 
Med Chem 1975,18: 917-21). The cytotoxicity of quinones 
may be due to two competing mechanisms: soft electrophilic 
arylation and redox cycling oxidation. (See for example, 
Brunmark A, Cadenas E, Free Radical Biol Med 1989, 
7:435-77; O’Brien P J, Chem-Biol Interact 1991, 80: 1 4 1 ;  30 and NR,; 
Monks T J, et al, Toxic01 Appl Pharmacol 1992, 112: 2-16). 
While complete two-electron reduction of the quinone ring 
by DT diaphorase produces a stable hydroquinone, partial 
one-electron reduction of the quinone ring by NADPH- 
oxidizing enzymes yields an unstable semiquinone free 
radical (FR) that can spontaneously autoxidize at the 
expense of molecular 0, to generate a cascade of reactive 0, 
species (ROS) and FRs, which can induce DNA damage, 
lipid peroxidation and cytotoxicity. However, most quinone 
antitumor agents used clinically, such as anthracycline 
antibiotics, mitomycin C and benzoquinone derivatives, 
have a complex chemical structure with a number of active 
functional groups and the exact contribution of the quinone 
group to their antitumor activity remains uncertain. (See for 
example, Myers C E, Chabner B A, Anthracyclines. In: 
Chabner B A, Collins J M, eds. Cancer chemotherapy: 
principles and practice. Philadelphia: Lippincott 1990: 
356-81; Rossi L, et al, Arch Biochem Biophys 1986, 251: 
25-35; Begleiter A, et al, Cancer Res 1988, 48: 1727-35; 
Qiu X B, et al, Free Radical Biol Med 1998, 24: 848-54). 
The anthracycline quinone antibiotics adriamycin (ADR) 
R’ 
X 
wherein Xis  selected from the group consisting of  H, R, SR 
Y is selected from the group consisting of  halogen 
(preferably C1, Br, I), R, NR,, SR and H; 
R and R1-’ are independently selected from the group 
consisting o f  H, halogen, OR, and hydrocarbyl 
(preferably lower alkyl, allyl, phenyl, aryl, substituted 
alkyl, substituted allyl, substituted phenyl, -CH,- 
(CH,),CO,H, -CH,+CH,),CH(NH,)CO,H, car- 
boxylic acid, substituted carboxylic acid, amine, sub- 
stituted amine, NHR, NR,, amino acid, RCO,(CH,) 
,NH, where one or both of the hydrogen atoms on CH, 
can be substituted with alkyl, allyl, phenyl, aryl, sub- 
stituted allyl, substituted phenyl, substituted carboxylic 
acid, amine, or substituted amine, and where n is an 
integer from 0 to 8); R3-4, independently of one 
another, are selected from the group consisting o f  H, 
halogen (preferably bromine), OR, R, SR and NR,; R5, 
independently of other R5s, is selected from the group 
consisting o f  =0, =N-OH, and =CHR; and 
reduced forms thereof; wherein in reduced forms, 
either ring A or ring C or both is replaced with 
35 
4o 
45 
and daunomycin (DAU) covalently bind to and intercalate 
into DNA, inhibit DNA replication and RNA transcription, 
are DNA topoisomerase (Topo) I1 poisons, produce oxida- 
tive stress and damage biomembranes, induce DNA break- ss 
age and chromosomal aberrations, trigger apoptosis and 
have a wide spectrum of anticancer activity. (See for 
example, Cadenas E, Free Radical Biol Med 1998, 24: 
Mimnaugh E G, et al, Cancer Res 1985, 45: 3296-304; 60 
Ganapathi R, et al, Biochem Pharmacoll990,40: 1657-62; 
dran C, et al, Anticancer Res 1997,17: 3369-76). However, 
the clinical effectiveness of DOX and DAU is severely 
limited by their cumulative cardiotoxicity and ability to 65 
induce multi-drug resistance, so it is important to develop 
drugs with improved bioactivity. 
X* or 
Y R2 
848-54; Liu L F, Annu Rev Biochem 1989, 58: 351-75; R5 R5 
Ling Y-H, et al, Cancer Res 1993, 53: 1845-52; Ramachan- and wherein in reduced forms, each R5 is H, c1-c8 Or -OR; 
and pharmaceutically acceptable salts of the foregoing, as 
The numbering scheme used herein is shown in the 
well as optical isomers thereof. 
example structure below: 
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alkyl, and Cl-C8 alkenyl and Z is selected from the 
group consisting of  R, COR, COOR, CONR,, OOCR 
and NRCOR; 
Y is selected from the group consisting o f  halogen, 
Cl-C8 alkyl, Cl-C8 alkenyl, OR, NR,, SR, H, COR, 
OCOR and NRCOR; 
R and R1-' , are independently selected from the group 
consisting of  H, OR, and hydrocarbyl; 
R3.4 ' , independently of one another, are selected from the 
group consisting of  H, OR, SR, and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of  =0, -H and -OT, where T is H or 
Cl-C8 alkyl or alkenyl; and pharmaceutically accept- 
able salts of the foregoing, as well as optical isomers 
thereof. 
Other compounds of the invention include those with 
R3 
0 
R' 10 
1s 
0 
Other compounds of the invention include those with formula: 
formula: 
20 
R'8 
2s X *' R4& R22 R5 R2 R' 
wherein X is selected from the group consisting of  H, R; SR 
35 and NR,: 
wherein 
R5 is selected from the group consisting of  R, halogen, NR,, 
SR and H; R6 is selected from the group consisting of  H, R, 
SR and NR,; R7 and Rs are independently selected from the 
group consisting of  H, halogen, OR and hydrocarbyl; R17 
and RlS are independently selected from the group consist- 
in o f  H, halogen, (preferably bromine), R, SR and NR,; 
R and RZo are, inde endentl of one another, H, R, or OR; 
and R16) are together =O or are independently H or -OR; 
R is selected from the group consisting of H, halogen, OR 
and hydrocarbyl; reduced forms thereof and pharmaceuti- 
cally acceptable salts of the foregoing, as well as optical 
isomers thereof. 
Other compounds of the invention include those with 
formula: 
B '  
(R9 and RIO) and (R 1P and R1 P ) and (R13 and R14) and (R1' 
il 
Y is selected from the group consisting of  halogen, NR,, 
SR, H, and R; 
R and R1-', are independently selected from the group 
consisting of  H, halogen, OR, and hydrocarbyl; 
R3.4 ' , independently of one another, are selected from the 
group consisting of  H, halogen (preferably bromine), R, 
SR, and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of  =0, =NOH, =C HR and reduced forms 
thereof; 
RZ1 and RZ2 are independently selected from the group 
consisting of  H, R, and OR; and reduced forms thereof 
and pharmaceutically acceptable salts of the foregoing, as 
well as optical isomers thereof. 
Also provided are compounds of the formula: 
R3 R3 
5s 
60 
65 
wherein X is -NW(CW,),Z, where the Ws are indepen- 
dently selected from the group consisting of  H, Cl-C8 
and the reduced forms thereof, wherein in said reduced 
forms, either ring A or ring C or both is reduced to 
5 
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-continued 
S 
Y R2 
R5 R5 10 
HO 
wherein all but one of X, Y, R1 and R2 is independently T r 3  
H, Cl-C6 alkyl, Cl-C6 alkenyl, OR, SR or NR2 
wherein each R is independently H or Cl-C6 alkyl and 15 
the other R1 or R2 is a solubilzing group; and each R5 
is independently H, Cl-C6 alkyl or OR. The solubi- 
lizing group may be of the formula: NR(CR,),X 
wherein X is a sugar, R, COR, COOR, CONR,, OOCR 2o 
and NRCOR; R is independently selected from the 
enyl; n is an integer from 1 to 8. 
group consisting of  H, Cl-C8 alkyl and Cl-C8 alk- X 
0 R5 Scheme 1 shows some of the compounds of the invention 
and abbreviations used herein 
Schemel 
?TO: triptycene 
T r l :  X =  Y = H 
Tr2 :  X = PMe, Y = H 
Tr13: X = OMe, Y = Br 
Tr14: X = NHMe, Y = Br 
T r l S :  X = MHNe, Y = OH 
Tr16: X = OMe, Y = Br, R2 = NMe2 
Tr17: X = NHCH2CH2C02H, Y = Br 
Tr18: X = NHCH2CH2C02Et, Y = OH 
Tr19: X = NH(CHZ)~CH~(NH~)CHCO~H, Y = Br 
Tr20: X = NH(CH&CH~(NHZ)CHCO~H, Y = OH 
Tr21: X = NHCH2CH2C02H, Y = OH 
Tr24A: X = OMe, Y = Br, R2 = NHMe 
Tr24B: X = OMe, Y = Br, R' = NHMe 
N analog 1: X = NH(CH&CH~(NHZ)CHCO~H, Y = Br 
N analog 2: Y = Br, X = 
2s 
5s 
TTS: X = R5 = OMe 
l T 7 :  X = R5 = H 
l T 9 :  X = OMe, R5 = H 
N analog 3: Y = Br, X = 
N N 
H 
I 
N analog 4: X = OMe, Y = Br, R2 = 
NH2 
I 
l-fi N N 
S analog 9: Y = Br, X = SCHzCH(C02H)NH2 
Tr6 :  X = R5 = R2' = RZ2 = H 
T r 8 : X = O M e , R 5 = R 2 ' = R Z 2 = H  
Tr10: X = COZMe, R5 = OMe, R2' = R22 = H 
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-continued and TT10. Another class of compounds of this invention 
includes homologs of the foregoing compounds. One class 
of compounds is the compounds TT1-13. Another class of 
compounds is TT14-20. One class of compounds are those 
where X is selected from the group consisting of  H, OMe 
and C0,Me; where Y is selected from the group consisting 
of  H, Br, and OMe; where R1=R2=H; and where positions 
1 , 4 , 5  and 8 are selected from the group OH, OMe, =0, H. 
Another class of compounds include those where one or 
more substituents contains one or more N atoms. Another 
class of compounds includes those where X and Y are not 
both members of the group containing: H, OMe, Br, CO, 
Me, while positions 1 ,4 ,5 ,  and 8 are substituted with -OH, 
-0Me or =0, or mixtures of those substituents. Another 
class of compounds include those which include at least one 
amine, amino acid or amine sugar substituent. 
A preferred class of compounds is those which are water 
2o soluble, where one or more substituents, particularly where 
X,Y,R1 and/or R2 substituents of formula I are replaced with 
water soluble group or groups that enhance the solubility of 
the compound and salts thereof. 
Apreferred class are those compounds of formula I where 
25 Xis  a water soluble group or a group that enhances the water 
solubility of the compound; and salts thereof. These com- 
pounds include those where X is RO,C (CH,),NH, where n 
is an integer from 1 to 8 and R is as defined for I. 
sulfur containing substituent. 
This invention also provides methods for inhibiting cel- 
lular transport of nucleosides; inducing DNA fragmentation; 
inhibiting nucleic acid and/or protein synthesis and decreas- 
35 ing the proliferation and viability of cancer cells (including 
wild type and multi-drug resistant) or other cells in which 
the proliferation or viability is desired to be reduced, com- 
prising contacting the cells with an effective amount of a 
compound of the invention as disclosed herein. This inven- 
tion provides such compounds in suitable pharmaceutical 
carriers in dosages effective to provide measurable nucleo- 
side transport blocking, nucleic acid and/or protein synthesis 
inhibition, DNA cleavage, and/or reduction in tumor cell 
45 (including wild type and multi-drug resistant) growth and/or 
viability. Preferably, the compounds used in the methods of 
this invention are almost or at least as effective as 
Daunomycin, a currently used anticancer drug. 
Also provided is a method of treating cancer in a host, 
comprising: administering to said host an effective amount 
of an active compound of the invention for an effective time. 
Administration routes include intravenously, parenterally, 
and other methods known in the art. As used herein, an 
5s “effective amount” is an amount which causes a measurable 
effect on a desired parameter. As used herein, an “effective 
time” is the time required to cause a measurable or desired The compounds listed above are useful in treating 
malaria, cancer, as well as other diseases. Other preferred effect On a desired parameter’ 
compounds include those specifically depicted and provided is a method for preparation Of triptycene 
described in this disclosure. 6o analogs, comprising in situ oxidation and [4+2] cycloaddi- 
A class of compounds of this invention includes those tion of substituted benzenes or quinones and optionally 
compounds listed above as presently preferred, Another substituted anthracenes; and optional oxidation of the result- 
class of compounds of this invention include TT2 and TT13. ing compounds. The resulting compounds Will be a mixture 
h o t h e r  class of compounds of this invention include n 1 ,  65 of methoxy-substituted and carbonyl-substituted triptycene 
TT7 and TT9. Another class of compounds of this invention analogs. This mixture can be separated into individual 
include one or members of the class 7T3, TT5, TT6, TT8 compounds with methods known in the art. The one pot 
0 R5 
T 1 1 :  X = H, R5 = OMe, RZ2 = H, RZ1 = C02Me 
C0.2Me 
C02Me 
n 4 :  R9 = R’o = R” = R12= ~ 1 3 =  ~ 1 4  = R E  = ~ 1 6  = 0
n 1 2 :  R9 = R” = RI3 = RI5 = H, R” = R” = RI4 = R16 = OH 
the most preferred those Another class of compounds includes those that contain a 
compounds of the formulas listed above wherein at least one 30 
of X, Y, R1 and R2 is selected from the group consisting of  
a nitrogen containing group, a water soluble group, and a 
sulfur containing group, and the following: 
40 . Br 
/ I  
&
H3CH2C02C-H2CH2C-HN 
0 
so &Br / /  (H3C)COzC- HzCHzC- HN 
0 0 
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synthesis may be separated into oxidation and cycloaddition 
steps, if desired. Synthesis of particular groups of com- 
Also provided is a method to synthesize 1,4- 
dimethoxyanthracene comprising reduction of quinizarin to 5 
give 1,4-anthraquinone; reduction of 1,4-anthraquinone to 
give 1,4-dihydroxyanthracene; and methylation of 1,4- 
dihydroxyanthracene to give 1,4-dimethoxyanthracene. 
These reactions are described in more detail herein. The 
reduction step (first step; with sodium borohydride) has been 
reported in: Bedworth, P. V.; Perry, J. W.; Marder, S. R. J. 
Chem. SOC. Chem. Commun. 1997, 1353-1354 for use in 
certain synthetic methods and the following two steps 
(reduction with sodium hydrosulfite and methylation) have 1s 
been used in certain syntheses, but preparation of 1,4- 
sequence of reaction. 
For example, in the following structure, 
pounds of the invention are described in more detail herein. R3 
10 
R’ 
X 
dimethoxyanthracene (l) has not been reported in One in reduced forms, either ring Aor  ring C or both is replaced 
with 
A new synthesis of the compound 7T2 is also provided. 
TT2. A new method to brominate triptycene analogs is also 
provided. Treatment of a triptycene analog which has a 
methoxy group on position 2 and a hydrogen on position 3 
with N-bromosuccinimide gives an analog with a bromine 
on position 3. This bromination reaction can be extended to 
on position 6 or 7, bromination will result in a bromine on 
position 7 or 6, respectively. If the starting compound has 
methoxy groups on positions 5 and 6, oxidation will give the 30 
corresponding analog with carbonyl groups on positions 5 
and 6. 
Triptycene analogs I bearing functionalities at C12 and 
C13 (R3 and R4), can be made in an analogous reaction as 
described below starting with 6,7-disubstituted 1,4- 3s 
dimethoxyanthracenes (analogs of compound 1). These 6,7- 
disubstituted 1,4-dimethoxyanthracenes are prepared from FIG. 1. Comparison of the abilities of novel TTs to inhibit 
the corresponding analogs of 6,7-disubstituted 1,4- the growth (open) and viability (striped) of L1210 cells after 
dihydroxy-9,lO-anthraquinones (by following the method 40 4 days in vitro. For tumor cell growth and viability, L1210 
described below). cells were respectively seeded in triplicate at initial densities 
Also provided are triptycene analogs prepared by the of lx104 and l . l lx104 cellsi0.5 mliwell in RPMI 1640 
methods described herein. medium containing 7.5% FCS and penicillin (100 IUim1)- 
Compounds containing any combination of substituents streptomycin (100 Kdml), and grown for 4 days in the 
or members of the Marhsh  groups specified above are 4s presence or absence (control) Of 256 nM concentrations Of 
within the scope of the invention, All substituents of the the indicated compounds in a humidified incubator at 37” C. 
compounds of the invention may be the same, all substitu- with 5% co, in air. Cell density was monitored using a 
ents may be different, or any combination of substituents Coulter counter. Cell growth results are expressed as % of 
may be the Same or different, Compounds having substitu- so the number of vehicle-treated control cells after 4 days in 
ents with a specified function, for example those that impart culture (1,465,110292,595; 10026%; open control). The 
water solubility to the compound form a special class of ability of viable cellsi0.5 ml to bioreduce 0.1 ml of 
compounds of this invention. MTS:PMS (20:l) reagent over a 3-h incubation period at 37” 
The substituents included in the compounds of the inven- C. was assessed by measuring the absorbamce of the water- 
tion and used in the methods of the invention may be any 5s soluble formazan products at A490 nm. Cell viability results 
substituent not having structures or reactivity which would are expressed as of the net d ~ o r b a n c e  of MTSiformazan 
substantially interfere with the desired activity of the after bioreduction by vehicle-treated control cells (A490 
experimentation by those skilled in the art, for example, by 6o culture. The blank value ,,=0.202) for cell-free 
using the assay methods disclosed herein and those methods medium supplemented with MTS:PMS reagent has been 
known to one of ordinary skill in the art. substracted from the results. Bars: means2SD (n=3). “Not 
The reduced forms of all compounds described herein are different from TT7 and TT9; bp<0.025, smaller than TT1, 
included in the disclosure. It is understood that when refer- TT7 and TT9 but not different from TT13; “p<o.o5, greater 
ring to reduced forms of structures herein, any quinone-like 6s than TT1, TT7 and 7T9 but not different from 7T5, TT6 and 
ring of the structure may be replaced with a hydroquinone- TT8; %ot different from control; ‘PeO.05, smaller than 
like ring, as known in the art. control. 
Either TT3, TT5 or a mixture of both is oxidized to give 20 R5 
x)& or 
2s Y R2 
other triptycene analogs. For example, if a methoxy group is R5 R5 
wherein in reduced forms, each R5 is independently a 
reduced form of =0, for example, OR. In the reduced 
forms, each R5 may also be H or Cl-C8 alkyl, for example, 
as known in the art. 
BRIEF DESCRIPTION OF THE DRAWINGS 
compound, as may readily be determined without undue nm=1.164+0.089; 10028%; striped control) after 4 days in 
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FIG. 2. The samc cxpcriment as in FIG. 1 with additional FIG. 9. Comparison of the concentration-dependent inhi- 
compounds. bitions of DNA synthesis by the TT analog TT2 (0) and 
FIG. 3. Comparison of the concentration-dependent inhi- DAU (0) in L1210 cells in vitro. Cells (1.14~10~10.5 ml of 
bitions of L1210 cell growth by the TT analog m 2  (.,a) RPMI 1640 medium) were incubated at 37” C. for 90 min in 
and DAU (Q.) at days 2 (open symbols) and 4 (closed 5 the presence or absence (control) of the indicated concen- 
symbols) in vitro. The protocol of the experiment was trations of dmgs, which are plotted on a logarithmic scale, 
identical to that of FIG. 1. The results are expressed as % of and then pulse-labeled for an additional 30 min to determine 
the numbers of vehicle-treated control cells (10024%; the rate of 3H-thymidine incorporation into DNA. DNA 
striped area) after 2 (213,79828,316 cells/ml) and 4 days synthesis in vehicle-treated control cells was 27,86021,931 
(1,311,274-..5.5,991 cellsiml) in culture. Drug concentrations cpm (10027%; striped area). The blank value (9162.52 cpm) 
are plotted on a logarithmic scale. Bars: means+SD (n=3). for cells incubated and pulse-labeled at 2” C. with 1 pCi of 
“Not different from control; bP<0.025 and “Pe0.01, smaller 3H-thymidine has been substracted from the results. Bars: 
than control. means+SD (n=3). “Not different from control; bPe0.05 and 
FIG. 4. Comparison of the concentration-dependent inhi- “Pe0.01, smaller than control. 
bitions of L1210 cell viability by the TT analog FIG. 10. Concentration-dependent inhibition of nucleo- 
and DAU ( Q W )  at days 2 (open symbols) and 4 (closed side transport by the TT analog TT2 in L1210 cells in vitro. 
symbols) in vitro. Cells were seeded in triplicate at initial cells (1,4gx106/o,5 ml of RPMI 1640 medium) were 
tivelY incubated for 2 Or 4 days in the Presence or absence (control) of the indicated concentrations of TT2 (0) and 
(control) of the indicated concentrations of dmgs, which are 2o DAU (o), which are plotted on a logarithmic scale, before 
plotted on a logarithmic scale. The ability of viable cellsi0.5 being exposed to 1 p c i  of 3H-thymidine for 30 sec at 37” c .  
ml to bioreduce 0.1 ml of MTS:PMS (2O:l) reagent Over a After washing thrice with PBS, intact cell pellets were 
3-h incubation period was assessed as described in FIG. 1. harvested by centrifugation, incubated for 30 min in 1 ml of 
Cell viability results are expressed as % of the net absor- HLB containing 0.2% Triton X-100, and these lysates were 
bance of MTSIformazan after bioreduction by vehicle- 25 mixed with scintillation cocktail and counted to estimate the 
treated control cells (10028%; striped area) at days 2 (A490 cellular uptake of 3H-thymidine. Results are expressed as ’3% 
,,=1.206+0.093) and 4 (A490 ,,=1.096+0.086). Blank Val- of 3H-thymidine transported into vehicle-treated control 
(A490 ,,=0.185 and 0.189 at days 2 and 4) for culture cells over 30 sec (15,0312872 cpm; 10026%; striped area). 
medium supplemented with MTS:PMS reagent have been B ~ ~ ~ :  means+SD (n=3), “Not different from control; 
substracted from the results. Bars: means+SD (n-3). “Not 3o bpe0,005, smaller than control, 
different from control; bP<0.005, “Pe0.025 and dpe0.05, FIG. 11. Comparison of the inhibitory effects of novel TT 
smaller than control. analogs on DNA synthesis (open) and nucleoside transport 
FIG. 5. Comparison of the concentration-dependent inhi- (striped) in ~ 1 2 1 0  cells in vitro, The cellular uptake of 
bitions of €L60-S ( 0 1 3  HL-60-RV (0) and HL-60-M (A) 3H-thymidine (striped) and the rate of 3H-thymidine incor- 
cell Proliferation by DAU at days 2 (A) and 4 (B) in vitro. 35 poration into DNA (open) were determined in cells ( 1 . 3 8 ~  
Cell growth results are expressed as % of the numbers of 10610.5 ml of RPMI 1640 medium) respectively preincu- 
vehicle-treated control tumor cells (100+5%, striped areas) bated at 37” c, for 15 or 90 min in the presence or absence 
after 2 (110,90325,878 cells/ml) and 4 days (253,4622122 (control) of 7 pM concentrations of the indicated com- 
166 cells/ml) in culture. Bars: means+SD (n=3). “Not dif- pounds. For the cellular transport of nucleosides, preincu- 
ferent from Control; bP<0.05, “P<o.o1 and dP<0.025, Smaller 4o bated cells were then exposed to 1 p c i  of 3H-thymidine for 
than control. 30 sec at 37” C. Results are expressed as % of 3H-thymidine 
FIG. 6. Comparison of the concentration-dependent inhi- transported into vehicle-treated control cells over 30 sec 
bitions of HL-60-S (O), HL-60-RV (W) and HL-60-R8 (A) (15,53921,767 cpm; 100+11%; striped control). For DNA 
cell proliferation by TT2 at days 2 (A) and 4 (B) in vitro. The synthesis, preincubated cells were then pulse-labeled with 1 
conditions of the experiments and the determination of the 45 pCi of 3H-thymidine for an additional 30 min at 37” C. 
results were identical to those of FIG. 5 .  Bars: means+SD Results are expressed as % of 3H-thymidine incorporation 
(n=3). “Not different from control; bPe0.05, “Pe0.025 and into DNA in vehicle-treated control cells over 30 min 
dPe0.005, smaller than control. (28,50522,594 cpm; 10029%; open control). The blank 
FIG. 7. Comparison of the concentration-dependent inhi- value (1,0752171 cpm) for cells incubated and pulse-labeled 
bitions of HL-60-S (o), HL-60-RV (0) and HL-60-R8 (A) 50 at 2” C. with 1 pCi of 3H-thymidine has been substracted 
cell viability by DAU at days 2 (A) and 4 (B) in vitro. Cell from the results. Bars: means+SD (n=3). “Not different from 
viability results are expressed as % of the net absorbance of TT3, TT7, ‘IT9 and TT11; bPeO.Ol, smaller than ‘IT1 but not 
MTSiformazan after bioreduction by vehicle-treated control different from TT13; “not different from control; dPe0.025, 
cel ls  (10026%,  s t r iped  areas) at days  2 (A,,, greater than TT1; ‘PeO.05, smaller than control. 
,m=1.635+0.105) and 4 (A490 ,,=1.428+0.086). Blank Val- 5s FIG. 12. Irreversibility of the inhibitory effects of the 
ues (A,,, ,=0.412 and 0.436 at days 2 and 4 ) for cell-free novel TT analog TT2 on DNA synthesis (open) and nucleo- 
culture medium supplemented with MTS: PMS reagent have side transport (striped) in L1210 cells in vitro. The reversible 
been substrated from the results. Bars: means+SD (n=3). inhibitory effects of the tricyclic pyrone HI0  are demon- 
“Not different from control; bP<0.05, “PeO.025 and dP<O.Ol, strated in the same experiment. The cellular uptake of 
smaller than control. 60 3H-thymidine (striped) and the rate of 3H-thymidine incor- 
FIG. 8. Comparison of the concentration-dependent inhi- poration into DNA (open) were determined in cells ( 1 . 6 4 ~  
bitions of HL-60-S (O), HL-60-RV (W) and HL-60-R8 (A) 106/0.5 ml of RPMI 1640 medium) respectively preincu- 
cell viability by TT2 at days 2 (A) and 4 (B) in vitro. The bated at 37” C. for 1.5 or 60 min in the presence or absence 
conditions of the experiments and the determination of the (control) of 10 and 25 pM ‘IT2 or 25 pM H10. The protocol 
results were identical to those of FIG. 5 .  Bars: means+SD 65 of the experiments and the determination of the results were 
(n=3). “Not different from control; bPe0.025, smaller than identical to those of FIGS. 9 and 10, except that, after 
control. preincubation, either the drugs were maintained in the 
( 0 3 0 )  15 
densities Of 100,000 or 11,100 cells/0.5 mliwell and respec- incubated for 15 min at 37” c, in the presence or absence 
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culture medium (+) or the cells were spun, washed, and trations of drugs, which are plotted on a logarithmic scale, 
resuspended in fresh medium in order to remove the drugs and then pulse-labeled for an additional 1 h to determine the 
(-). After preincubation, vehicle-treated controls were simi- rate of 3H-leucine incorporation into protein. Protein syn- 
larly spun and washed. For the cellular transport of thesis in vehicle-treated control cells was 13,812+1,070 cpm 
nucleosides, preincubated cells were then exposed, in the s (10028%; striped area). The blank value (2,4362298 cpm) 
presence (+) or absence (-) of TT2 or H10, to 1 pCi of for cells incubated and pulse-labeled at 2” C. with 2.5 pCi of 
3H-thymidine for 30 sec at 37” C. Results are expressed as 3H-leucine has been substracted from the results. Bars: 
% of 3H-thymidine transported into vehicle-treated control means+SD (n=3). “Not different from control; bPe0.025 and 
cells over 30 sec (11,0542754 cpm; 10027%; striped “Pe0.01, smaller than control. 
control+; 14,48621,260 CPm; 10029%; striped control-). 10 FIG. 18. Effects of the novel TT analog TT2 and DAU on 
For DNA synthesis, Preincubated cells were then Pulse- the mitotic index of L1210 cells in vitro. The antimitotic 
labeled with 1 pCi of 3H-thymidine for an additional 30 min activities of VCR and the tricyclic pyrone ~ 1 0  are demon- 
at 37” c .  in the Presence (+> Or absence (-> of TT2 Or strated in the same experiment. Cells (106/0.5 ml of RPMI 
Results are expressed as % of 3H-thymidine incorporation 1640 medium) were incubated in triplicate for 24 h at 370 c, 
into DNA in vehicle-treated control cells over 30 min IS in the presence or absence (control) of 0,256, 0.64, 1.6 and 
(34,052212566 CPm; 10025%; open control+; 28,81122,506 4 pM TT2, 0.256, 0.64 and 1.6 pM DAU, 0.2 pM VCR or 
CPm; 10029%; open control-). The blank value (1,328286 1 pM H10. After fixation with Me0H:acetic acid (3:l) and 
CPm) for cells incubated and Pulse-labeled at 2” c .  with 1 staining with 0.1% crystal violet, about 500 cellsislide were 
pCi of 3H-thymidine has been substracted from the results. scored for mitotic figures and the mitotic index was 
Bars: means+SD (n=3). Values with similar superscripts are 20 expressed as the % of mitotic cells in drug-treated cultures 
not significantly different from each others. divided by the % of mitotic cells in non-treated controls. The 
FIG. 13. The open columns represents the rate of 3H mean % of mitotic cells in control at 24 h was 1.86+0.43%. 
-Thymidine incorporation into DNA over 30 minutes, Bars: means+SD (n=3). “Not different from control; 
whereas the striped and closed columns represents the bPe0.05, “Pe0.01 and dPe0.005, smaller than control; 
cellular transport of 3H -adenosine and 3H-thymidine occur- 25 ‘PeO.005, greater than control but smaller than VCR. 
ring over only 30 seconds in vitro. FIG. 19. Comparison of the concentration-dependent 
FIG. 14. Comparison of the concentration-dependent effects of novel TT analogs and known DNA-damaging 
inhibitions of DNA synthesis by DAU (open symbols in A) anticancer drugs on DNA cleavage in L1210 cells in vitro. 
and TT2 (closed symbols in B) in HL-60-S (circles), HL-60- Cells (106/0.5 ml of RPMI 1640 medium) were prelabeled 
RV (squares) and HL-60-R8 (triangles) cells in vitro. DNA 30 with 1 pCi of 3H-thymidine for 2 h, washed and resuspended 
synthesis in vehicle-treated control cells was 14,26921,106 in fresh FCS-containing medium, and incubated at 37” C. for 
cpm (loo&%, striped areas). The blankvalue (404238 cpm) 24 h in the presence or absence (control) of the indicated 
for control cells incubated and pulse-labeled at 2” C. with 1 concentrations of TT1 (o), TT2 (O), DAU (W) or CPT (A), 
pCi of 3H-thymidine has been substracted from the results which are plotted on a logarithmic scale. After lysing the 
Bars: means+SD (n=3). “Not different from control; bPe0.05 35 cells in HLB containing 0.2% Triton X-100, the detergent- 
and “Pe0.025, smaller than control. soluble DNA fragments present in the supernatants and the 
FIG, 15, ~~~~~~i~~~ of the concentration-dependent intact chromatin DNA remaining in the pellets were sepa- 
inhibitions of the cellular transport of purine (A) and pyri- rated by centrifugation and their radioactivity estimated by 
midine (B) nucleosides by DAU (open symbols) and TT2 L s c .  Results are expressed as [CPm in SuPernatanthm in 
(closed symbols) in HL-60-S (circles), HL-60-RV (squares) 40 SUpernatant+pellet]Xloo at 24 h. For untreated Controls 
and HL-60-R8 (triangles) cells in vitro, Results are (5.3+0.6% DNA fragmentation; striped area), the superna- 
expressed as % of 3H-adenosine (26,03222,239 cpm, tant is 741279 CPm and the Pellet is 13,29321,446 CPm. 
1o029%, striped area in A) and 3 ~ - t h ~ ~ i d i ~ ~  (17,934~1, Bars: means+SD (n=3). “Not different from control; bPe0.05 
398 cpm, loo&%, striped area in B) transported into and “p<o.o1, greater than control; dp<0.05, smaller than 
vehicle-treated control cells over 30 s .  Bars: means+SD 45 CPT but not different from 10 IuM T T k  ‘p<o.05, greater 
(n=3). “Not different from control; bPe0.025, “Pe0.01 and than TT1 but not different from CPT. 
dPe0.005, smaller than control. FIG. 20. Comparison of the abilities of novel TT analogs 
FIG, 16, ~~~~~~i~~~ of the concentration-dependent to induce DNA cleavage in L1210 cells in vitro. Cells 
inhibitions of ~ ~ ~ ~ ~ ~ t h ~ ~ i ~  by the TT analog T T ~  (0) and containing prelabeled DNA were incubated at 37” C. for 24 
DAU (0) in L1210 cells in vitro. Cells (1.2~10~10.5 ml of h in the Presence Or absence (control) of 7 PM Concentra- 
presence or absence (control) of the indicated concentrations experiment and the determination of the results were iden- 
of drugs, which are plotted on a logarithmic scale, and then tical to those of FIG. 12. Bars: means+SD (n=3). “Not 
pulse-labeled for an additional 1 h to determine the rate of 55 different from TT7 and TT9; bp<0.05, greater than TT9 but 
3 ~ - ~ ~ i d i ~ ~  incorporation into RNA, RNA synthesis in not different from TT13; “Pe0.05, smaller than TT7; %ot 
vehicle-treated control cells was 47,11723,204 cpm different from control; ‘pe0.01, greater than control, 
(10027%; striped area). The blank value (1,7462155 cpm) p<o.o25, greater than T T l l  but not different from TT3, TT6, 
for cells incubated and pulse-labeled at 2” C. with 2 pCi of TT8 and n 1 0 ;  fp<o.ol, greater than control. 
3H-uridine has been substracted from the results. Bars: 60 FIG. 21. Same experiment as FIG. 20 with additional 
means+SD (n=3). “Not different from control; bPe0.05 and analogs. 
“Pe0.025, smaller than control. FIG. 22. Irreversibility of the effects of novel TT analogs 
FIG. 17. Comparison of the concentration-dependent and known DNA-damaging anticancer drugs on DNAcleav- 
inhibitions of protein synthesis by the TT analog TT2 (0) age in L1210 cells in vitro. Cells containing prelabeled DNA 
and DAU (0) in L1210 cells in vitro. Cells (1 .51~10~i0.5 ml 65 were incubated at 37” C. for various periods of time in the 
of RPMI 1640 medium) were incubated at 37” C. for 3 h in presence or absence (control) of 10pM TT1 or TT2 and 1.6 
the presence or absence (control) of the indicated concen- pM DAU or CPT. The protocol of the experiment and the 
RPMI 1640 medium) were incubated at 37” C, for 3 h in the tions Of the indicated compounds. The protocol Of the 
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determination of the results at 24 h were identical to those 2-ethylbutyl, 1-ethylbutyl, 1,3-dimethylbutyl, n-heptyl, 
of FIG. 19, except that the drugs were either maintained in 5 - m e t h y l h e x y l ,  4 -methylhexyl ,  3 -methylbexyl ,  
the medium for the whole 24-h period of incubation (open) 2-methylhexyl, 1-methylhexyl, 3-ethylpentyl, 2-ethylpentyl, 
or removed after the first 3 (striped) and 8 h (closed). After l-ethylpentyl, 4,4-dimethylpentyl, 3,3-dimethylpentyl, 2,2- 
spinning and washing the appropriate samples to remove the s d i m  e th  Y 1P e n tY 1, 1 , 1  - d i m  e thy  1P e n tY 1, n - 0 C tY 1, 
drugs, cells were resuspended in 0.5 ml of fresh medium to 6-methY1hePtY1, 5-methY1hePtY1, 4-methY1hePtY1, 
complete the 24-h period of incubation in the absence of 3-methYlhePtY1, 2-methYlhePtY1, l-methYlhePtYl, 
drugs, Vehicle-treated controls were similarly spun and l-ethylhexyl,  l-propylpentyl,  3-ethy1hexy1, 5,5- 
washed at 3 and 8 h, Bars: means2SD (n=3), Values with dimethylhexyl, 4,4-dimethylhexyl, 2,2-diethylbutyl, 333- 
diethylbutyl, and 1-methyl-1-propylbutyl. Alkyl groups are similar superscripts are not significantly different from each i o  optionally substituted. Lower alkyl groups are C,-C, alkyl 
TT1 but not different from CPT; dP<0.05, smaller than CPT. isopropyl groups, 
FIG. 23. Comparison of the concentration-dependent The term ~~cycloalkyl” refers to alkyl groups having a 
inductions Of DNA by DAU (‘pen in A) hydrocarbon ring, particularly to those having rings of 3 to 
and TT2 7 carbon atoms, Cycloalkyl groups include those with alkyl 
taining 3H-prelabeled DNAin vitro. Results are expressed as include straight-chain and branched-chain portions, 
[qm in supernatant/qm in supernatant+pelletlxloo at 24 h. C y c ~ o a ~ k y ~  groups include but are not limited to 
For untreated (14.721.7% DNA fragmentation, c y c ~ o p r o p y ~ ,  c y c ~ o b u t y ~ ,  c y c ~ o p e n t y ~ ,  c y c ~ o h e x y ~ ,  
striped areas)2 the supernatant (DNA fragments) is 2o cycloheptyl, cyclooctyl, and cyclononyl. Cycloalkyl groups 
12,81521,358 cpm and the pellet (intact DNA) is 74,40629, 
078 cpm. Bars: means2SD (n=3). “Not different from con- 
ep<0’005’ than the effect Of 1’6 pM DAU in 
Others’ different from DAU; “p<0.025, greater than and include among others methyl, ethyl, and 
in B, at 24 in HL-60-S 
HL-60-RV (squares) and HL-60-R8 ‘On- group substitution on the ring, Cycloalkyl groups can 
can optionally be substituted, 
Aryl groups may be substituted with one, two or trol; bp<0’05, “p<0’025 and dp<o.ol, greater than simple substituents including, but not limited to, lower alkyl, 
but not different from the effect Of 0’1024 pM 25 sulfato; su~fony~oxy; carboxy; carbo-~ower-a~koxy, e,g,, 
amino; mono- and di-lower- 
e.g., methyl, ethyl, butyl; halo, e.g., chloro, bromo; nitro; HL-60-S 
DAU in HL-60-S different from the effect Of carbomethoxy, carbethoxy; 
0’04096 IUM DAU in HL-60-S 
from the effect Of 
different from the effect of 10 pM TT2 in HL-60-RV and 30 
HL-60-R8 cells; iP<0.005, smaller than control. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Definitions 
gp<0’05’ greater than alkylamino, e.g., methylamino, ethylamino, dimethylamino, 
methoxy, ethoxy; and lower-alkanoyloxy, e.g., acetoxy. 
The term “unsaturated alkyl” group is used herein gen- 
erally to include alkyl groups in which one or more carbon- 
carbon single bonds have been converted to carbon-carbon 
double or triple bonds. The term includes alkenyl and 
35 alkynyl groups in their most general sense. The term is 
intended to include groups having more than one double or 
The term “hydrocarbyl’’ is used herein to refer generally triple bond, or combinations of double and triple bonds. 
to organic groups comprised of carbon chains to which Unsaturated alkyl groups include, without limitation, unsat- 
hydrogen and optionally other elements are attached. CH, or urated straight-chain, branched Or CYcloalkYl groups. Unsat- 
CH groups and C atoms of the carbon chains of the hydro- 4o urated alkyl groups include without limitation: vinyl, allyl, 
carbyl may be replaced with one or more heteroatoms (i.e., Propenyl, isoProPanY1, butenY1, PentenYl, hexenY1, 
non-carbon atoms). Suitable heteroatoms include but are not heXadienY1, hePtenY1, cYcloProPenY1, CYclobutenYl, 
limited to 0, S, P and N atoms. The term hydrocarbyl CYcloPentenYl, CYcloPentadienYl, CYclohexenYl, 
includes, but is not limited to alkyl, alkenyl, alkynyl, ether, CYclOhexadienYl, l-ProPenYl, 2-butenY1, 2-methyl-2- 
polyether, thioether, straight chain or cyclic saccharides, 45 butenY1, ethynyl, ProPargYl, 3-methYl-l-PentYnY1, and 
ascorbate, aminoalkyl, hydroxylalkyl, thioalkyl, aryl and 2-hePtYnYl. Unsaturated alkyl groups can OPtionallY be 
heterocyclic aryl groups, optionally substituted tricyclic substituted. 
molecules, amino acid, polyalcohol, glycol, groups which Substitution of alkyl, cycloalkyl and unsaturated alkyl 
have a mixture of saturated and unsaturated bonds, carbocy- groups includes substitution at one or more carbons in the 
clic rings and combinations of such groups. The term also 50 group by moieties containing heteroatoms. Suitable substitu- 
includes straight-chain, branched-chain and cyclic structures ents for these groups include but are not limited to OH, SH, 
or combinations thereof Hydrocarbyl groups are optionally NH,, COH, CO,H, OR,, SR,, P, PO, NR,R,, CONR,R,, and 
substituted. Hydrocarbyl substitution includes substitution halogens, particularly chlorines and bromines where R, and 
at one or more carbons in the group by moieties containing R,, independently, are alkyl, unsaturated alkyl or aryl 
heteroatoms. Suitable substituents for hydrocarbyl groups 55 groups. Preferred alkyl and unsaturated alkyl groups are the 
include but are not limited to halogens, including chlorine, lower alkyl, alkenyl or alkynyl groups having from 1 to 
fluorine, bromine and iodine, OH, SH, NH,, COH, CO,H, about 3 carbon atoms. 
OR,, SR,, NR,R,, CONR,R,, where R, and R, indepen- The term “aryl” is used herein generally to refer to 
dently are alkyl, unsaturated alkyl or aryl groups. aromatic groups which have at least one ring having a 
The term “alkyl” takes its usual meaning in the art and is 60 conjugated pi electron system and includes without limita- 
intended to include straight-chain, branched and cycloalkyl tion carbocyclic aryl, aralkyl, heterocyclic aryl, biaryl 
groups. The term includes, but is not limited to, methyl, groups and heterocyclic biaryl, all of which can be option- 
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- ally substituted. Preferred aryl groups have one or two 
butyl, n-pentyl, neopentyl, 2-methylbuty1, 1-methylbutyl, aromatic rings. 
1-ethylpropyl, 1,l-dimethylpropyl, n-hexyl, 1-methylpentyl, 65 “Carbocyclic aryl” refers to aryl groups in which the 
2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 3,3- aromatic ring atoms are all carbons and includes without 
dimethylbutyl, 2,2-dimethylbutyl, 1,l-dimethylbutyl, limitation phenyl, biphenyl and napthalene groups. 
the effect Of pM TT2 in HL-60-RV but not different methy~ethy~amino; amido; hydroxy; ~ower-a~koxy, e,g,, IUM TT2 in HL-60-R8 
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“Aralkyl” refers to an alkyl group substituted with an aryl 
group. Suitable aralkyl groups include among others benzyl, 
phenethyl and picolyl, and may be optionally substituted. 
Aralkyl groups include those with heterocyclic and carbocy- 
clic aromatic moieties. 
“Heterocyclic aryl groups” refers to groups having at least 
one heterocyclic aromatic ring with from 1 to 3 heteroatoms 
in the ring, the remainder being carbon atoms. Suitable 
heteroatoms include without limitation oxygen, sulfur, and 
nitrogen. Heterocyclic aryl groups include among others 
furanyl, thienyl, pyridyl, pyrrolyl, N-alkyl pyrrolo, 
pyrimidyl, pyrazinyl, imidazolyl, benzofuranyl, quinolinyl, 
and indolyl, all optionally substituted. 
“Heterocyclic biaryl” refers to heterocyclic aryls in which 
a phenyl group is substituted by a heterocyclic aryl group 
ortho, meta or para to the point of attachment of the phenyl 
ring to the decalin or cyclohexane. Heterocyclic biaryl 
includes among others groups which have a phenyl group 
substituted with a heterocyclic aromatic ring. The aromatic 
rings in the heterocyclic biaryl group can be optionally 
substituted. 
“Biaryl” refers to carbocyclic aryl groups in which a 
phenyl group is substituted by a carbocyclic aryl group 
ortho, meta or para to the point of attachment of the phenyl 
ring to the decalin or cyclohexane. Biaryl groups include 
among others a first phenyl group substituted with a second 
phenyl ring ortho, meta or para to the point of attachment of 
the first phenyl ring to the decalin or cyclohexane structure. 
Para substitution is preferred. The aromatic rings in the 
biaryl group can be optionally substituted. 
Aryl group substitution includes substitutions by non-aryl 
groups (excluding H) at one or more carbons or where 
possible at one or more heteroatoms in aromatic rings in the 
aryl group. Unsubstituted aryl, in contrast, refers to aryl 
groups in which the aromatic ring carbons are all substituted 
with H, e.g. unsubstituted phenyl (-C6H5), or naphthyl 
(-CloH7). Suitable substituents for aryl groups include 
among others, alkyl groups, unsaturated alkyl groups, 
halogens, OH, SH, NH,, COH, CO,H, OR,, SR,, NR,Rf, 
CONR,Rp where Re and Rf independently are alkyl, unsat- 
urated alkyl or aryl groups. Preferred substituents are OH, 
SH, OR,, and SR, where Re is a lower alkyl, i.e., an alkyl 
group having from 1 to about 3 carbon atoms. Other 
preferred substituents are halogens, more preferably chlo- 
rine or bromine, and lower alkyl and unsaturated lower alkyl 
groups having from 1 to about 3 carbon atoms. Substituents 
include bridging groups between aromatic rings in the aryl 
group, such as -CO,--, -CO--, -0-, 4--, -P-,
-NH--, -CH=CH- and -(CH,), where 1 is an 
integer from 1 to about 5, and particularly -CH,-. 
Examples of aryl groups having bridging substituents 
include phenylbenzoate. Substituents also include moieties, 
such as +CH,),, -O+CH,), or -0CO-(CH,),, 
where 1 is an integer from about 2 to 7, as appropriate for the 
moiety, which bridge two ring atoms in a single aromatic 
ring as, for example, in a 1, 2, 3, 4-tetrahydronaphthalene 
group. Alkyl and unsaturated alkyl substituents of aryl 
groups can in turn optionally be substituted as described 
supra for substituted alkyl and unsaturated alkyl groups. 
The terms “alkoxy group” and “thioalkoxy group” (also 
known as mercaptide groups, the sulfur analog of alkoxy 
groups) take their generally accepted meaning. Alkoxy 
groups include but are not limited to methoxy, ethoxy, 
n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, 
tert-butoxy, n-pentyloxy, neopentyloxy, 2-methylbutoxy, 
1 -methylbutoxy, 1 -ethyl propoxy, 1 , l  -dimethylpropoxy, 
18 
n-hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy, 
3 - m e t h y l p e n t y l o x y ,  4 - m e t h y l p e n t y l o x y ,  3 , 3 -  
dimethylbutoxy, 2,2-dimethoxybutoxy, 1-1-dimethylbutoxy, 
2-ethylbutoxy, 1-ethylbutoxy, 1,3-dimethylbutoxy, 
5 n-pentyloxy, 5-methylhexyloxy, 4-methylhexyloxy, 
3-methylhexyloxy, 2-methylhexyloxy, 1-methylhexyloxy, 
3-ethylpentyloxy, 2-ethylpentyloxy, 1-ethylpentyloxy, 4,4- 
dimethylpentyloxy,  3 ,3-dimethylpentyloxy,  2 ,2-  
dimethylpentyloxy, 1,l-dimethylpentyloxy, n-octyloxy, 
6-methylheptyloxy, 5-methylheptyloxy, 4-methylheptyloxy, 
3-methylheptyloxy, 2-methylheptyloxy, 1-methylheptyloxy, 
1-ethylhexyloxy, 1-propylpentyloxy, 3-ethylhexyloxy, 5,5- 
d imethylhexyloxy,  4 ,4-d imethylhexyloxy,  2 , 2 -  
diethylbutoxy, 3,3-diethylbutoxy, 1-methyl-1-propylbutoxy, 
15 ethoxymethyl, n-propoxymethyl, isopropoxymethyl, sec- 
butoxymethyl, isobutoxymethyl, (1-ethyl propoxy)methyl, 
(2  -e t  h y lbu  to x y) me t h y 1, ( 1 -et  h y lbu  to x y)me t h y 1, 
(2-ethylpentyloxy)methyl, (3-ethylpentyloxy)methyl, 
2-methoxyethyl ,  1-methoxyethyl ,  2-ethoxyethyl ,  
2o 3-methoxypropyl, 2-methoxypropyl, 1-methoxypropyl, 
2-ethoxypropyl, 3-(n-propoxy)propyl, 4-methoxybutyl, 
2 -methoxybuty l ,  4 -e thoxybuty l ,  2 -e thoxybuty l ,  
5-ethoxypentyl, and 6-ethoxyhexyl. Thioalkoxy groups 
include but are not limited to the sulfur analogs of the alkoxy 
“Optional” or “optionally” means that the subsequently 
described event or circumstance may or may not occur, and 
that the description includes instances where said event or 
circumstance occurs and instances in which it does not. For 
3o example, “optionally substituted phenyl” means that the 
phenyl radical may or may not be substituted and that the 
description includes both unsubstituted phenyl radicals and 
phenyl radicals wherein there is substitution. 
“Amino acids” as used herein include naturally occurring 
35 and commercially available amino acids and optical isomers 
thereof. Typical natural and commercially available amino 
acids are glycine, alanine, serine, homoserine, threonine, 
valine, norvaline, leucine, isoleucine, norleucine, aspartic 
acid, glutamic acid, lysine, ornithine, histidine, arginine, 
40 cysteine, homocysteine, methionine, phenylalanine, 
homophenylalanine, phenylglycine, 0-, m-, and p-tyrosine, 
tryptophan, glutamine, asparagine, proline and hydroxypro- 
line. “Amino acid” as used herein includes amino acid 
residues and amino acid side chains. An “amino acid resi- 
45 due” is an amino acid radical -NHCH(R)C(O)--, wherein 
R is an amino acid side chain, except for the amino acid 
residues of proline and hydroxyproline which are 
-N(CH,-CH,-CH,)CHC(O)- and -N(CH- 
CHOHCHJCHC(0)--, respectively. An amino acid side 
50 chain is a radical found on the a-carbon of an a-amino acid, 
where the radical is either hydrogen (side chain of glycine), 
methyl (side chain of alanine), or is a radical bonded to the 
a-carbon by a methylene (-CH,-), or phenyl group. 
“Contacting” reaction components with each other refers 
5s to providing a medium and/or reaction chamber in which the 
reaction components are placed together so that they can 
react with each other. Preferably, the reaction components 
are suspended or dissolved in a carrier fluid which is a liquid 
medium. “Maintaining reaction components in contact” 
60 means keeping the components together in such a way that 
they can react with each other. 
“Straight chain or cyclic saccharides” include mono-, di- 
and poly-, straight chain and cyclic saccharides that are 
optionally substituted with an amino group which is option- 
65 ally acetylated. Straight chain saccharides that are useful in 
this invention include but are not limited to those molecules 
with a chain of 5 or 6 carbon atoms with one or more -OH 
25 groups specifically listed supra. 
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groups attached, and either an aldehyde or ketone group. or esters of this invention in association with a pharmaceu- 
Cyclic saccharides are saccharides that are in a ring form. tically acceptable carrier or excipient adapted for use in 
Disaccharides are compounds wherein two monosaccharide human or veterinary medicine. Such compositions may be 
groups are h k e d .  PolYsaccharides are compounds wherein prepared for use in conventional manner in admixture with 
more than two ~O~Osaccharide groups are h k e d .  Specific s one or more physiologically acceptable carriers or excipi- 
examples of saccharides useful in this invention include ents, The compositions may optiona~~y further contain one 
glucose, ribose and glucosamine, among others. or more other therapeutic agents. The compounds, salts or 
Substituents which impart water solubility include but are esters of this invention are present in these pharmaceutical 
not limited to alcohols; polyalcohols; straight chain or cyclic compositions in an amount or in a combined amount 
saccharides; amines and polyamines; sulfate groups; phos- 10 cient to elicit a measurable positive effect on a desired 
phate groups; ascorbate groups; chains optionally parameter, or a desired physiological effect, The triptycene substituted with -OH at any position; glycols, including compounds, salts and esters of this invention may be for- polyethylene glycols, and polyethers. Substituents which mulated for oral, buccal, parenteral, topical or rectal admin- impart water solubility are also referred to as solubilizing istration. In particular, they may be presented in unit dose groups. 
IS form. The compositions may take such forms as This invention is also directed to pharmaceutically accept- suspensions, solutions, or emulsions in oily or aqueous able salts of the various formulas and structures disclosed vehicles, and may contain formulatory agents such as herein. Acid addition salts are prepared by contacting com- suspending, stabilizing and/or dispersing agents. pounds having appropriate basic groups therein with an acid Alternatively, the active ingredient may be in powder form whose anion is generally considered suitable for human or 
20 for constitution with a suitable vehicle, e.g. sterile, pyrogen- animal consumption. Pharmacologically acceptable acid free water, before use. addition salts include but are not limited to the 
hydrochloride, hydrobromide, hydroiodide, sulfate, The pharmaceutical compositions according to the inven- 
phosphate, acetate, propionate, lactate, maleate, malate, tion may contain Other active ingredients, such as 
succinate, and tartrate salts. All of these salts can be prepared 
by conventional means by reacting, for example, the 25 The invention further provides a process for preparing a 
selected acid with the selected basic compound. Base addi- pharmaceutical composition which comprises bringing a 
tion salts are analogously prepared by contacting corn- triptycene analog of the invention into association with a 
pounds having appropriate acidic groups therein with a base pharmaceutically acceptable excipient or carrier. The carrier 
whose cation is generally considered to be suitable for or excipient being selected as is known in the art for 
human or animal consumption. Pharmacologically accept- 30 compatibility with the desired means of administration, for 
able base addition salts, include but are not limited to compatibility with the selected compounds and to minimize 
ammonium, amine and amide salts. detrimental effects to the patient. 
agents, Or preservatives. 
Pharmaceutically acceptable esters of compounds of this The magnitude of a prophylactic or therapeutic dose of a 
invention are prepared by conventional methods, for 35 particular compound will, of course, vary with the nature of 
example by reaction with selected acids. Pharmaceutically the severity of the condition to be treated, the particular 
acceptable esters include but are not limited to carboxylic triptycene analog and its route of administration. It will also 
acid esters RCOO-D (where D is a cationic form of a vary according to the age, weight and response of the 
compound of this invention and where R is H, alkyl or aryl individual patient, all as will be readily ascertainable to 
groups). 
Effective dosages of the compounds of this invention may The compounds of the present invention are preferably 
be easily determined by those skilled in the art following the formulated prior to administration. The present pharmaceu- 
teachings hereof and principles known to the art. tical formulations are prepared by known procedures using 
The compounds of these inventions may be administered well-known and readily available ingredients. In making the 
in the form of pharmaceutical preparations including the 45 compositions of the present invention, the active ingredient 
compounds of these inventions in suitable pharmaceutical will usually be mixed with a carrier, or diluted by a carrier, 
carriers to form solutions, lotions, creams, and other dosage or enclosed within a carrier which may be in the form of a 
forms known to the art. Combinations of such compounds capsule, sachet, paper or other container. When the carrier 
with pharmaceutical carriers are also provided by this inven- serves as a diluent, it may be a solid, semi-solid or liquid 
tion. Combinations of triptycene analogs described herein so material which acts as a vehicle, excipient or medium for the 
along with other compounds which may include other active ingredient. The compositions can be in the form of 
triptycene analogs described herein are also provided by this tablets, pills, powders, lozenges, sachets, cachets, elixirs, 
invention. suspensions, emulsions, solutions, syrups, aerosols (as a 
This invention is also directed to prodrugs and analogs solid or in a liquid medium), ointments containing for 
which on being metabolized will result in any of the effec- 5s example up to 10% by weight of the active compound, soft 
tive triptycene analogs of this invention. For example, and hard gelatin capsules, suppositories, sterile injectable 
alkoxy or acetate groups can be metabolized to hydrogens. solutions and sterile packaged powders. 
Labile substituents may be protected employing conven- Some examples of suitable carriers, excipients, and dilu- 
tional and pharmaceutically acceptable protecting groups ents include lactose, dextrose, sucrose, sorbitol, mannitol, 
removable on metabolism. Pharmaceutically active com- 60 starches, gum acacia, calcium phosphate, alginates, 
pounds may be derivatized by conventional methods to tragacanth, gelatin, calcium silicate, microcrystalline 
provide for extended metabolic half-life, to enhance soh-  cellulose, polyvinylpyrrolidone, cellulose, water, syrup, 
bility in a given carrier, to provide for or facilitate slow- methyl cellulose, methyl and propylhydroxybenzoates, talc, 
release or timed-release or enhance or affect other drug magnesium stearate and mineral oil. The formulations can 
delivery properties. 65 additionally include lubricating agents, wetting agents, 
Pharmaceutical compositions according to the present emulsifying and suspending agents, preserving agents, 
invention comprise one or more triptycene compounds, salts sweetening agents or flavoring agents. The compositions of 
4o those skilled in the art. 
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the invention may be formulated so as to provide quick, 
sustained or delayed release of the active ingredient after 
administration to the patient by employing procedures well 
known in the art. 
The term "unit dosage form" refers to physically discrete 
units suitable as unitary dosages for human subjects and 
other mammals, each unit containing a predetermined quan- 
tity of active material calculated to produce the desired 
therapeutic effect, in association with a suitable pharmaceu- 
tical carrier. 
This invention is further directed to therapeutic methods 
employing the triptycene compounds of this invention and 
pharmaceutical compositions containing them in the treat- 
ment of disorders or physiological conditions involving 
abnormal cell growth or activity. These methods comprise a 
step of administering to a patient having the disorder or 
symptoms thereof a pharmaceutical composition comprising 
one or a mixture of the compounds, salts or esters of this 
invention where the compounds, or mixtures of compounds 
of this invention are present in the composition at a level or 
a combined level sufficient to effect a positive biological 
response. The present invention provides triptycene analogs 
that can be used in place of or in combination with currently 
known pharmaceuticals active against disorders such as 
cancer and malaria. Compounds of this invention exhibit 
improved properties (enhanced activity and/or decreased 
undesired side-effects) for treatment of such disorders as 
compared to previously known compounds useful for such 
treatments. 
Table 1 lists the chemical names of the compounds 
depicted in Scheme 1. 
TABLE 1 
Nomenclature of various substituted 9,10-Dihydro-9,10-[1',2'] 
benzenoanthracene-l,4,S&tetraones. 
TTl: 9,10-Dihydro-9,10-[1',2']benzenoanthracene-l,4,S,S-tetraone. 
T T Z :  2-Methoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene-l,4,S,S- 
tetraone. 
TT13: 2-Bromo-3-methoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene- 
1,4,S,S-tetraone. 
TT14: 2-Bromo-3-(methylamino)-9,lO-dihydro-9,10-[1',2'] 
benzenoanthracene-l,4,S&tetraone. 
TT3: 1,4-Dihydroxy-2,5,8-trimethoxy-9,10-dihydro-9,10-[1',2'] 
benzenoanthracene. 
TTS: 2,5,8-Trimethoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene-1,4- 
dione. 
TT7: 9,10-Dihydro-9,10-[1',2']benzenoanthracene-l,4-dione. 
TT9: 2-Methoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene-l,4-dione. 
TT6: (4aS*,9aR*)-4a,9,9a,lO-Tetrahydro-9,10-[l',2']benzenoanthracene- 
1,Cdione. 
TTS: (4aS*,9aR*)-2-Methoxy-4a,9,9a,lO-tetrahydro-9,10-[1',2'] 
benzenoanthracene-l,4-dione. 
TTlO: (4aS*,9aR*)-S,S-Dimethoxy-~-methoxycarbonyl-4a,9,9a,lO- 
tetrahydro-9,10-[ 1',2']benzenoanthracene-l,4-dione. 
TTll: (4aR*,9aR*)-S,S-Dimethoxy-4a-methoxycarbonyl-9,9a,l0-trihydro- 
9,10-[1',2']benzenoanthracene-l,4-dione. 
TT4: (4aS*,7aR*,llaS*,14aR*)-Tetramethyl 1,4,4a,S,6,7,7a,8,11,lla,12, 
13,14,14a-tetradecahydro-5,7,12,14-tetraoxo-6,13-[1',2'] 
benzenopentacene-2,3,9,lO-tetracarboxylate. 
TTl2: (4aS*,SS*,7R*,12S*,14R*,7aR*,llaS*,14aR*)-Tetramethyl 
1,4,4a,5,6,7,7a,8,11,11a,12,13,14,14a-tetradecahydro-S,7,12,14- 
tetrahydroxy-6,13-[ 1',2']benzenopentacene-2,3,9,lO-tetracarboxylate. 
TTlS: 2-Hydroxy-3-(methylamino)-9,10-dihydro-9,10-[1',2'] 
benzenoanthracene-l,4,S&tetraone. 
TT16: 2-Bromo-3-methoxy-6-(dimethy1amino)-9,10-dihydro-9,10-[1',2'] 
benzenoanthracene-l,4,S&tetraone. 
TT17: 2-Bromo-3-[2-(ethoxycarbonyl)ethylamino]-9,lO-dihydro-9,10- 
[ 1',2']benzenoanthracene-1,4,S,S-tetraone 
TTlS: 2-hydroxy-3-[2-(ethoxycarbonyl)ethylamino]-9,1O-dihydro-9,10- 
[ 1',2']benzenoanthracene-1,4,S,S-tetraone 
TTZO:  2-Hydroxy-3-[ (S)-5-(hydroxycarbonyl)-5-aminopentylamino]- 
9,10-dihydro-9,10-[1',2']benzenoanthracene-l,4,S,S-tetraone 
EXAMPLES 
The following non-limiting examples are intended to aid 
in understanding the invention. 
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In contrast to their inactive parent compound triptycene 
(code name TTO), several triptycene (TT) analogs were 
shown to prevent L1210 leukemic cells from synthesizing 
macromolecules and growing in vitro. TT2 blocks the cel- 
lular transport of both purine and pyrimidine nucleosides 
(ICso: 6 pM) over a 30-sec period in vitro, in contrast to the 
quinone antitumor drug daunomycin. The concentration- 
dependent induction of DNA cleavage at 24 h and internu- 
cleosomal DNA fragmentation at 48-72 h by TT2 peaks at 
4-10 pM but disappears at 25 pM. TT2 induction of DNA 
cleavage is inhibited by actinomycin D, cycloheximide and 
the caspase inhibitor 2-VAD-fmk, suggesting that TT2 acti- 
vates endonucleases and triggers apoptosis. 
The antitumor activity of TT2 has been compared to that 
of daunomycin (DAU), a clinically valuable anthracycline 
antibiotic which is structurally different from TT2 but also 
contains a quinone moiety. TT2 inhibits the proliferation 
(ICso: 300 nM at day 2 and 150 nM at day 4) and viability 
(ICso: 250 nM at day 2 and 100 nM at day 4) of L1210 cells 
to the same maximal degree than DAU, suggesting that the 
cytostatic and cytotoxic activities of 7T2 are a combination 
of drug concentration and duration of drug exposure. Since 
TT2 does not increase the mitotic index of L1210 cells at 24 
h like vincristine, it is unlikely to be an antimitotic drug that 
disrupts microtubule dynamics. Like DAU, a 1.5- to 3-h 
pretreatment with TT2 is sufficient to inhibit the rates of 
DNA, RNA and protein syntheses determined over 30- to 
60-min periods of pulse-labeling in L1210 cells in vitro 
(ICso: 6 pM). In contrast to DAU, which is inactive, a 
15-min pretreatment with 7T2 has the advantage of also 
inhibiting the cellular transport of nucleosides occuring over 
a 30-sec period in vitro (ICso: 6 pM), suggesting that TT2 
prevents the incorporation of 3H-thymidine into DNA 
because it rapidly blocks the uptake of 3H-thymidine by the 
tumor cells. After 24 h, TT2 induces as much DNAcleavage 
as camptothecin and DAU, two anticancer drugs producing 
DNA-strand breaks and known to respectively inhibit DNA 
topoisomerase I and I1 activities. Interestingly, the abilities 
of TT2 to block nucleoside transport, inhibit DNA synthesis 
and induce DNA fragmentation are irreversible upon drug 
removal, suggesting that this compound may rapidly interact 
with various molecular targets in cell membranes and nuclei 
to disrupt the functions of nucleoside transporters and 
nucleic acids and trigger long-lasting antitumor effects 
which persist after cessation of drug treatment. Because 
inhibition of nucleoside transport is highly unusual among 
DNA-damaging drugs, the use of bifunctional TTs with 
antileukemic activity in the nM range in vitro provides a 
considerable advantage in polychemotherapy to potentiate 
the action of antimetabolites and sensitize multidrug- 
resistant tumor cells. 
Materials and Methods 
Cell Culture and Drug Treatments 
TTO was purchased from Aldrich (Milwaukee, Wis.). All 
solutions of synthetic TTs and tricyclic pyrone H10, vinc- 
ristine (VCR; a gift from Lilly Researeh Laboratories, 
Indianapolis, Ind.) and camptothecin (CPT; from Sigma 
Chemical Co., St Louis, Mo.) were dissolved and diluted in 
dimethyl sulfoxide (DMSO), whereas daunomycin (DAU) 
(from Sigma) solutions were prepared in 0.1 M potassium 
phosphate buffer, pH 7.4, containing 0.9% NaC1. Suspension 
cultures of murine L1210 lymphocytic leukemia cells 
(American Type Culture Collection, Rockville, Md.) were 
maintained in continuous exponential growth by twice-a- 
week passage in RPMI 1640 medium supplemented with 
7.5% fortified bovine calf serum (FCS; HyClone 
Laboratories, Logan, Utah) and penicillin (100 IU/ml)- 
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streptomycin (100 pgiml), and incubated in the presence or Decreasing concentrations of cells, such as 1x10' and 1 . 1 1 ~  
absence of drugs at 37" C. in a humidified atmosphere lo4 cellsi0.5 mliwell, were initially plated at time 0 in order 
containing 5% CO,. Since drugs were supplemented to the to collect control samples with approximately equal cell 
culture medium in 1 pl aliquots, the concentration of DMSO densities after 2 and 4 days in culture, respectively. The 
in the final incubation volume (0.5 ml) never exceeded 0.2% s viability of TT-treated cells was assessed from their ability 
and did not affect the rates of macromolecule syntheses and to bioreduce the 3-(4,5-dimethylthiazo1-2-y1)-5-(3- 
growth in L1210 cells. Control cells incubated in the carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
absence of drugs were similarly treated with vehicle only (MTS) reagent (Promega, Madison, Wis.) in the presence of 
and, in every experiment, all incubates received the same phenazine methosulfate (PMS; Sigma) into a water-soluble 
volume of solvent. For drug removal, incubates were spun at i o  formazan product which absorbs at 490 nm. At the appro- 
200xg for 10 min, drug-containing supernatants were priate time after drug treatment, cell samples (about 106/0.5 
discarded, and intact cells were washed thrice with 1 ml of mliwell for controls) were further incubated at 37" C. for 3 
the above RPMI 1640 culture medium and resuspended in h in the dark in the presence of 0.1 ml of MTS:PMS (2:O.l) 
0.5 ml of fresh medium for further incubation. reagent and their relative cell viability was estimated by 
Suspension cultures of WT, drug-sensitive, human is recording the Abs. at 490 nm, using a Cambridge model 750 
HL-60-S promyelocytic leukemia cells, were obtained from automatic microplate reader (Packard, Downers Grove, Ill.). 
American Type Culture Collection (Manassas, Va.), main- Blank values for culture medium supplemented with 
tained in continuous exponential growth by twice-a-week MTS:PMS reagent in the absence of cells were substracted 
passage in RPMI 1640 medium supplemented with 8.25% from the results. 
fortified bovine calf serum (FCS; Hyclone Laboratories, 20 Macromolecule Synthesis 
Logan, Utah) and penicillin (100 IUim1)-streptomycin (100 For nucleic acid and protein syntheses, L1210 cells were 
pgiml), and incubated in the presence or absence of drugs at resuspended in fresh FCS-containing RPMI 1640 medium at 
37" C. in a humidified atmosphere containing 5% CO,. The a density of about 1 .1 -1 .6~10~  cellsi0.5 ml. To estimate the 
MDR HL-60-RV and HL-60-R8 cells were developed in rate of DNA synthesis, HL-60-S, HL-60-RV and HL-60-R8 
Melvin S. Center's laboratory (Kansas State University) and zs cells were resuspended in fresh FCS-containing RPMI 1640 
similarly maintained in RPMI 1640 medium in the absence medium at a density of 5x10' cellsi0.5 ml. Except when 
of drugs (Marsh W, et al, Cancer Res 46: 4053-4057, 1986; otherwise specified, the cells were incubated at 37" C. for 90 
McGrath T et al, and Center M S: Biochem Biophys Res rnin in the presence or absence of drugs and then pulse- 
Commun 145: 1171-1176, 1987; Marsh W and Center M s: labeled for an additional 30 rnin with 1 pCi of [me th~ l -~H]  
Cancer Res 47: 5080-5086, 1987; McGrath T, et al, Bio- 30 thymidine (50 Ciimmol; Amersham Corp., Arlington 
chem Pharmacol 38: 3611-3619, 1989; Marquardt D, et al, Heights, Ill.) to estimate the rate of DNAsynthesis. For RNA 
Cancer Res 50: 1426-1430, 1990; Marquardt D and Center and protein syntheses, cells were incubated at 37" C. for 3 
M S: J Natl Cancer Inst 83: 1089-1109, 1991; Krishnama- h in the presence or absence of drugs and then pulse-labeled 
chary N and Center M S; Cancer Res 53: 3658-3661,1993). for an additional 1 h with 2 pCi of (5,6-3H]uridine (46 
Every 4 weeks, these HL-60-RV and HL-60-R8 sublines 3s Ciimmol; ICN Biomedicals, Irvine, Calif.) or 2.5 pCi of 
were exposed to 41 nM DAU for 48 h to stabilize their MDR [4,5-3H]L-leucine(100 Ciimmol; Moravek Biochemicals, 
phenotype. This concentration of DAU, which is not cyto- Brea, Calif.), respectively. The incubations were terminated 
toxic to MDR HL-60 sublines, was removed from the by the addition of 0.5 ml of 10% trichloroacetic acid (TCA). 
culture medium at least 48 h before experimentation. Since After holding on ice for 15 min, the acid-insoluble material 
drugs were supplemented to the culture medium in 1 pl 40 was recovered over Whatman GFiA glass microfibre filters 
aliquots, the concentration of vehicle in the final incubation and washed thrice with 2 ml of 5% TCA and twice with 2 
volume (0.5 ml) did not affect basal activity levels in control ml of 100% EtOH. After drying the filters, the radioactivity 
tumor cells incubated in the absence of drugs. RFs were bound to the acid-precipitable material was determined by 
determined by dividing the IC,, of the MDR cells by that of liquid scintillation counting (LSC) in 10 ml of Bio-Safe NA 
the sensitive WT parent cell line. 4s (Researeh Products International Corp., Mount Prospect, 
Cell Proliferation Assay Ill.). 
For tumor cell growth, L1210 cells were resuspended in Nucleoside Transport 
fresh FCS-containing RPMI 1640 medium, plated at an L1210 cells (about 1 . 5 ~ 1 0 ~  cellsi0.5 ml) were preincu- 
initial density of lx104 cellsi0.5 ml, and incubated in bated for 15 rnin at 37" C. in the presence or absence of TTs 
48-well Costar cell culture plates (Costar, Cambridge, SO and then exposed to 1 pCi of 3H-thymidine for only 30 sec 
Mass.). Except when otherwise specified, cells were grown to assess the cellular uptake of nucleoside over such very 
for 4 days in the presence or absence of drugs and their short period of time. HL-60-S, HL-60-RV and HL-60-R8 
density was monitored every 24 h using a Coulter counter cells ( 1 . 2 ~ 1 0 ~  cellsi0.5 ml) were preincubated for 15 rnin at 
(Coulter Electronics, Luton Beds, UK). 37" C. in the presence or absence (control) of drugs and then 
HL-60-S, HL-60-RV and HL-60-R8 cells were resus- ss exposed to 1 pCi of [2,8-3H]adenosine (30 Ciimmol; Ameri- 
pended in fresh FCS-containing RPMI 1640 medium, can Radiolabeled Chemicals, St. Louis, Mo.) or [methyl- 
seeded in triplicate at an initial density of 1 . 5 ~ 1 0 ~  cellsi0.5 3H]thymidine (50 Ciimmol; Amersham, Arlington Heights, 
ml and incubated at 37" C. in 48-well Costar cell culture Ill.) for only 30 s to, respectively, assess the cellular uptake 
plates (Costar, Cambridge, Mass.). Tumor cells were grown of purine and pyrimidine nucleosides over such very short 
for 4 days in the presence or absence (control) of drugs and 60 period of time Reactions were diluted with 2 ml of ice-cold 
their density was monitored every 24 h using a Z1 dual Ca2'/Mg2'-free Dulbecco's phosphate buffered saline (PBS) 
threshold Coulter counter (Beckman Coulter, Miami, Fla.). and the unincorporated radiolabel was removed by centrifu- 
Cell Viability Assay gation at 200xg for 10 min. After washing thrice with 2 ml 
L1210, HL-60-S, HMO-RV and HL-60-R8 cells sus- of ice-cold PBS, intact cell pellets were harvested by cen- 
pended in FCS-containing RPMI 1640 medium were grown 65 trifugation and incubated for 30 rnin in 1 ml of hypotonic 
in 48-well Costar cell culture plates for up to 4 days in the lysis buffer (HLB) containing 10 mM Tris-HC1, pH 8.0, 1 
presence or absence of drugs to evaluate drug cytotoxicity. mM EDTA and 0.2% Triton X-100. Cell lysates were mixed 
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with 9 ml of Bio-Safe I1 (Researeh Products International) and its C2-brominated derivative TT13 at 256 nM, can 
and counted to estimate the cellular uptake of 3H-thymidine. inhibit leukemic cell proliferation and viability by 67-68% 
Drug inhibition was expressed as % of 3H-thymidine or and 73-75%, respectively (FIG. 1). FIG. 2 shows the same 
3H-adenosine transported into vehicle-treated control cells experiment for additional TT compounds. 
over similar 30-sec period. DAU is a clinically valuable anthracycline antibiotic, 
Mitotic Index which also contains a quinone moiety. At concentrations 
L1210 cells (about 1 ~ 1 0 ~ 1 0 . 5  ml of FCS-containing 2640 nM, TT2 inhibits almost totally the proliferation and 
RPMI 1640 medium) were incubated in triplicate for 24 h at viability of L1210 cells at day 4 but these maximal cytostatic 
37" C. in the presence or absence of TTs or known antimi- and cytotoxic activities of TT2 can be mimicked by con- 
totic drugs, and collected by centrifugation at 200xg for 10 i o  centrations of DAU as low as 102 nM and the smallest 
rnin to determine their mitotic index. For hypotonic concentrations of TT2 and DAU that can induce significant 
treatment, cells were resuspended in 1 ml of 75 mM KC1 for antiproliferative and cytotoxic effects after 4 days are 41 and 
20 rnin at 4" C. After fixation in 1 ml of Me0H:acetic acid 16 nM, respectively (FIGS. 3 & 4). These relative potencies 
(3:1), the final cell pellets were collected by centrifugation, of TT2 and DAU can easily be compared using the full 
resuspended in 75 pl of Me0H:acetic acid (3:1), dispensed is concentration-response curves of FIGS. 3 and 4, where the 
onto glass slides, air dried, and stained by spreading 4Opl of striped areas at 100% represent the control levels of L1210 
0.1% crystal violet under a coverslip. The % of cells in cell growth and viability after 2 and 4 days in culture. The 
mitosis was determined microscopically by counting 500 magnitudes of the cytostatic and cytotoxic effects of both 
cellsislides. The mitotic index was calculated as the % of TT2 and DAU are clearly related to the combination of their 
mitotic cells in drug-treated cultures divided by the % of 20 increasing concentration and duration of action. For 
mitotic cells in non-treated controls. instance, 16 nM DAU and 41 nM TT2 are ineffective at day 
DNA Cleavage 2 but their antiproliferative (FIG. 3) and cytotoxic (FIG. 4) 
Drug-induced DNA cleavage was determined by intact activities become apparent at day 4. Moreover, 41 nM DAU 
chromatin precipitation, using L1210, HL-60-S, HL-60-RV and 256 nM TT2 are moderately cytostatic (42 and 44% 
and HL-60-R8 cells which were prelabeled with 1 pCi of zs inhibition, respectively) and cytotoxic (32 and 49% 
3H-thymidine for 2 h at 37" C., washed with 3x1 ml of inhibition, respectively) at day 2 but respectively decrease 
ice-cold PBS, collected by centrifugation, and resuspended L1210 cell proliferation by 77 and 68% and L1210 cell 
in fresh FCS-containing RPMI 1640 medium at a density of viability by 65 and 79% at day 4 (FIGS. 3 & 4). As a result, 
about 1x106 cellsi0.5 ml for L1210 and 0 . 5 ~ 1 0 ~  cellsi0.5 ml the antiproliferative activities of DAU and TT2 are respec- 
for HL cells. Except when otherwise specified, such cells 30 tively characterized by IC,, values of 50 and 300 nM at day 
containing prelabeled DNA were then exposed for 24 h to 2 but 25 and 150 nM at day 4, suggesting that DAU is about 
TTs and drugs known to induce DNA fragmentation. After 6 times more cytostatic than TT2 in the L1210 tumor system 
centrifugation at 200xg for 10 rnin to discard the drugs and in vitro (FIG. 3). Similarly, the inhibitions of tumor cell 
wash the cells, the intact cell pellets were lysed for 30 rnin viability by DAU and TT2 are respectively characterized by 
in 0.5 ml of HLB, centrifuged at 12,OOOxg for 30 rnin to 3s IC,, values of 70 and 250 nM at day 2 but 30 and 100 nM 
collect the supernatants, and resuspended in 0.5 ml of HLB. at day 4, suggesting that DAU is about 3.5 times more 
After another similar centrifugation, the radioactivities in cytotoxic than TT2 in this leukemic system in vitro (FIG. 4). 
the pooled supernatants (detergent-soluble low molecular HL 
weight DNA fragments) and the pellet (intact chromatin The concentration-dependent inhibitions of HL-60-S, 
DNA) were determined by LSC: % DNA fragmentation= 40 HL-60-RV and HL-60-R8 cell proliferation by DAU are 
[cpm in supernatanticpm in supernatant+pellet]xlOO. Before respectively characterized by IC,, values of 14,500 and 320 
being counted in 6 ml of Bio-Safe NA, the intact pelleted nM at day 2 (FIG. 5A) and 9,275 and 225 nM at day 4 (FIG. 
chromatin was incubated for 2 h at 60" C. in the presence of 5B). Such RFs of 22.9-35.7 at day 2 and 25.0-30.6 at day 
0.6 ml of NCS tissue solubilizer (Amersham). 4 demonstrate that DAU is about 30 times less effective as 
Results 4s a cytostatic agent in MDR than in WT HL-60 cells (FIG. 5).  
Drugs In contrast, the concentration-dependent inhibitions of 
The TT quinones under study were synthesized in the HL-60-S, HL-60-RV and HL-60-R8 cell proliferation by 
laboratory by an in-situ oxidation of substituted dihydroxy- TT2 are respectively characterized by similar IC,, values of 
benzenes followed by [4+2]cycloaddition with 1,4- 400,500 and 350 nM at day 2 (FIG. 6A) and 300,260 and 
dimethoxyanthracene and then oxidation. This method of SO 290 nM at day 4 (FIG. 6B). These negligible RFs (0.9-1.3 
synthesis is reported below. The chemical structures of the at day 2 and 0.9-1.0 at day 4) suggest that TT2 retains its 
TTs tested for their antileukemic activity in vitro are shown effectiveness as a cytostatic agent in MDR cells that have 
in Scheme 1 (serial numbers indicate the order of synthesis). become 30 times less sensitive to the antiproliferative action 
Inhibition of Tumor Cell Growth and Viability by TTs of DAU (FIG. 6). 
L1210 ss Since DAU decreases the viability of HL-60-S, HL-60- 
When tested at 256 nM over a 4-day period, several 7Ts RV and HL-60-R8 cells with respective IC,, values of 80,1,  
inhibit the rate of tumor cell growth in relation with their 900 and 2,500 nM at day 2 (RFs: 23.8-31.3) and 15,450 and 
ability to decrease tumor cell viability (FIG. 1). Although 380 at day 4 (RFs: 25.3-30.0), this drug is about 28 times 
most of these drugs are much more active at higher less potent as a cytotoxic agent in MDR than in WT HL-60 
concentrations, at this lower concentration of 256 nM, TT4 60 cells (FIG. 7). In contrast, TT2 reduces cell viability as 
and TT12 are inactive and T T l l  and TTlO have only effectively in HL-60-S (IC,,: 1,300 and 230 nM at days 2 
marginal and weak inhibitory effects. In contrast, 256 nM and 4) as in HL-60-RV (IC,,: 1,100 and 340 nM at days 2 
TT3, TT5, TT6 and TT8 have moderate cytostatic (32-45% and 4) and HL-60-R8 (IC,,: 1,600 and 350 nM at days 2 and 
inhibition) and cytotoxic (41-54% inhibition) activities. 4) cells (FIG. 8). Such negligible RFs (0.9-1.2 at day 2 and 
Under similar conditions, TT1, TT7 and TT9 are more 65 1.5 at day 4) demonstrate that the cytotoxic potency of TT2 
effective and can reduce the number and viability of L1210 persists in MDR tumor sublines that have become 28 times 
cells at 4 days by 55-57% and 61-66%, respectively. TT2 less sensitive to the cytotoxic activity of DAU (FIG. 8). 
s 
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Inhibition of DNA Synthesis and Nucleoside Transport by 2.5 pM) and HL-60-R8 (IC,,: 1.7 pM) cells are character- 
TTs ized by RF values of 8.1-11.9 (FIG. 14A). In contrast, TT2 
L1210 inhibits the rate of incorporation of 3H-thymidine into DNA 
A 2-h treatment with TT2 is sufficient to inhibit, in a as effectively in HL-60-S (IC,,: 1.8 pM) as in HL-60-RV 
concentration-dependent manner, the rate of DNA synthesis s (IC,,: 2.1 pM) and HL-60-R8 (IC,,: 2.1 pM) cells and there 
determined over a 30-min period of pulse-labeling in L1210 are no significant RFs (1.2), indicating that TT2 maintains its 
cells in vitro (FIG. 9). DNA synthesis is totally inhibited by ability to inhibit DNAsynthesis in MDR tumor sublines that 
25 pM TT2 but, as compared to DAU which becomes have become 10 times less sensitive to the action of DAU 
effective against DNAsynthesis at 0.256 pM, concentrations (FIG. 14B). 
greater than 1.6 pM must be used to demonstrate the i o  DAU, which fails to significantly inhibit nucleoside trans- 
inhibitory effect of TT2 on DNA synthesis. Hence, the port in WT HL-60-S parental cells, is also unable to do so 
concentration-dependent inhibitions of DNA synthesis by in their two MDR sublines (FIG. 15). In contrast, TT2 is a 
DAU (IC,,: 1 pM) and 7T2 (IC,,: 6 pM) suggest that, under quinone antitumor drug that has the advantage of rapidly 
these experimental conditions, DAU prevents L1210 cells blocking, in a concentration-dependent manner, the cellular 
from synthesizing DNA about 6 times more effectively than is transport of both purine and pyrimidine nucleosides in 
TF2 (FIG. 9). HL-60-S cells (FIG. 15). Moreover, the ability of TT2 to 
Acritical finding is that, in contrast to DAU which serves prevent the cellular transport of 3H-adenosine and 
as a negative control in the assay, a 15-min treatment with 3H-thymidine in WT HL-60-S cells (IC,,: 3.3 and 2.0 pM, 
TT2 is sufficient to block, in a concentration-dependent respectively) fully persists (RFs: 1.0-1.2) in both the MDR 
manner, the cellular transport of 3H-thymidine occuring over 20 HMO-RV (IC,,: 3.2 and 2.0 pM, respectively) and HL-60- 
only 30 sec in vitro (FIG. 10). Nucleoside transport is totally R8 (IC,,: 3.7 and 2.3 pM, respectively) cell lines (FIG. 15). 
inhibited in L1210 cells treated with 25 pM TT2. But 10 pM Inhibition of RNA and Protein Syntheses by TTs 
DAU is totally unable to alter the cellular transport of Besides DNAsynthesis, a 3-h treatment with TT2 can also 
3H-thymidine (FIG. lo), even though such concentration of inhibit, in a concentration-dependent manner, the rates of 
DAU inhibits maximally the incorporation of 3H-thymidine zs RNA (FIG. 16) and protein (FIG. 17) syntheses determined 
into DNA(F1G. 9). Interestingly, the concentration-response over 60-min periods of pulse-labeling in L1210 cells in 
curves for the inhibitory effects of TT2 on nucleoside vitro. The concentration-response curves for the inhibitions 
transport (FIG. 10) and DNA synthesis (FIG. 9) are nearly of RNA (FIG. 16) and protein (FIG. 17) syntheses by TT2 
identical and share similar IC,, values of 6 pM, suggesting are nearly identical to that for the inhibition of DNA 
that the inhibition of 3H-thymidine incorporation into DNA 30 synthesis (FIG. 8): concentrations of TT2 greater than 1.6 
caused by TT2 at 2 h (FIG. 9) may largely be due to the pM must be used to demonstrate effectiveness, total inhibi- 
ability of this TT quinone to immediately block the uptake tion is achieved at 25 pM, and the IC,, value in all cases is 
of 3H-thymidine by the cells (FIG. 10). about 6 pM. Under similar conditions, DAU inhibits the 
Moreover, when compared on an equal 7 pM concentra- respective syntheses of RNA (IC,,: 0.8 pM) and protein 
tion basis, the different magnitudes at which various 7Ts 3s (IC,,: 2 pM) about 7.5 and 3 times more effectively than 
inhibit DNA synthesis at 2 h correlate with the different TT2 (FIGS. 16 & 17). 
abilities of these compounds to block the cellular transport Effects of TTs on the Mitotic Index 
of nucleosides after 15 min (FIG. 11). Indeed, among all TTs Control populations of L1210 cells cultured for 24 h in the 
tested at this concentration, TT4 and TT12 alter neither DNA absence of drugs contain only 1.86% of mitotic cells (FIG. 
synthesis nor nucleoside transport, whereas TT2 and TT13, 40 IS). In relation with their ability to block tubulin polymer- 
which block the most the cellular transport of 3H-thymidine ization and cell cycle progression in M-phase, 24-h treat- 
(72-75% inhibition), are also the most potent against the ments with VCR and the tricyclic pyrone H10 respectively 
incorporation of 3H-thymidine into DNA (69-71% produce 16- and 7-fold increases in the mitotic index (FIG. 
inhibition) (FIG. 11). Under similar conditions, TT1, 7T3, IS). Such known microtubule de-stabilizing anticancer 
TT7, TT9 and T T l l  inhibit nucleoside transport by 44-57% 4s drugs, therefore, serve as positive controls in this antimitotic 
and DNAsynthesis by 41-58%, whereas TT5, TT6, TT8 and assay. In contrast, none of the concentrations of TT2 tested, 
TTlO are less effective, inhibiting both responses in the even those in the pM range that are highly cytostatic and 
20-35% range only (FIG. 11). cytotoxic at 24 h, are able to raise the mitotic index of L1210 
Finally, the abilities of 10 and 25 pM TT2 to respectively cells (FIG. IS), suggesting that TT quinones are unlikely to 
inhibit nucleoside transport by 67 and 93% and DNA SO be antimitotic drugs that disrupt microtubule dynamics to 
synthesis by 69 and 97% are both irreversible upon drug trigger their anticancer activity. In relation with its known 
removal (FIG. 12), suggesting that, after a 15- to 60-min ability to first accumulate cells in G, and then inhibit cell 
pretreatment, the presence of TT quinone in the culture cycle traverse as its concentration increases, DAU actually 
medium is no longer required to continually block the decreases the % of mitotic cells by 74-91% (FIG. IS). Since 
cellular transport of 3H-thymidine and thereby prevent its ss the highest concentrations of TT2 tested significantly 
incorporation into DNA. For the sake of comparison, the decrease the % of mitotic cells by 3 8 4 8 %  (FIG. IS), TTs 
inhibitions of nucleoside transport and DNA synthesis might also prevent tumor cell cycle progression to mitosis. 
caused by the novel tricyclic pyrone analog H10, which are Induction of DNA Cleavage by TTs 
fully reversible upon drug removal, are demonstrated as a L1210 
positive control under similar experimental conditions in the 60 L1210 cells containing 3H-thymidine-prelabeled DNA 
L1210 tumor assay system (FIG. 12). were used to quantitatively determine whether TTs could 
As shown in FIG. 13, TT16 is as potent as 7T2 on both induce DNA fragmentation over a 24-h period in vitro. CPT 
DNA synthesis and the cellular transport of adenosine and and DAU, two anticancer drugs known to induce DNA- 
thymidine. strand breaks by respectively inhibiting Top0 I and I1 
HL 65 activities, are used as positive controls in this DNA frag- 
The concentration-dependent inhibitions of DNA synthe- mentation assay (FIG. 19). As reported before with anthra- 
sis by DAU in HL-60-S (IC,,: 0.21 pM), HL-60-RV (IC,,: cycline quinone antibiotics, the concentration-dependent 
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induction of DNAcleavage caused by 24-h DAU treatments by DAU is biphasic, peaking 67% above control level (15% 
is biphasic, peaking at 45% in response to 1.6 pM DAU but DNA fragmentation) in HL-60-S cells treated for 24 h with 
declining back to control level (5%) at higher concentrations 1.6 pM DAU but declining back to (18% above control at 4 
of DAU (FIG. 19). In contrast, the concentration-dependent pM), or even below (11 and 14% below control at 10 and 25 
increase of DNAcleavage produced by 24 h CPT treatments s pM, respectively), control level at higher concentrations of 
reaches 57% in response to 1.6 pM CPT but remains at a DAU (FIG. 23A). Although 7T2 is somewhat less potent 
plateau of maximal stimulation (60-70%) at higher concen- than DAU, the concentration-dependent induction of DNA 
trations of CPT (FIG. 19). After 24 h, the maximal levels of cleavage caused by this compound in HL-60-S cells is 
DNAcleavage caused by 10 pM 7T1(45%) and TT2 (61%) similarly biphasic, with a peak 37% above the control % of 
respectively match those induced by 1.6 pM DAU and CPT i o  DNA fragmentation at 4 pM, followed by a decline toward 
(FIG. 19). Although concentrations of 7Ts higher than those (14% above control at 10 pM), or even below (11% below 
of DAU are required to induce such peak of DNA cleavage, control at 25 pM), the control % of DNA fragmentation at 
the shape of the concentration-response curves for the ability higher concentrations (FIG. 23B). Interestingly, the ability 
of 7T1 and TT2 to break DNAresembles more that of DAU of DAU to trigger maximal or submaximal DNAcleavage in 
than that of CPT (FIG. 19), suggesting that the DNA- is WT cells is totally lost, drastically reduced and/or shifted 
damaging effects of TT quinones and DAU might share toward higher concentrations in the MDR cell lines (FIG. 
some similarity. 23A). For instance, the 0.04-0.64 pM concentrations of 
Overall, the different TTs compared at 7 pM induce DAU producing submaximal stimulations of DNAcleavage 
various levels of DNA cleavage at 24 h (FIG. 20) in relation (11-58% above the control level of 15%) in HL-60-S cells 
with their respective cytostatic and cytotoxic activities when 20 are almost totally unable to a do so in the HL-60-RV and 
tested at 256 nM for 4 days (FIG. 1). Indeed, TT2 and TT13, HL-60-R8 cell lines. Moreover, the magnitude of the peak of 
which are the most potent against L1210 cell proliferation maximal DNA cleavage caused by DAU in WT cells is not 
and viability (FIG. l) ,  again induce the most DNAfragmen- only reduced by 60 and 79% in HL-60-R8 and HL-60-RV 
tation (54-57%) after 24 h (FIG. 20), whereas TT4 and cells, respectively, but it is also shifted from 1.6 to 10 pM in 
TT12, which have no antileukemic activity in the growth zs the latter MDR subline (FIG. 23A). As a result, the ability 
and viability assays (FIG. l) ,  also fail to significantly raise of 10-25 pM DAU to decrease DNAcleavage below control 
the level of DNA cleavage (4-6%) over control (5%) (FIG. level in WT cells is totally or partially lost in the MDR cell 
20). TT1, TT7 and TT9, which have good antileukemic lines. In contrast, the ability of TT2 to induce a peak of DNA 
activities (FIG. l) ,  also produce substantial levels of DNA cleavage at 4 pM and abolish the basal level of DNA 
fragmentation (31-40%) (FIG. 20). Moreover, the extent of 30 cleavage at 25 pM in WT cells is pretty much unaltered in 
DNA cleavage is only 14-18% in L1210 cells treated with the two MDR sublines, although the magnitude of maximal 
TT3, TT5, TT6, TT8 or TTlO and the ability of T T l l  to stimulation observed in HL-60-S cells is reduced by 35 and 
break DNA is minimal (7%) (FIG. 20), in relation with the 39% in the HL-60-R8 and HMO-RV cells, respectively 
weak and marginal antiproliferative and cytotoxic effects of (FIG. 23B). 
these compounds in the L1210 system in vitro (FIG. 1). FIG. 3s The comparison studies show that the different magni- 
21 shows the same experiment as in FIG. 20 with additional tudes at which equimolar concentrations of various TT 
analogs. analogs inhibit tumor cell proliferation match very well the 
Finally, L1210 cells treated for only 3 and 8 h with 10pM different cytotoxic activities of these compounds (FIG. 1). 
TT1 or TT2 have the same level of DNAfragmentation at 24 Moreover, the different levels of DNA fragmentation 
h (36-45% or 58-67%, respectively) than if they are 40 induced by the various TT analogs (FIG. 20) match exactly 
exposed for the whole 24-h incubation period to TT1 or TT2 the ranking of these compounds for their cytostatic/cytotoxic 
(40 or 63%, respectively) (FIG. 22). Under similar effects (FIG. l) ,  suggesting that the ability of TT analogs to 
conditions, 1.6 pM DAU and CPT also rapidly trigger break DNA plays a significant role in their molecular 
molecular events, which are irreversible and produce iden- mechanism of antitumor activity. In addition, the various TT 
tical levels of DNA fragmentation at 24 h (33-41% and 4s analogs inhibit DNA synthesis in relation with their effec- 
51-58%, respectively), whether or not those drugs are tiveness against nucleoside transport (FIG. l l ) ,  suggesting 
maintained in the culture medium after 3 or 8 h (FIG. 20). that they prevent DNA assembly because they block the 
It should be noted that no significant elevation of DNA cellular uptake of DNA precursors. Because of their ability 
cleavage is detectable in this assay after 3 and 8 h of drug to interact with both membrane and nuclear targets to block 
exposure and that the increases of DNA fragmentation SO nucleoside transport, inhibit nucleic acid and protein 
caused by TTs, DAU and CPT only appear after 12 h to syntheses, cleave DNA, and reduce tumor cell growth and 
reach a maximal level at 24 h (data not shown), suggesting viability in the nM range in vitro, these TT analogs represent 
that the irreversible events triggered by those drugs during a novel synthetic class of bifunctional anticancer drugs 
the initial 3 h still require a substantial period of time, valuable to develop new means of polychemotherapy. 
irrespective of the continual presence or absence of drugs, to ss The cytostatic and cytotoxic effects of each concentra- 
fully induce DNA fragmentation. These results suggest that, tions of TT2 increase with the time in culture (FIGS. 3 and 
like anticancer drugs known to induce DNA-strand breaks, 4), suggesting that the effectiveness of TT analogs as inhibi- 
TT quinones interact rapidly with cellular targets to induce tors of tumor cell proliferation and viability in vitro is a 
long-lasting DNA-damaging effects, which develop and combination of drug concentration and duration of drug 
persist after drug removal. 60 exposure. As a result, TT2 inhibits L1210 tumor cell growth 
HL at 2 and 4 days with IC,, values of 300 and 150 nM, 
Tumor cells containing 3H-thymidine prelabeled DNA respectively, in relation with its ability to reduce L1210 
were used to quantitatively determine whether TT2 would tumor cell viability with IC,, values of 250 nM at day 2 and 
induce DNA fragmentation as effectively in WT as in MDR 100 nM at day 4. The IC,, required to reduce tumor cell 
HL-60 cell lines that have become resistant to the DNA- 65 viability at day 4 (100 nM) may be lower and perhaps more 
damaging effects of DAU (FIG. 23). As reported before, the accurate than that observed for tumor cell growth inhibition 
concentration-dependent induction of DNA cleavage caused at day 4 (150 nM) because the Coulter counter data include 
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all viable and nonviable tumor cells that have previously 
accumulated and remain in the medium at day 4, irrespective 
of their present metabolic status and reproductive ability. 
Moreover, decreased tumor cell viability after several days 
of drug treatment may be a better predictor of anticancer 
activity than antiproliferation since growth delay may allow 
survivors to resume dividing and expand clonally once the 
drug is catabolized or eliminated and its effect is waning. 
Overall, the new TT bisquinone TT2 is a potent antitumor 
agent, which is active in the nM range and is only 3.5-6 
times less cytostatic/cytotoxic after 4 days than equimolar 
concentrations of the clinically proven anthracycline 
quinone antibiotic DAU, a very potent anticancer drug used 
as an arbitrary reference in our L1210 tumor cell studies in 
vitro (FIGS. 3 and 4). When IC,, values are compared, TT2 
also inhibits the syntheses of DNA, RNA and protein in 
L1210 cells after 2-3 h about 3-6 times less effectively than 
DAU (FIGS. 9,16 and 17) and concentrations of TT2 about 
6 times higher than those of DAU are also required to induce 
the same peak of DNA cleavage in L1210 cells after 24 h 
(FIG. 19). But in addition to mimicking all the antitumor 
effects of DAU studied, the data demonstrate that TT2 
remarkably blocks the cellular transport of nucleosides, 
which DAU cannot do (FIG. lo), suggesting that these novel 
antitumor TT bisquinones may have a more versatile mecha- 
nism of action and be advantageous in polychemotherapy to 
potentiate the anticancer effects of antimetabolites and cir- 
cumvent multidrug resistance (MDR). For both DAU and 
TT2 concentrations in the 25-150 nM range are sufficient to 
inhibit tumor cell growthiviability (FIGS. 3 and 4), whereas 
higher concentrations in the 0.8-10 pM range must be used 
to inhibit macromolecule syntheses (FIGS. 9,16 and 17) and 
maximally induce DNAfragmentation (FIG. 19). But appar- 
ent discrepancies in potencies may be due in part to different 
experimental conditions and cellular responses to various 
periods of drug exposure: the rates of nucleic acid and 
protein syntheses over 3&60 min are inhibited in cells 
treated for only 2-3h with TT2 or DAU, whereas the level 
of DNA cleavage and the reduction of tumor cell growth/ 
viability are the results of 1- and 4-day long drug treatments, 
respectively. It should be noted that no significant DNA 
fragmentation can be detected within the first 8 h of TT2 or 
DAU treatments and that concentrations of DAU and TT2 
respectively greater than 0.25 and 1.6 pM must be used to 
induce substantial antiproliferative and cytotoxic effects 
after only 24 h of drug exposure (data not shown). 
The fact that, within 24 h, TT1 and TT2 can produce as 
much internucleosomal DNA fragmentation in L1210 cells 
than the known Top0 I and I1 inhibitors CPT and DAU (FIG. 
19) suggests that the ability of TT quinones to produce 
DNA-strand breaks may play a major role in their mecha- 
nism of antitumor activity. Since the shapes of the 
concentration-response curves for the effects of TT1 and 
TT2 on DNA cleavage resemble the biphasic response to 
DAU, which has already been reported and discussed 
before, it is tempting to speculate that the mechanisms by 
which TT quinones and DAU induce DNA fragmentation 
share some similarity and that DNA cleavage is not always 
necessary for high concentrations of TT quinones and DAU 
to be cytotoxic. The Top0 11-associated DNA lesions occur- 
ing in cells exposed to anthracycline quinone antibiotics 
may facilitate subsequent internucleosomal DNA fragmen- 
tation by endogenous nucleases and trigger apoptosis. Since 
apoptosis is an active and cell cycle phase specific process, 
which requires the expression of specific genes, the synthe- 
ses of new RNA and proteins and the activation of endo- 
nuclease enzymes, inhibitors of such mechanisms can pre- 
32 
vent DNA fragmentation in anthracycline-treated cells. In 
spite of their increasing cytotoxicity, the highest concentra- 
tions of TT1, TT2 and DAU tested in our study might inhibit 
RNA and protein syntheses, reduce the level of Top0 I1 
5 targets, inactivate endonucleases and/or arrest cell cycle 
traverse to such degrees that they actually block the molecu- 
lar mechanisms required for internucleosomal DNA frag- 
mentation and apoptosis and produce the paradoxical bipha- 
sic curve of DNA cleavage shown in FIG. 19. Taken 
together, the irreversibilities of the inhibitions of nucleoside 
transportDNA synthesis and of the induction of DNA 
fragmentation upon TT2 removal suggest that, because TT 
analogs may rapidly and tightly interact with various mem- 
brane and intracellular targets, their presence is soon no 
longer required in the medium to disrupt the structures/ 
functions of nucleoside transporters, nucleic acids and pro- 
teins and to trigger long-lasting antitumor events, which 
persist after cessation of drug treatment. 
Combining drugs, which target different molecules and 
achieve complementary or synergistic antitumor effects, is 
20 an important strategy in cancer chemotherapy. ATT quinone 
inhibiting nucleoside transport and inducing DNA cleavage 
might disrupt a wider spectrum of molecular targets in 
populations of unsynchronized tumor cells than another drug 
affecting a single of these events. Nucleoside transporters in 
25 mammalian plasma membranes function by equilibrative 
(facilitated diffusion) or Na'-dependent (concentrative) 
mechanisms. All nucleosides are substrates for the Na'- 
independent transporters but Na'-dependent transporters 
generally accept purine rather than pyrimidine nucleosides 
a s  s u b s t r a t e s .  D i p y r i d a m o l e  ( D P R ) ,  6 - ( 4 -  
30 nitrobenzy1mercapto)purine ribonucleoside (NBMPR) and 
dilazep are standard potent inhibitors of equilibrative 
nucleoside transport, whereas phloridzin specifically inhib- 
its Na'-dependent nucleoside transport. Like TT2, NBMPR 
and DPR also reduce 3H-thymidine incorporation into DNA. 
35 Nucleoside transport inhibitors block equally well the influx 
and efflux of nucleosides. L1210 cells possess 3 distinct 
nucleoside transporters: 2 equilibrative transporters sensi- 
tive (es) or insensitive (ei) to NBMPR and one Na'- 
dependent transporter (cif), of low sensitivity to NBMPR 
For nucleotide synthesis, cells use purine and pyrimidine 
nucleosides generated either through de novo synthesis or 
through the utilization of salvage pathways. MDR is some- 
times associated with increases in the number of nucleoside 
45 transporters and their rate of transport, resulting in the 
increased uptake of adenosine. By blocking the rescue effect 
of exogenous nucleosides, NBMPR, DPR and dilazep may 
potentiate or prolong the antitumor activity of antimetabo- 
lites which inhibit the de novo pathway for nucleoside 
SO synthesis. The clinical effectiveness of ADR and DAU is 
limited by their cumulative cardiotoxicity and ability to 
induce MDR. The multifactorial mechanisms of MDR to 
anthracycline quinone antibiotics may include altered 
expressions of P-glycoprotein (P-gp), Top0 I1 and multidrug 
ss resistance-associated protein, increased DNA repair and 
glutathione-dependent detoxifying enzyme activities, and 
alterations in cell cycle progression and apoptotic pathways. 
DPR circumvents ADR resistance and its analog, BIBW 22, 
is a bifunctional modulator which reverses the MDR phe- 
60 notype by interfering with both P-gp and nucleoside trans- 
port in MDR cells. As bifunctional inhibitors of nucleoside 
transport and inducers of DNAcleavage, TT quinones might 
be valuable in polychemotherapy to potentiate the antitumor 
activity of methotrexate and 5-fluorouracil and sensitize 
65 MDR tumor cells that have become unresponsive to the 
cytotoxicity of other conventional DNA-damaging antican- 
cer agents. 
10 
40 and DPR. 
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7T2 is also cytostatic (ICso: 300 nM) and cytotoxic (ICso: 
230 nM) to WT human HL-60-S leukemic cells in the 
present study. Another attractive feature of TT2 identified in 
sdlmlL2 
the present study is the finding that this new quinone NaBH4 
RV antitumor and HL-60-R8 drug retains sublines its effectiveness that have in developed two MDR different HL-60- 5 c'rc!"; M;o:i€y 
mechanisms of resistance to DAU and, therefore, might not (95% yield) 
be recognized by either the P-gp or the MRP. 
The magnitude at which TT2 inhibits HL-60-S, HL-60- 
RV and HL-60-R8 cell proliferation (ICso values: 26Ck300 
values: 230-350 nM) in the same WT and MDR tumor cell 
lines at day 4. Moreover, the cytostatic and cytotoxic effects 
of each concentrations of TT2 obviously increase with the 15 
time in culture at days 2 and 4, suggesting that the effec- 
tiveness of TT2 as an inhibitor of tumor cell proliferation 
and viability is a combination of drug concentration and 
duration of drug exposure. Decreased WT and MDR tumor 
predictor of anticancer activity in vivo. However, it should 
be noted that DAU is about 3.5-6 times more cytostatic/ 
cytotoxic than TT2 in L1210 cells, even though TT2 appears 
more potent in the L1210 than in the HL-60-S cells. Hence, 
TT2 inhibits tumor cell growth, viability and DNAsynthesis 25 
respectively 33, 15 and 9 times less effectively than DAU in 
0 OH 
nM) matches its ability to decrease cell viability (ICso 3 
Na2S204 
1,4-dioxane 
H20 
r.t. 3 h cq)0 (87% yield) * 
cell viability after TT2 treatment in vitro may be a reliable 20 4 
NaH, Me1 
DMF, r.t. @ (80% yield) * 
the HL-60-S leukemic system (FIGS. 5-8, 10). Moreover, OH 
concentrations of TT2 at least 2.5 times greater than those of 5 
DAU are required to induce more than 50% of DNA 3o 
cleavage in HL-60-S cells at 24 h (FIG. 23). Nevertheless, 
the magnitudes of the inhibitory and stimulatory effects 
trigged by DAU and somewhat higher concentrations of 
TT2 are nearly identical in HL-60-S cells. But the critical 
finding is that the ability of TT2 to inhibit tumor cell growth, 35 
viability and DNA synthesis in HL-60-S cells persists unal- 
tered in the HL-60-RV and HL-60-R8 cell lines (RFs: 
0.9-1.5) while DAU becomes dramatically less effective 
against DNA synthesis (RFs: 8.1-11.9), cell proliferation 
(RFs: 22.9-35.7) and cell viability (RFs: 23.8-31.3) in these 40 
MDR HL-60 sublines than in their parental WT counter- 
parts. Finally, 7T2 which, in contrast to DAU, has the 
unique ability to rapidly block the cellular transport of both 
purine and pyrimidine nucleosides in L1210 (13) and Ashort syntheses of TT2, TT3, and TT5 were discovered. 
HL-60-S cells, retains such additional advantage in the 4s  Without the use of quinones as the dienophiles in the 
MDR HL-60 sublines (FIG. 15). These observations sub- Diels-Alder reaction, such as 2-methoxyquinone (8), a one- 
stantiate the hypothesis that, because of its bifunctional Pot Oxida t ion  [4+21cYc10addition O f  
mechanism of action, TT2 is a quinone antitumor drug 2-methoxyhydroquinone (6) with anthracene 1 was found 
which may be more versatile than DAU and able to circum- (Scheme 3). Hence, treatment of 2 equiv of 6, 1 equiv of 
vent MDR. anthracene 1, 2 equiv of silver oxide, and 0.2 equiv of zinc 
iodide in refluxing toluene for 24 h gave diketone 7 (51% 
yield; based on reacted l) ,  hydroquinone TT3 (26% yield; 
based on reacted l) ,  quinone TT5 (13% yield; based on 
In Situ Oxidation Followed by [4+2]-Cycloaddition: 
SYNTHESIS EXAMPLES 
Synthesis of TT2, 7T13 and Their Analogs: 
has been reported (Criswell, et al., J. Org. Chem. 1974, 39, 
sequential reduction of the diketo function with sodium 
borohydride in diglyme, the dificulty in the reduction steps 
ration of 1. Reduction of 3 with sodium borohydride in / / 
prompted us to investigate an easier method in the prepa- 60 
MeOH followed by quenching with HC1 gave a 95% yield 
of 1,4-anthraquinone (4) (Scheme 2). Reduction of the \ \ 
quinone moiety of 4 with aqueous sodium hydrosulfite in 
Although the preparation of 1,4-dimethoxyanthracene (1) ss reacted 1) and 55% recovery of 1. 
77Ck774) by using methylation of quinizarin (3) followed by Scheme.l 
@ 
1,4-dioxane provided 1,4-dihydroxyanthracene (5). Methy- 65 OMe 
lation of 5 with sodium hydride in DMF at room temperature 1 
gave excellent yield of 1. 
OMe 
I 
OMe 
1 
35 
-continued 
OH 
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-continued 
OMe 
i Agz0 
Zn12 
toluene 
reflux 24 h 
- 
Me0 
6 H  
6 
0 
8 
1s 
+ 
20 
7 
2s 
HO M e d  
Tr3 
4:2:1 
5 
1 OMe 
toluene 
sealed tube 
10 Me0 150" C., 24 h 
Me0 
M e 0  
7 
(48% yeild) 
30 Diketone 7 was converted into hydroquinone TT3 with 10 
equiv of KOH in 1,4-dioxane and water at 25" C. for 1 h in 
quantitative yield (Scheme 5). Oxidation of TT3 with 2 
equiv of silver oxide and sodium sulfate (anhydrous) in 
dried acetone under reflux for 6 h gave TT5 in quantitative 
yield. Oxidation of TT5 or TT3 or a mixture of 7T3 and TT5 
with ceric ammonium nitrate in acetonitrile-1,4-dioxane- 
water at 25" C. for 12 h gave excellent yields of TT2. 
3s 
SchemeS 
KOH 
1,Cdioxane 
* 
148 H20, r.t. 10 min 
(100% yield) 
M e 0  
T r S  
4a 108 
98 sa 8-7 
4 31 Alternatively, 7 can be obtained from the Diels-Alder reaction of quinone 8 with anthracene 1 (Scheme 4). Hence, 50 MeO 
oxidation of 6 with 1.5 equiv of silver oxide and 1.2 equiv 
of potassium carbonate in benzene at 25" C. for 3 h afforded 0 M e 0  
quantitative yield of quinone 8 which underwent cycload- 7 
dition with 1 gave a 48% yield of 7 as a mixture of endo- and 
exo-isomers (a ratio of 1:l)  at C4a and C9a. 
Scheme4 
OH 
Agz0 
benzene 
3 h  
K2c03 . 
Me0 
OH 
6 
5s 
60 
Ce(NH4)2(N03)6 
CH3CN, H20 
orland 
T r S  
(99% yield) 
65 
Ag20 
Na2S.04 
acetone 
reflux 6 h 
(100% yield) 
Tr3 D ? T  
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-continued 2-chlorohydroquinone ( l l ) ,  under similar reaction 
conditions, reacted with 1,4-dimethoxyanthracene (1) in the 
presence of silver oxide and zinc iodide under refluxing 
toluene to give a 73% yield of the chloro derivative 12 
(Scheme 7). 
!S&Cmd 
M e 0  
OMe 
1 
Agz0 
Zn12 
toluene 
reflux 24 h 
0 
T r 2  
Selective Bromination of 2-Methoxy Triptycene Quinone: 
A new bromination reaction was found (Scheme 6). 
Hence, when TT5 was treated with N-bromosuccinimide 
(NBS) in DMF at 40" C. for 12 h, a quantitative yield of the 
C-2 brominated product 9 was obtained. Without 
purification, compound 9 was directly subjected to the ceric 20 
ammonium nitrate oxidation and a 59% yield of TT13 was 
achieved. 
15 
. 
c1 
Schemek 2s 
6 H  
11 
NBS, DMF 
40" C. 12 h 
T r S  
13 
Ce(NH4)2(N03)6 * 
(59% overall yield) 
9 
13 
Tr13 
Syntheses of 2-Ch1oro-4a,9,9a,10-tetrahydro-9,10-[1',2'] 
benzenoanthracene-l,4-dione (lo), 7T8, TT9 and TT7: 
The in-situ oxidation and cyclization reaction is appli- 
cable to other hydroquinone substrates. For instance, 
40 
12 
Schemef( 
4s  
13 
Agz0 
Znl2 
toluene 
reflux 24 h 
- so 
M e 0  
OH 
6 
5s 
1) KOH, H20 
60 1,4-dioxane 
* 
2) Agz0 
Na2S04 
acetone 
(80% yield) 
M e 0  
0 
65 
Tr8 
39 
-continued 
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with 2 equiv of silver oxide and 1.2 equiv of potassium 
carbonate in benzene at 50" C. for 10 min under dark gave 
a quantitative yield of the corresponding quinone 16 
(Scheme 9). Diels-Alder reaction of 15 and anthracene 1 at 
5 70" C. for 14 h and then under reflux for 5 h gave 58% yield 
of 7Tll (as a mixture of endo- and exo-isomers) and 37% 
yield of TT10. 
Schrmr9 
10 M e 0  
Ag20 
SO" c .  
10 min. 
(100% yield) 
K2c03 * 
OH 
OMe 
0 
T r 9  
15 Me02C 
13 
toluene 
reflux 24 h 
(98% yield) 
- 20 
0 
2 
1) KOH, H20 
1,4-dioxane 
30 
2) Agz0 
Na2S04 
acetone 
(70% yield) 
0 
T r 6  
3s 
40 
0 
15 
13 
+ 
Tr13 & - 5> 4s  4 31 AMe 0 148 / lob 
4a 108 
5h 0 
98 sa 8-7 
Tr7 /31  
so Me02C 
M e 0  0 Similarly, treatment of 2-methoxyhydroquinone (6) with 
yield of the 2-methoxy derivative TT8 (Scheme 8). Basic 
isomerization of ketone 14 with 3 equiv of KOH in 1,4- 
dioxane and water at 25" C. for 2 h followed by oxidation ss Syntheses of TT4 and TT12: 
with silver oxide and sodium sulfate (anhydrous) in dried The triptycene bis-quinones such as TT1 could be treated 
acetone at 25" c .  for 3 h to give an 80% yield of quinone with dienes to produce various substituted triptycene ana- 
TT9. Quinone TT7 was prepared by the Diels-Alder reaction logs such as 7T4 and TT12 (Scheme 10). Hence, treatment 
of benzoquinone (2) with anthracene 13 to give adduct TT6 of TT1 with 2.2 equiv of dimethyl butadiene-2,3- 
(98% yield) which under similar isomerization and oxida- 60 dicarboxylate (16) (Hamon, et al., J. Chem. SOC. Chem. 
tion as those for the conversion of TT8 into TT9 gave TT7 Commun. 1981,873-4) in toluene under reflux for 20 h gave 
(70% yield for the last two steps). a 54% yield of TT4 and 14% yield of monoadduct 17. The 
Syntheses of TTlO and 7 T l l :  stereochemistry of TT4 was firmly established by a single- 
Contrary to the above results, when methyl gentisate (14) crystal X-ray analysis. Reduction of TT4 with 10 equiv each 
was used in the in-situ oxidation followed by [4+2] 65 of sodium borohydride and cerium trichloride heptahydrate 
cycloaddition reaction, only small amount of a mixture of in MeOH at room temperature for 12 h afforded an 89% 
products was isolated. Compound 14 was then oxidized first yield of TT12. The 'H and I3C NMR spectrum of TT12 
anthracene (13) and silver oxide and zinc iodide gave a 56% Tr10 
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indicated a single stereoisomer. It is anticipated that the 
hydride (sodium borohydride) should attack the carbonyl 
group from the exo face (b-face) and the stereochemistry is 
therefore assumed. 
Syntheses of TT14, TT15, and TT16: 
methylaminoquinone TT14 in 25% yield along with a 29% 
yield of TT15 by the treatment with methylamine in THF at 
room temperature for 20 min (Scheme 11). This reaction is 
unusual in that the nucleophile, methylamine, displaces the 
methoxy group of TT13 instead of the bromine. Again, 
unexpectedly, when TT13 was treated with dimethylamine 
in THF at 0" C., 7T16 was isolated as the only identificable 1s 
product (Scheme 12). The regiochemistry of the dimethy- 
lamino group of TT16 is tentatively assigned. 
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Bromomethoxyquinone TT13 can be converted into Me02C 
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\ 
C02Me 
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CeC13-7H20 
'lT4 MeOH,r.t 
(89% yield) 
* 
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* 
3s 
40 
Tr13 
13 
Tr14 
4s 
HO & 9a 1Ob 88 
10 
4a 108 5 67 / 3 4  MeNH 
0 0 
tr15 
Similar to the addition reaction of methylamine with 
TT13, other primary amines, such as ethyl b-alanine and 
L-lysine also add to 7T13 to provide the corresponding 
amino acid adducts 7T17-TT20 (Scheme 13). Hence, treat- 
ment of 7T13 with ethyl b-alanine (derived from ethyl 
b-alanine hydrochloride with 1 equiv of sodium hydride in 
THF) in THF and DMF at 25" C. to give a mixture of TT17 
and TT18 (based on the proton NMR spectrum of the crude 
product). Column chromatographic separation on silica gel 
gave TT18 in 69% yield. The ethyl ester function of TT18 
can be removed by treatment with sodium iodide in DMF 
with heat to give amino acid TT21 which is water soluble. 
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Under similar reaction conditions, TT13 was treated with 6.6816 g (MW 174; 0.0384 mol) of sodium hydrosulfite in 
L-lysine (derived from L-lysine monohydrochloride and 1 50 mL of distilled water and 50 mL of 1,4-dioxane were 
equiv of NaH in THF) in THF and DMF to give adducts added. The resulting mixture was stirred at room tempera- 
TT19 and TT20 which were purified on HPLC to give TT20 ture for 2-3 hours. The reaction progress is checked with 
(7T19 most likely hydrolyzes on the column to give TT20) s TLC (using CH,Cl,:hexanes:ether 1:1:0.2 as the eluant). 
.Hence, a number of water-soluble drugs can be obtained by The mixture was transferred to a 500-mL beaker slowly, 
adding amino acids or amino sugars onto TT13, by reactions cooled over an ice-water bath, and added 100 mL of distilled 
that are known in the art. water. Dark green solids precipitated. The beaker was cov- 
13 
1T13 
THF-DMF, rt * 
C02H 
H2N NH2 
(L-lysine) 
13 13 
+ 
1T19 1T20 
Icolumn chromatography (HPLC)t 
Preparation of 1,4-anthracenedione (4): ered with aluminum foil, and placed in the refrigerator for 1 
To a dried 100 mL-round-bottom flask equipped with h. The solid was filtered through a glass fritted funnel and 
stirring bar and serum cap, was added 1 g (MW 240.21; the product was washed with 30 mL of distilled water twice. 
0.0042 mol) of quinizarin (3). The compound was dried 45 The solid product was dried under vacuum to give 1.754 g 
under vacuum, and then maintained under argon. Methanol (87% yield), mp 167-169" C.; 'H NMR (CDC1, contains a 
(distilled over Mg), 20 mL, was added via syringe. The small amount of p-dioxane) d 8.7 (m, 2H, C 9,lO Hs), 8.05 
solution was stirred to dissolve the quinizarin and then (m, 2H, C 5,8 Hs), 7.5 (s,  2H, C 6,7 Hs), 6.6 (s,  2H, C 2,3 
cooled over an ice-water bath equipped with a thermometer. Hs). The diol is insoluble in chloroform but soluble in 
To it, 0.638 g (MW 38; 0.0168 mol) of sodium borohydride DMSO and DMF. 
was added. The resulting mixture was stirred at 0" C. for 1 Preparation of 1,4-Dimethoxyanthracene (1): 
hour. The progress of the reaction was monitored by TLC To a dried flask, 0.549 g (0.011 mol; 50% oil) of sodium 
(using hexanes: ether 1 : l  as the eluant). The reaction was hydride was added. The material was dried under vacuum 
quenched by adding carefully 11 mL of 6 N HC1 dropwise and flame and maintained under argon. To it 3 mL of 
at 0" C. over a period of 10 minutes. Orange solids precipi- distilled ether was added, stirred, and the ether layer con- 
tate. The solids were collected by filtration over a fritted 55 taining the oil was removed and discarded. To the sodium 
filter funnel, and washed several times with distilled water hydride flask, 1 g (0.0048 mol) of diol 5 was added and the 
to remove the acid. The solid was then dried under vacuum mixture was dried under vacuum and flame and maintained 
and recrystallize from acetone-ether to give 0.83 g (95% under argon. DMF (10 mL) was added via syringe and the 
yield) of yellow crystals, mp 204-206" C. solution was stirred at room temperature for 1.5 h. TLC of 
'H NMR (CDC1,) d ppm: 7.1 (s,  2H, C 2,3 Hs), 7.7 (dd, 60 a sample from the reaction solution indicated no starting 
J=6.4, 3.2 Hz, 2H, C 6,7 Hs), 8.1 (dd, J=6.4, 3.2 Hz, 2H, C material. The solution was diluted with 20 mL of water and 
5,8 Hs), 8.6 (s,  2H, C 9,lO Hs); I3C NMR (CDC1,) d ppm: 6 N HC1 until pH=2. The mixture was extracted with ethyl 
184.68 (s,  C=O), 140.06 (d), 134.83 (s) ,  130.22 (d), 129.59 acetate three time. The combined extract was washed with 
(d), 128.87 (d), 128.37 (s) .  water twice and brine, dried (MgSO,), concentrated to give 
Preparation of 1,4-Dihydroxyanthracene (5): 65 1.07 g (94% yield) fo the crude product (proton NMR 
To a 250 ml-round-bottom flask, was added 2 g (MW 208; spectrum indicated >90% pure). The product was recrystal- 
0.0096 mol) of 1,4-anthracenedione (4). To it a solution of lized from ether:hexane to give 0.89 g (78% yield) of black 
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solids, mp 255-258" C. 'H NMR (CDC1,) d 8.70 (s,  2H, 2-Bromo-3,5,8-trimethoxy-9,lO-dihydro-9,10-[1',2'] 
C9,10H), 7,97 (dd, J=6.1, 3.6 Hz, 2H, C5,8H), 7.40 (dd, benzenoanthracene-l,4-dione (9): 
J=6.6,3.2 Hz, 2H, C6,7H), 6.55 (s, 2H, C2,3H), 3.97 (s, 6H, To a solution of 90 mg (0.24 mmol) of TT5 in 5 mL of 
OCH,); l3CNMR (CDC1,) d 149.47 (s,  C8a,lOa), 131.45 (s,  DMF under argon at room temperature was added 52 mg 
C4a,9a), 128.51 (d, C9,10), 125.47 (d, C5,8), 120.73 (d, 5 (0.3 mmol) of N-bromosuccinimide (NBS). The solution 
C6,7), 100.88 (d, C2,3), 55.61 (s,  OCH,); M.S. (FAB): was stirred at 40" C. for 12 h. A sample was withdrawn and 
m/z=238 (M), 239 (MH'). checked by TLC to show that no starting material presented. 
2,5,8-Trimethoxy-4a,9,9a,l0-tetrahydro-9,10-[1',2'] The solution was diluted with ether and washed with twice 
benzenoanthracene-l,4-dione (7), 1,4-Dihydroxy-2,5,8- with water and once with brine, dried (MgSO,), concen- 
triethoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene trated to give 109 mg (quantitative yield) of the crude 
(TT3), and 2,5,8-Trimethoxy-9,1O-dihydro-9,10-[ 1',2'] product. This material was used in next step without puri- 
benzenoanthracene-l,4-dione (7T5). fication. 'H NMR (CDC1,) d 7.44 (dd, J=5.5, 3 Hz, 2H, 
A m i x t u r e  of 0 . 2  g ( 0 . 8 4  m m o l )  of 1 , 4 -  C12,13Hs),7.01(dd,J=5.5,3Hz,2H,C11,14Hs),6.54(~, 
dimethoxyanthracene (l) ,  0.235 g (1.68 mmol) of methoxy- 2H, C6,7 Hs), 6.29 (s,  lH), 6.22 (s,  lH), 4.14 (s,  3H, C3 
hydroquinone (6), 0.39 g (1.68 mmol) of silver oxide and 54 OMe), 3.81 (s,  3H, OMe), 3.79 (s,  3H, OMe). 
mg (0.17 mmol) of zinc iodide in 20 mL of toluene (distilled 2 - B r o m o  - 3 - m e t  ho  xy  - 9 , l O -  d i  h y d r o  - 9 , l O  -[ 1 ' , 2 ' ]  
over CaH,) was heated to reflux under argon for 24 h. The benzenoanthracene-l,4,5,8-tetraone (TT13): 
reaction mixture was cooled to room temperature, concen- To the above product, compound 9, in a solution of 5 mL 
trated and directly subjected to a silica gel column. After of acetonitrile, 6 mL of p-dioxane, and 2 mL of water was 
elution with a gradient mixture of hexane and ether and then added 0.66 g (1.2 mmol) of ceric ammonium nitrate. The 
with ethyl acetate and methanol, 0.11 g (55% recovery) of 20 solution was stirred at room temperature for 6 h, diluted with 
compound 1, 0.11 g of methoxy-1,4-quinone, 73 mg (51% ether. The mixture was transferred into a separatory funnel, 
yield) of 7, 37 mg (26% yield) of TT3, and 18 mg (13% washed with water and brine, dried (MgSO,), concentrated, 
yield) of TT5 were isolated. and column mg (59% yield) of pure TT13; mp 207-210" C. 
Compound 7: 'H NMR(CDC1,) d 7.24-7.18 (m, 2H, 'H NMR (CDC1,) d 7.48 (dd, J=5.5, 3 Hz, 2H, C12,13 Hs), 
C12,13 Hs), 7.08-7.04 (m, 2H, C11,14 Hs), 6.65 (s,  2H, zs 7.09 (dd, J=5.5,3 Hz, 2H, C11,14 Hs), 6.66(s, 2H, C6,7 Hs), 
C6,7 Hs), 5.61 (s,  lH), 5.33 (s,  lH), 3.82 (s,  6H, OMe), 3.48 6.23 (s ,  lH), 6.16 (s,  lH), 4.17 (s,  3H, C3 OMe). I3C NMR 
(s,  3H, OMe), 3.10 (q, J=9 Hz, 2H, C4a,9a Hs). Compound (CDC1,) d 182.2 (s,  Cl),  182.0 (s,  C4), 176.2 (s,  C=O), 
10 
TT3: 'H NMR (CDC1,) d 7.43 (dd, J=5.5, 3 Hz, lH), 7.38 
(dd, J=5.5,3 Hz, lH), 6.96 (dd, J=5.5,3 Hz, 2H, C11,14 Hs), 
175.5 (s, C=O), 156.2, 151.6, 151.4, 150.2, 141.8, 135.5, 
135.4, 126.2, 126.1, 126.07,126.0, 125.6, 125.4, 117.2,61.7 
6.51 (s,  2H, C6,7 Hs), 6.29 (s,  lH, C3H), 6.09 (s,  1 H), 5.98 30 (q, OMe), 43.0 (d), 42.1 (d). MS EI, miz 424 & 422 ( l : l ,  
(s,  lH), 5.3 (s,  lH,  OH), 4.96 (bs, lH,  OH), 3.81 (s,  3H, M+), 344 (M-Br), 300, 287, 232, 152, 126. 
OMe), 3.805 (s,  3H, OMe), 3.66 (s,  3H, OMe). Compound 2-Chloro-5,8-dimethoxy-4a,9,9a,lO-tetrahydro-9,10-[1',2'] 
TT5: 'H NMR (CDC1,) d 7.43 (dd, J=5.5,3 Hz, 2H, C12,13 benzenoanthracene-l,4-dione (12): 
Hs), 7.0 (dd, J=5.5,3 Hz, 2H, C11,14 Hs), 6.52 (s, 2H, C6,7 A s o l u t i o n  of 0 . 1  g ( 0 . 4 2  m m o l )  of 1 , 4 -  
Hs), 6.25 (s,  lH), 6.23 (s,  lH), 5.71 (s,  lH, C3H), 3.79 (s,  35 dimethoxyanthracene (l) ,  0.121 g (0.84 mmol) of chloro- 
6H, OMe), 3.72 (s,  3H, OMe). hydroquinone ( l l ) ,  0.195 g (0.84 mmol) of silver oxide, and 
Isomerization of 7 to TT3: 27 mg (0.084 mmol) of zinc iodide in 10 mL of toluene was 
To a solution of 0.77 g (2 mmol) of 7 in 30 mL of heated under reflux for 10 h. The mixture was concentrated 
p-dioxane and 30 mL of water was added 1.12 g (20 mmol) on a rotary evaporator and the residue was subjected to a 
of KOH. The solution was stirred at room temperature for 1 40 silica gel column. After elution of a gradient mixture of 
h, acidified with 1 M HC1, and extracted with methylene hexane and ether, 64 mg (73% yield based on reacted 1) of 
chloride three times. The combined extract was washed with 12 and 45 mg (45% recovery) of 1. Compound 12: 'H NMR 
brine, dried (MgSO,), concentrated to give 0.77 g (100% (CDC1,) d 7.42 (m, 2H, C12,13 Hs), 7.18 (dd, J=5.5, 3 Hz, 
yield) of TT3. 
Oxidation of TT3 to TT5: 
2H, C11,14 Hs), 6.64 (d, J=6 Hz, lH), 6.61 (d, J=6 Hz, lH), 
45 6.55 (s, lH, C3H), 5.31 (d, J=3 Hz, lH), 5.28 (d, J=3 Hz, 
To a mixture of 0.77 g (2 mmol) of 7T3 and 0.6 g of lH), 3.76 (s,  3H, OMe), 3.75 (d, 3H, OMe), 3.17 (qd, J=9, 
sodium sulfate (anhydrous) in 15 mL of dried acetone under 2.6 Hz, 2H, C4a,9a Hs). 
argon at room temperature was added 0.557 g (4 mmol) of 2-Methoxy4a,9,9a,10-tetrahydro-9,10-[1',2'] 
silver oxide. The mixture was heated under reflux for 6 h, benzenoanthracene-l,4-dione (TT8): 
cooled to room temperature, diluted with methylene SO A mixture of 0.5 g (2.8 mmol) of anthracene (13), 0.787 
chloride, and filtered through Celite. The filtrate was con- g (5.6 mmol) of methoxyhydroquinone (6), 1.298 g (5.6 
centrated to give 0.77 g (100% yield) of 7T5. 'H NMR mmol) of silver oxide and 0.179 g (0.56 mmol) of zinc 
spectrum indicates it to be the desired product and was used iodide in 10 mL of toluene was heated under reflux for 24 
in the next step without purification. h under argon. The mixture was diluted with methylene 
2-Methoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene-l, ss chloride and water, filtered through Celite, and the filtrate 
4,5,8-tetraone (TT2): was transferred into a separatory funnel. After washing with 
To a solution of 0.77 g (0.002 mol) of TT5 in 16 mL of brine, the organic layer was dried (MgSO,), concentrated to 
acetonitrile, 26 mL of p-dioxane and 10 mL of water was give dark green solids; NMR spectrum of this material 
added 2 g (3.6 mmol) of ceric ammonium nitrate at room indicated desired product. The solid was recrystallized from 
temperature. The solution was stirred for 12 h, diluted with 60 ether to give 0.50 g (56% yield) of TT8 as light green white 
methylene chloride, and washed with water. The organic solids, mp 182-184" C.; 'H NMR (CDC1,) d 7.4 (m, 2H), 
layer was dried (MgSO,), concentrated to give the crude 7.2 (m, 4H), 7.1 (m, 2H), 5.64 (s,  C3H), 4.89 (s,  2H, C9,lO 
product. Recrystallization from ether gave 0.68 g (99% Hs), 3.51 (s,  3H, MeO), 3.17 (qd, J=9.5, 3 Hz, 2H, C4a,9a 
yield) of TT2. 'H NMR (CDC1,) d 7.48 (dd, J=5.5,3 Hz, 2H, Hs); I3C NMR (CDC1,) d 193.25 (s,  C=O), 162.84,161.76, 
2H, C6,7 Hs), 6.2 (s,  lH), 6.18 (s,  lH), 5.78 (s,  lH,  C3H), 124.91, 124.61, 123.89, 123.82, 113.57, 56.12 (OMe), 
3.78 (s,  3H, OMe). MS, CI, miz 345 (M+l). 49.56, 49.15, 48.87, 48.84. 
C12,13 Hs), 7.07 (dd, J=5.5, 3 Hz, 2H, C11,14 Hs), 6.65 (s, 65 141.63, 139.84, 139.29, 126.68, 126.66, 126.57, 126.51, 
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2-Methoxy-9,10-dihydro-9,10-[1',2']benzenoanthracene-l, Dimethoxy-4a-methoxycarbonyl-9,9a,l0-trihydro-9,10-[1', 
4-dione (TT9): 2']benzenoanthracene-1,4-dione (TT11): 
TO a solution of 0.2 g (0.63 mmol) of ketone TT8 in 5 mL Amixture of 0.2 g (0.00119 mol) of methyl gentisate (14), 
of P-dioxane and 1 mL of water was added 0.106 g (1.9 0.2 g (0.0014 mol) of potassium carbonate and 0.6 g (0.0026 
mmol) of KOH. The solution was stirred at room tempera- s mol) of silver oxide in 10 mL of benzene (freshly distilled) 
for h, with HC1, and extracted with was stirred at 50" C. (bath temperature) under argon for 10 
methylene chloride twice. The combined extract was 
crude product This was in the amount of ether, concentrated on a rotary evaporator and 
i o  then under vacuum to give 0.198 g (100% yield) of ing oxidation reaction without purification. A solution of the above diol, 0.4 g (2.8 mmol) of sodium sulfate (anhydrous), methoxycarbonyl-1,4-benzoquinone (15); 'H NMR and 0.4 (1.7 mmol) of silver oxide in 12 mL of acetone was (CDC1,) d 7.13 (s,  lH,  C3 H), 6.84 (s,  2H, C5,6 Hs), 3.92 stirred at room temperature for 3 h. The mixture was diluted 
with methylene chloride, filtered through Celite, washed ('3 3H3 The proton NMR 'pectrum indicates the 
matographed on silica gel using a gradient mixture of without Purification. 
hexane and ether as eluant to give 0.16 g (80% yield) of Asohtion o f 7 3  mg (0.44 mmol) of 15 and 70 mg (0.294 
TT9; mp 195-197' C.; 'H NMR (CDC1,) d 7.43 (m, 2H, mmol) of 1,4-dimethoxyanthracene (1) in 1 mL of toluene 
C12,13 Hs), 7.03 (dd, J=5, 3 Hz, 2H, C11,14 Hs), 5.83 (s, was heated at 70" C. for 14 h and under reflux for 5 h under 
lH), 5.80 (s,  lH), 5.74 (s,  lH,  C3H), 3.76 (s,  3H, OMe); I3C argon. The solution was cooled to room temperature and 
NMR (CDC1,) d 183.45 (s,  C=O), 178.2 (s,  C=O), 158.48 20 subjected to a silica gel column using gradient mixtures of 
(s) ,  152.93 (s) ,  150.07 (s) ,  143.71 (s,  2 C), 143.57 (s,  2 C), hexane, ether and ethyl acetate to give 69 mg (58% yield) of 
125.52 (d, 4 C), 124.43 (d, 2 C), 124.3 (d, 2 C), 105.71 (d), T T l l  and 44 mg (40% yield) of TT10. Compound TT11: mp 
56.48 (q, OMe), 47.5 (d), 47.17 (d). 176-178" C.; 'H NMR (CDC1,) d 7.24 (m, lH), 7.18 (m, 
4a,9,9a,10-Tetrahydro-9,10-[1',2']benzenoanthracene-l,4- lH), 7.05 (dd, J=5,3 Hz, 2H), 6.65 (dd, J=10,9 Hz, 2H, C6,7 
Asolution of 1 g (5.6 mmol) of anthracene (13) and 2.42 C3H), 5.67 (s,  lH,  ClOH), 5.27 (d, J=2.4 Hz, lH,  C9H), 3.86 
g (22 mmol) of 1,4-benzoquinone (2) in 20 mL of toluene (s,  3H, OMe), 3.81 (s,  3H, OMe), 3.61 (s,  3H, OMe), 3.5 (d, 
was heated under reflux under argon for 24 h. The solution J=2.4 Hz, lH, C9a H); I3C NMR (CDC1,) d 196.67 (s,  
was cooled to room temperature, diluted with 100 mL of C=O), 193.48 (s,  C=O), 169.23 (s,  C=O of ester), 149.85 
methylene chloride, washed with water, dried (MgSO,), and 30 (s) ,  148.08 (s) ,  140.61 (2), 140.22 (d), 139.31 (d), 131.4 (s) ,  
concentrated to give yellow solids. Proton NMR spectrum 129.11 (s) ,  126.7 (d), 126.59 (d), 125.93 (d), 124.68 (d), 
indicated desired product and starting quinone 2. The solids 111.2 (s) ,  109.4 (d), 104.36 (d), 63.4 (s) ,  56.23 (9),55.91(9), 
were washed with ether several time (the product is 53.9 (q), 53.17 (d), 45.02 (d), 42.1 (d). Compound TT10: 'H 
insoluble in ether and benzoquinone dissolves), and the NMR (CDC1,) d 7.4 (m, 2H), 7.18 (m, 2H), 6.54 (s,  2H), 
remaining solids were dried under vacuum to give 1.56 g 35 6.42 (s,  1H of one isomer, exo or endo), 6.25 (s,  1 H of one 
(98% yield) of TT6; mp 219-221" C.; 'H NMR (CDC1,) d isomer), 5.28 (m, lH), 5.25 (m, lH), 3.86 (s,  3H, OMe), 3.83 
7.40 (dd, J=5, 3 Hz, 2H), 7.2-7.17 (m, 4H), 7.08 (dd, J=5, (s,  3H, OMe), 3.82 (s,  3H, OMe), 3.15 (m, lH), 3.12 (m, 
3 Hz, 2H), 6.32 (s,  2H, C2,3 Hs), 4.87 (s,  2H, C9,lO Hs), 1H). 
3.14 (s,  2H, C4a,9a Hs); I3C NMR (CDC1,) d 198.29 (s,  9,10-Dihydro-9,10-[1',2']benzenoanthracene-l,4,5,8- 
C=O), 141.49 (s) ,  140.53 (d), 139.64 (s) ,  126.68 (d), 126.59 40 tetraone (TT1): 
(d), 124.68 (d), 123.83 (d), 49.0 (d), 48.85 (d). Preparation of endo-(5aS,8aR,9S,lOR )-1,4-dimethoxy- 
9,10-Dihydro-9,10-[1',2']benzenoanthracene-l,4-dione 5a,8a,9,10-tetrahydro-9,10[1',2']benzenoanthracene-5,8- 
(7T7): dione (Ma) and exo-(5aR,8aS,9S,10R)-1,4-Dimethoxy-5a, 
8a,9,10-tetrahydro 9,lO-[ lt,2']benzenoanthracene-5,8-dione 
TT9 from 7T8. A solution of 1 g (3.5 mmol) of TT6 and 45 (18b). 
0.784 g (14 mmol) of KOH in 50 mL of p-dioxane and 10 To a so lu t ion  of 1 . 1 9  g ( 0 . 0 0 5  mol )  1 , 4 -  
mL of water was stirred at room temperature for 2 h. The dimethoxyanthracene (1) in 20 mL of toluene was added a 
solution was acidified with 1 N HC1 until pH=l,  extracted solution of 0.54 g (0.005 mol) 1,4-benzoquinone (2) in 15 
twice with methylene chloride, and the combined methylene mL of toluene, the resulting solution was heated at reflux for 
chloride layer was washed with brine, dried (MgSO,), SO 3 hr., added 1.08 g (0.01 mol) 1,4-benzoquinone. After 24 
concentrated to give dark brown solids. The proton NMR hr., another portion of 1.08 (0.01 mol) 1,4-benzoquinone 
spectrum indicated a mixture of the diol (major product) and was added. The solution was refluxed for 19 h. Subsequent 
TT7 (minor). The mixture was stirred with 2 g (8.6 mmol) evaporation of solvent and sublimation of excess 1,4- 
of silver oxide and 2 g (14 mol) of anhydrous sodium sulfate benzoquinone gave a mixture of 1.85 g of isomers 18a and 
in 60 mL of dried acetone at room temperature under argon ss 18b (-100% yield) in a ratio of 1: l .  Further purification was 
for 3 h. The mixture was filtered through Celite, rinse with performed and the products (1.73 g) were used for the next 
methylene chloride, and the filtrate was concentrated to give step. The endo-, exo-isomers were assigned according to 'H 
dark brown solids. Column chromatographic separation of NMR spectra analysis. The deshielding effect between 
the crude product with silica gel using a gradient mixture of enone ring and benzene ring in the exo-configuration 
hexane and ether to give 0.7 g (70% yield) of TT7. Mp 60 resulted in a downfield shift of proton signals on these two 
295-298" C.; 'H NMR (CDC1,) d 7.42 (dd, J=5 ,3  Hz, 4H), rings, especially the benzene protons (7.41 ppm, 7.17 ppm), 
7.03 (dd, J=5, 3 Hz, 4H), 6.6 (s,  2H, C2,3 Hs), 5.8 (s,  2H, compared with those of endo-isomer (7.20 ppm, 7.06 ppm). 
C9,lO Hs); I3C NMR (CDC1,) d 183.52 (s,  C=O), 151.92 Mp. 198-201" C.; 18a (endo-): 'HNMR (CDC1,) d 7.20 (dd, 
(d, 4 C), 47.36 (d, C9,lO). 65 5'H), 6.59 (s,  2H, C2,3H), 6.28 (s,  2H, C6,7H), 5.31 (s,  2H, 
5,8-Dimethoxy-2-methoxycarbonyl-4a,9,9a,lO-tetrahydro- C9,10H), 3.82 (s,  6H, OMe). 18b (exo-): Mp 218-221" C. 
9,10-[1',2']benzeno-anthracene-1,4-dione (7T10) and 5,8- 'HNMR (CDC1,) d 7.41 (dd, J=5.5, 3.2 Hz, 2H, C3',6H'), 
min under dark, The reaction mixture was cooled to 
washed with brine, dried (MgS04), concentrated to give the temperature, filtered through &lite, rinsed with small 
with brine, dried (MgSO,), concentrated, and column chro- is about loo% pure and is in the next step 
dione (TT6): 25 Hs), 6.38 (d, J=10 Hz, lH, C2H), 6.28 (d, J=10 Hz, lH,  
The procedure is the same as that of the preparation of 
(s), 143.57 (s, 4 C), 135.39 (d, 2 C), 125.57 (d, 4 C), 124.42 J=5.5, 3.2 Hz, 2H, C3',6'), 7.06 (dd, J=5.5, 3.2 Hz, 2H, C4', 
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7.17 (dd, J=5.5, 3.2 Hz, 2H, C5',4'H), 6.59 (s,  2H, C2,3H), Preparation of Dimethyl Butadiene-2,3-dicarboxylate (16): 
6.31 (s,  2H, C6,7H), 5.31 (s,  2H, C9,10H), 3.75 (s,  6H, (Z)-Dimethyl 2,3-dimethyl-2-butenedioate (21): 
OMe). The structure of this exo isomer (the two C4a,9a Hs To a solution of 2 g (0.0158 mol) of 2,3-dimethylmaleic 
orient at the same side with the phenyl ring) was proven by anhydride in 40 mL of methanol was added 0.2 mL of 
a single crystal X-ray diffraction. s concentrated sulfuric acid. After refluxing for 7 days, the 
Exoisomer: I3C NMR (CDC1,) d 198.44, 148.500, solution was diluted with 100 mL of methylene chloride, 
140.46, 139.95, 131.21, 126.52, 124.86, 109.09, 56.04, neutralized with aqueous sodium bicarbonate solution. The 
48.51, 42.16. methylene chloride layer was washed with 30 mL of brine, 
the aqueous layer was extracted with methylene chloride 
141.808, 140.29, 128.32, 126.45, 123.99, 109.32, 126.45, i o  four times (30 mL twice and 15 mL twice). The combined 
123.99, 109.76, 56.39, 48.80, 42.38. methylene chloride layer and extracts were dried over anhy- 
Preparation of 1,4dimethoxy-5,8-dihydroxy-9,lO-dihydro- drous magnesium sulfate, concentrated to give 2.11 g of 
9,lO-[ 1',2']benzenoanthracene (19): crude product. 'H NMR check indicated about 25% of 
To a solution of 1.73 g (0.005 mol) of 18a&b in 100 mL starting material existing, the crude mixture with 0.2 mL of 
of 1,4-dioxane was added 10.61 g of potassium hydroxide in is concentrated sulfuric acid in 40 mL of methanol was heated 
100 mL of water. The resulting mixture was stirred at 35" C. at reflux again for 5 days. The solution was concentrated 
for 18.5 hr., neutralized by 6N hydrochloric acid solution, until 30% of methanol was left, neutralized with saturated 
and extracted with methylene chloride twice (40 ml each), sodium bicarbonate aqueous solution, followed by addition 
and once with ethyl acetate (40 ml). The combined extracts of 30 mL of brine solution, and the mixture was extracted 
were dried over anhydrous magnesium sulfate, and concen- 20 with ethyl acetate four times (100 mL once, 30 mL three 
trated to give 1.75 g of crude product 19 (-100% crude times). The combined ethyl acetate extracts were dried over 
yield). No purification was performed at this stage. 'H NMR anhydrous magnesium sulfate, concentrated to give 3.26 g of 
(CDC1,) d: 3.80 (s,  6H, -OCH,), 6.20 (s,  2H, C 9,lO Hs), crude product 21 (-100% yield). It was of satisfactory purity 
6.34 (s,  2H, C 6,7 Hs), 6.51 (s,  2H, C 2,3H s), 7.00 (dd, for the next step. 'H NMR (CDC1,) d 3.77 (s,  6H, OMe), 
J=5.5,3.2 Hz, 2H, C 12,15 Hs), 7.43 (dd, J=5.5,3.2 Hz, 2H, zs 1.95 (s,  6H, Me) 
C 13,14 Hs). (Z)  - and (E)  - D im e t h y 1 - 2 ,3  - b is[ b r o m o me t h y 11 - 2 - 
5,8-Dimethoxy-9,10-dihydro-9,10[1'2']benzenoanthracene- butenedioate (22a & 22b): 
1,4-dione (20): A mixture of 3.2384 g (0.0188 mol) of butenedioate 21, 
A mixture of 1.73 g (0.005 mol) of crude 19, 6 g (0.042 7.37 g (0.04 mol) of N-bromosuccinimide (NBS) and 100 
mol) of sodium sulfate and 5.8 g (0.025 mol) of silver oxide 30 mg (cat.) of 2,2'-azobisisobutyronitrile (AIBN) in 50 mL of 
in 150 mL of acetone was heated at reflux for 22 hr. The carbon tetrachloride was heated under reflux and irradiated 
reaction mass was filtered through Celite and washed with with a 275 W sunlamp for 3 h. The reaction solution was 
methylene chloride. The filtrate was dried over anhydrous cooled, diluted with 150 mL of ether, and filtered. The 
magnesium sulfate, concentrated and column chromato- filtrate was concentrated, and flash column chromato- 
graphed on silica gel using a gradient mixture of ethyl 3s graphed using a gradient mixture of ether-hexane as eluant 
acetate and hexane as eluant to give 1.15 g of pure 20 in a to give 1.33 g of oily liquid trans-isomer 22b (18.4% yield) 
yield of 67.25% (based on crude 19). The melting point and and 4.40 g of oily liquid cis-isomer 22a (71.6% yield) with 
IR agree with reported data.' M.p. 266-271" C. (decom.), a total yield of 90%. The assignment of 22a and 22b was 
lit.' 271.5-272.5' C.; IR: 3060 cm-' (A-H), 1660 cm-' based on the reported 'H NMR data. 
(C=O), 1584 cm-' (aromatic C=C), 1258 cm-' (C-0); 40 22a: 'H NMR (CDC1,) d 4.50 (s,  4H, CH, Br), 3.91 (s,  
'H NMR (CDC1,) d 7.44 (dd, J=5.3,3.2 Hz, 2H, C12,13 Hs), 6H, OMe); I3C NMR (CDC1,) d 165.54 (s,  C=O), 136.95 
7.00 (dd, J=5.3, 3.2 Hz, 2H, C11,14 Hs), 6.54 (s,  2H, C6,7 (s,  C=), 52.97 (s,  OMe), 26.75 (t, CH,Br) 
Hs), 6.51 (s,  2H, C2,3 Hs), 6.23 (s,  2H, C9,lO Hs), 3.79 (s,  22b: 'H NMR (CDC1,) d 4.24 (s,  4H, CH,Br), 3.84 (s,  6H, 
6H, OMe); I3C NMR (CDC1,) d 183.52 (s,  C=O), 152.75 OMe); I3C NMR (CDC1,) d 165.96 (s,  C=O), 137.06 (s,  
(s ,  C-OMe), 149.51 (s) ,  144.14 (s) ,  135.23 (d), 133.44 (s) ,  4s C=), 52.99 (s,  OMe), 23.95 (CH,Br). 
125.28 (d), 124.51 (d), 109.36 (d, C2,3), 56.30 (s,  OMe), Dimethyl 1,3-butadiene-2,3-dicarboxylate (16): 
41.30 (d, CH). To a solution of 6.53 g (0.02 mol) of bromoesters 22 in 20 
P r e p a r a t i o n  o f  9,10-Dihydro-9,10-[1',2']- mL of acetone was added 9.49 g (0.06 mol) of sodium 
benzenoanthracene-l,4,5,8-tetrone (TT1): thiosulphate and 9.96 g (0.06 mol) of potassium iodide. 
To a solution of 0.4 g (1.17 mmol) of compound 20 in 30 SO After refluxing for 2 hr., The mixture was cooled, poured 
mL of acetonitrile was added dropwise a solution of 3.2 g onto 50 g of ice, and extracted with methylene chloride three 
(5.84 mmol) of ceric ammonium nitrate in 70 mL of a times (150 mL once, 50 mL twice). The combined methyl- 
mixture of dioxane and water (3:l) at r.t under argon. After ene chloride extracts were washed with 20 mL of saturated 
stirred for 3 h, the reaction mixture was extracted with aqueous sodium chloride, dried over anhydrous magnesium 
methylene chloride four times (40 mL each). The combined ss sulfate, concentrated, and column chromatographed on 
methylene chloride extracts were dried over anhydrous silica gel using a gradient mixture of hexane-ethyl acetate as 
magnesium sulfate, concentrated and column chromato- eluant to give 2.8206 g of butadiene 16 in a yield of 83%. 
graphed on silica gel using a gradient mixture of ethyl 'H NMR (CDC1,) d 6.71 (dd, J=1.4, 0.6 Hz, 2H, =CH), 
acetate and petrolium ether as eluant to give 0.37 g of 5.83 (dd, J=1.4,0.6 Hz, 2H, =CH), 3.76 (s,  6H, OMe); I3C 
bisquinone TT1 in a yield of about 100%. Recrystallization 60 NMR (CDC1,) d 166.20 (s,  C=O), 138.42 (s,  =C), 127.79 
in methylene chloride and petroleum ether gave TT1 as (t, =CH,), 52.09 (q, OMe). 
yellow needle-like crystals; m.p. 303-305" C. (dec.), (4aS*,7aR*,llaS*,14aR*)-Tetramethyl 1,4,4a,5,6,7,7a,8, 
lit.'>22O0C. (dec.); 'H NMR (CDC1,) d 7.49 (dd, J=5.3,3.0 ll,lla,12,13,14,14a-tetradecahydro-5,7,12,14-tetraoxo-6, 
Hz, 2H, C12,13 Hs), 7.08 (dd, J=5.3, 3.0 Hz, 2H, C11,14 13-[1',2']benzenopentacene-2,3,9,lO-tetracarboxylate (TT4) 
Hs), 6.65 (s,  4H, =CH-CO), 6.18 (s,  2H, CH); I3C 65 and Compound 17: 
NMR(CDC1,) d 182.22 (s,  C=O), 151.51 (s) ,  142.20 (s) ,  A solution of 0.14 g (0.45 mmol) of TT1 and 0.17 g (11 
135.41 (d), 125.91 (d), 125.47 (d), 42.13 (d). mmol) of compound 16 in 5 mL of toluene was maintained 
Endoisomer: I3C NMR (CDC1,) d 198.12, 149.13, 
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under argon and heated under reflux for 22 h. The solution acetate as eluant to give 5 mg of recovered starting material 
was directly subjected onto a silica gel column and eluted TT13 and 28 mg of the product TT16. 'H NMR (CDC1,) d 
with a gradient mixture of hexane, methylene chloride, and 7.45 (m, 2H, Ar-H), 7.04 (m, 2H, Ar-H), 6.22 (s,  lH), 
ethyl acetate to give 0.160 g (54% yield) of TT4 and 30 mg 6.15 (s,  lH), 5.4 (s,  lH,  C7H), 3.81 (s,  3H, OMe), 3.12 (s,  
(14% yield) of compound 17. Recrystallization of TT4 from s 6H, Me,N). 
methylene chloride gave light yellow crystals. Single crystal 2-Bromo-3-[2-(ethoxycarbonyl)ethylamino]-9,lO-dihydro- 
X-ray diffraction analysis was carried on a crystal and the 9,10-[1',2']benzenoanthracene-l,4,5,8-tetraone (7T17) and 
structure was solved. The following Figure shows the 2- hydroxy-3 - [ 2-( e t ho x yc arb0 ny1)e t h y lamino ] - 9,lO - 
ORTEP drawing of the compound. 'H NMR (CDC1,) d 7.45 dihydro-9,lO-[ 1',2']benzenoanthracene-1,4,5,8-tetraone 
(m, 2H), 7.09 (m, 2H), 6.07 (s,  2H, C6,13 Hs), 3.75 (s,  12H, i o  (TT18). 
OMe), 3.2 (bs, 4H, 3C4a,7a,lla,14a Hs), 2.62-2.5 (m, 8H); To a mixture of 0.5 g (0.00325 mol) of b-alanine ethyl 
I3C NMR (CDC1,) d 192.36 (s,  C=O), 167.12 (s,  C=O of ester hydrochloride in 5 mL of THF under argon, 0.156 g 
ester), 154.04 (d), 141.49 (s) ,  132.51 (d), 126.02 (s) ,  125.57 (0.00325 mol; 50% oil dispersion) was added. The mixture 
(s) ,  52.33 (q, OMe), 45.5 (d), 43.27 (d), 25.48 (t). was stirred at room temperature for 1 h, THF was evaporated 
Compound 17: 'H NMR (CDC1,) d 7.42 (dd, J=5, 3 Hz, is under vacuum and while solids, b-alanine ethyl ester and 
2H), 7.01 (dd, J=5,3 Hz, 2H), 6.38 (s,  2H), 6.10 (s,  2H), 3.71 sodium chloride, were obtained. 
(s,  6H, OMe), 3.17 (bs, 2H, CHC=O), 2.60 (dd, J=17,4 Hz, To a solution of 64 mg (0.151 mmol) of TT13 in 2 mL of 
2H), 2.43 (dd, J=17, 4 Hz, 2H). (19). THF and 0.5 mL of DMF under argon was added 0.302 
(4aS*, 5S*, 7R*, 12S*, 14R*, 7aR*, l laS*,  14aR*)- mmol each of the above mixture of b-alanine ethyl ester and 
Te tr ame t h y 1 1,4,4a ,5,6,7,7a,8,11,11 a, 12,13,14,14a - 20 sodium chloride. The solution was stirred at room tempera- 
te tr adec a h y dr o - 5,7,12,14 -tetra hydroxy - 6,13 -[ 1 ' ,2 ']  ture for 16 hours, diluted with methylene chloride, the 
benzenopentacene-2,3,9,lO-tetracarboxylate (TT12): organic layer was washed with water twice, brine, dried 
To a solution of 0.10 g (0.15 mmol) of TT4 in 7 mL of (MgSO,), and concentrated. The proton NMR spectrum of 
methanol (distilled over magnesium turning) under argon the crude products indicated a mixture of TT17 and 7T18. 
were added 0.52 g (1.4 mmol) of CeC1,.7H,O and 51 mg zs This crude product was subjected to column chromato- 
(1.4 mmol) of sodium borohydride. The solution was stirred graphic separation on silica gel using a gradient mixture of 
at room temperature for 12 h, diluted with 70 mL of hexane and ethyl acetate as eluant to give 46 mg (69% yield) 
methylene chloride, and washed with aqueous ammonium of TT18. 'H NMR (CDC1,) d 7.45 (m, 2H,Ar-H), 7.04 (m, 
chloride and brine. The organic layer was dried (MgSO,), 2H, Ar-H), 6.42 (ABq, J=8.4 Hz, 2H, C6,7 H's), 6.23 (s,  
concentrated to give 88 mg (89% yield) of TT12. Proton 30 lH,  C9H), 6.10 (s,  lH,  ClOH), 4.15 (q, J=7 Hz, 2H, CH,), 
NMR spectrum indicates the material is pure. 'H NMR 4.10 (broad S, 2H, CH,N), 2.64 (t, J=6 Hz, 2H, CH,CO), 
5.15 (s,  2H, C6,13 Hs), 4.47 (bs, 4H, CHO), 3.74 (s,  12H, 2-Hydroxy-3-[(S)-5-(hydroxycarbonyl)-5- 
OMe), 3.2 (bs, 4H, OH), 2.53 (dd, J=17,4 Hz, 4H), 2.27 (dd, a m i n o p  e n t y l a m  in01  - 9 , l O  - d i  h y d r  o - 9 , l O  - [ 1 ' , 2 ' ]  
J=17, 4 Hz, 4H), 2.06(m, 4H); I3C NMR (CDC1, and 35 benzenoanthracene-l,4,5,8-tetraone (TT20). 
acetone-d6) d 168.24 (s,  C=O of ester), 145.74 (s) ,  145.45 To a mixture of 0.5 g (0.0027 mol) of L-lysine monohy- 
(s) ,  134.46 (s) ,  123.49 (d), 121.76 (d), 68.32, 59.66, 51.28, drochloride in 5 mL of THF under argon was added 0.1315 
49.36, 34.19. g (0.0027 mol; 50% oil) of sodium hydride. The mixture was 
2-Bromo-3-(methylamino)-9,10-dihydro-9,10-[ 1' ,2 ']  stirred at room temperature for 2 h, concentrated to dryness 
benzenoanthracene-l,4,5,8-tetraone (7T14) and 2-hydroxy- 40 under vacuum to give a mixture of L-lysine and sodium 
3-(methylarnino)-9,10-dihydro-9,10-[1',2'] chloride as white solids. To a solution of 40 mg (0.095 
benzenoanthracene-l,4,5,8-tetraone (TT15): mmol) of TT13 in 2 mL of THF and 0.5 mL of DMF was 
A solution of 24 mg (0.057 mmol) of TT13 and 1.8 mg added 20 mg of the above mixture of L-lysine and sodium 
(0.057 mmol) of methylamine in 1 mL of THF was stirred chloride. The mixture was stirred at room temperature for 2 
under argon at room temperature for 20 min. The solution 45 days, concentrated to dryness under vacuum and the crude 
was diluted with ether, washed with water and brine, dried product was purified by HPLC using a Econosphere C8 (10 
(MgSO,), and concentrated. Column chromatographic sepa- m) semi-preparative column (250 mmxlO mm), 40% aceto- 
ration of the crude on silica gel using a gradient mixture of nitrile in water as solvent, to give pure 7T20 (came out in 2 
hexane and ether as eluant to give 6 mg (24% yield) of TT14 minutes). 'H NMR (D,O) d 7.54 (m, 2H, Ar-H), 7.10 (m, 
and 6 mg (29% yield) of TT15. For TT14: 'H NMR (CDC1,) SO 2H, Ar-H), 6.56 (s,  2H, C6,7 H's), 6.2 (s,  lH,  C9H), 6.07 
(dd, J=5 ,3  Hz, 2H), 6.64 (s,  2H, C6,7 Hs), 6.28 (s,  lH), 6.11 7 Hz, 2H, CH,N), 1.90 (m, 2H, CH,), 1.72 (m, 2H, CH,), 
(s,  lH), 5.88 (bs, lH, NH), 3.33 (d, J=5.6 Hz, 3H, MeN). For 1.48 (m, 2H, CH,). 
TT15: 'H NMR (CDC1,) d 7.45 (m, 2H, Ar-H), 7.04 (m, 
One Pot Synthesis of 5,8-Disubstituted Triptycene 
Monoquinones and Inhibition Studies 
Hz, 3H, MeN). In the reported synthesis of 5,8-disubstituted triptycene 
2-Bromo-3-methoxy-6-(dimethylamino)-9,lO-dihydro-9, monoquinones, (Bartlett, P. D.; Ryan, M. J.; Cohen, S. G. J. 
10-[1',2']benzenoanthracene-1,4,5,8-tetraone (TT16): Am. Chem. SOC. 1942, 64, 2649; Skvarehenko, V. R.; 
To a solution of 35 mg (0.083 mmol) of TT13 in 2 mL of 60 Shalaev, V. K.; Klabunovskii, E. I. Russ. Chem. Rev. 1974, 
THF, a stream of dimethylamine was added via a syringe for 43, 951; Iwamura, H.; Maino, K. An intramolecular trip- 
few minutes. The solution turned dark brown color tycene quinhydrone. J. Chem. SOC. Chem. Commun. 1978, 
immediately, the dimethylamine gas was disconnected, and 720.; Quast, H.; Fuchsbauer, H. -L. Chem. Ber. 1986, 119, 
the solution was stirred at 0" C. for 10 minutes. The solvent 1016-1038; Quast, H.; Fuchsbauer, H. -L. Chem. Ber. 1986, 
and excess of dimethylamine were removed via rotary 65 119, 2414; Patney, H. K. Synthesis 1991, 694. Charge- 
evaporator and residue was column chromatographed on transfer complexes; Lipczynska-Kochany, E.; Iwamura, H. 
silica gel using a gradient mixture of hexane and ethyl Chem. Lett. 1982, 1075; Daub, J.; Jakob, L.; Salbeck, J. 
(CDC1,) d 7.3 (dd, J=5 ,3  Hz, 2H), 7.01 (dd, J=5 ,3  Hz, 2H), 1.25 (t, J=7 Hz, 3H, CH,). 
d 7.48 (dd, J=5, 3 Hz, lH), 7.45 (dd, J=5, 3 Hz, lH), 7.07 (s, lH,  ClOH), 3.76 (t, J=6 Hz, lH,  CH), 3.03 (dd, J=8 Hz, 
2H,Ar-H), 6.41 (2d, J=6.3 Hz, 2H, C6,7-Hs), 6.23 (s, lH), 55 
6.1 (s, lH), 5.9 (bs, lH,  NH), 4.8 (s, lH, OH), 3.33 (d, J=5.8 
US 6,828,450 B2 
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Chem. Ber. 1988,121,2187. Radical Anions: Russell, G. A,; 
Suleman, N. K. J. Am. Chem. SOC. 1981, 103, 156Ck1561. 
Liquid Crystals; Norvez, S. J. Org. Chem. 1993, 58, 2414) 
a sequence of three reactions was carried out: Diels-Alder 
reaction of 1,4-dimethoxyanthracene (Criswell, T. R.; 
Klanderman, B. H. J. Org. Chem. 1974, 39, 770) and 
p-benzoquinone followed by isomerization of the adducts 
(endo- and exo-adducts) with potassium hydroxide and then 
oxidation with silver oxide. These three reactions have been 
56 
-continued 
I! 
0 successfully combined into one simple operation. Hence, 
heating of anthracene 2 (derived from the reduction of 
1,4-anthracenedione (Perchellet, E. M.; Magill, M. J.; 
Huang, X.; Brantis, C. E.; Hua, D. H.; Perchellet, J. P. 
Anti-cancer Drugs, 1999, 10,749) with sodium hydrosulfite 
followed by sodium hydride and iodomethane), 1.4 equiv of 
methoxyhydroquinone (3), 2.7 equiv of silver oxide, and 0.2 
equiv of zinc iodide in toluene under reflux for 4 days gave 
a 70% yield of triptycene monoquinone 4 (Scheme 14). 2o 
methoxy-p-benzoquinone which undergoes Diels-Alder 
reaction with anthracene 2 to give adducts 5 (endo- and 
4 
2 
toluene 2g:3 - 
benzene 150" c .  
OMe - 
Presumably, silver oxide oxidizes methoxyhydroquinone to 0 
6 
exo-isomers). Compound 5 then undergoes oxidation with 
M e d  
&Me 
silver oxide to give quinone 4. A catalytic amount of zinc 25 
iodide was added to facilitate the Diels-Alder reaction. No 
other regioisomers (such as isomers with methoxy substitu- 
ent attached at C4a) were detected. To verify the reaction 
sequence, methoxyquinone 6, obtained from the oxidation of 3o 
3 with silver oxide and potassium carbonate in benzene 
(98% yield), was treated with anthracene 2 in toluene at 150" 
C. in a sealed tube to give adducts 5 (48% yield). Isomer- 
/ \  
- M e 0  
ization of ketones 5 with KOH in p-dioxane and water 0 M e 0  
followed by oxidation with silver oxide gave monoquinone 35 5 
4 (95% overall yield). Oxidation of monoquinone 4 with 1.KOH 
dioxane-Hz0 Ce(NH4)2(N02)6 
- 4  
ceric ammonium nitrate afforded a 94% yield of triptycene 
bisquinone 7. Regioselective bromination of 7 was achieved 
by the treatment with N-bromosuccinimide (NBS) in DMF 
at 25" C. for 10 h to give bromoquinone 1 (45% yield). 
Alternatively, compound 1 can also be obtained from the 
bromination of monoquinone 4 with NBS in DMF at 40" C. 
followed by oxidation with ceric ammonium nitrate (59% 
overall yield). The bromination of quinones with NBS has 45 
not been reported previously, and apparently, reactivity of 
the methoxyquinone moiety towards NBS is greater than 
2. Ag20 
* 
Na2S04 
40 
NBS, DMF . 
that of quinone and 1,4-dimethoxyphenyl moieties. Likely, M e 0  
the methoxy substituent of 7 or 4 (at C2) enhances nucleo- 0 so philicity of adjacent double bond carbon resulting the bro- 
mination. 
Schemel4 55 
OMe Ag20,ZnI2 
toluene 
reflux 60 
- 
OMe OH 
2 3 
65 
7 
1 
1. NBS, DMF 
2. Ce(NH4)2(N03)6 
- 1  4 
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To synthesize new analogs, 1 was treated with primary 
and secondary amines (Scheme 15). Surprisingly, compound 
1 reacts with primary amines such as methylamine and 
secondary amines such as dimethylamine to give different 
regio-isomeric products. Hence, addition of bromide 1 with 
of displacement product 8. On the other hand, when 1 was 
treated with dimethylamine in THF at 0" C., a 96% yield of 
regioisomers 9 and 10 (a ratio of 1:l)  was isolated. Com- 
pounds 9 and 10 were separated by silica gel column 
been determined. The presence of bromine atom in the 
products was indicated by their mass spectra in which the 
M+2 peaks ("Br isotope) almost equal in intensity to the 
molecular (EI) or quasimolecular (CI) ions. No other 
by-products are identifiable in these reactions. These 
unusual addition reactions are unprecedented. It has been 20 
with aliphatic primary amines to give a mixture of products 
including mono- and di-adducts from the 1,4-addition 
reactions, and tetrachloro-1,4-benzoquinone and 2,3- 2s 
dichloro-1,4-naphthoquinone react with secondary amines 
to give displacement products (addition to the double bond 
followed by elimination of chlorine). Contrary to these 
methoxy group instead of bromine with primary amines and 
simple 1,4-addition on the unsubstituted quinone ring fol- 
lowed by oxidation with secondary amines, exclusively. 
Presumably, a less basic primary amine, methylamine, 3s 
deficient bromoquinone ring. Since the C2-bromine of 1 is 
addition of an amine on C3 would be more stabilized than 
that from the addition on C2; resulting a displacement of 
methoxy group to provide compound 8. On the other hand, 
a more basic secondary amine, dimethylamine, is less 
affected by electronic (since it is a more reactive amine) 
effect of the quinone ring and is more affected by steric 4s 
effect, in turn it prefers the addition on the unsubstituted 
(less hindered) quinone moiety to provide compounds 9 and 
-continued *A  MeNH, THF methylamine in THF at 0" C. for 20 min. gave a 66% yield 0" c .  Br 
/ /  + 
10 Me0  
0 0 NMe2 
chromatography. The regiochemistry of 9 and 10 has not 9 
reported that p-benzoquinone undergoes addition reactions NMe2 
Me0  
10 
Due to the Potent anticancer activity of amine 8 (vide 
amines containing ester function were used to synthesize 
various triptycene quinones, and their biological activities 
were studied (Scheme 16). 
literature results, bromide 1 undergoes displacement of the 3o infra) and a need Of water primary 
undergoes 1,4-addition reaction on the greater electron- 
W C O Z E t  an electron-withdrawing group, the anion resulted from the H2N * 
Schrmrlk 
THF 
40 
E t 0 2 C w N H  
0 10. 
1 
MeNH2, THF 
0" c .  
* 
so 
11 
H2N W C o 2 - t - B u  
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1 
1. CF3C02H 
2. NaOH 
5s 
Br 
60 
0 
65 
12 
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US 6,828,450 B2 
59 
-continued 
60 
-continued 
Me2NH, THF 
0" C. 
13: R = H 
14: R = Na 
1s 
Treatment of bromide 1 with ethyl 2-aminopropanoate in 
THF at -40" C. for 6 h afforded a 46% yield of displacement 
product 11 along with starting material 1 (30% recovery). 
No other regioisomers were detected. Similarly, reaction of 2o 
1 with t-butyl2-aminopropanoate at -40" C. for 8 h gave a 
62% yield of 12. Recrystallization of 12 in hexane:ethyl 
acetate (5:l) afforded single crystals which structure was 
unequivocally shown by X-ray analysis. Deprotection of the 
t-butyl ester of 12 with trifluoroacetic acid in dichlo- 2s 
romethane gave a quantitative yield of acid 13. Sodium salt 
14, a water soluble material, w=as obtained from the treat- 
ment of 13 with 1 equiv of sodium hydroxide. 
When compound 1 was treated with dimethylamine in 30 
THF (1 M solution in THF; purchased from Aldricb Chemi- 
cal Company), a mixture of 9 and 10 (1:l) was obtained 
(Scheme 18). However, when compound 1 was treated with 
dimethylamine in THF which prepared by adding dimethy- 
lamine (a gas purchased from Linde Company) gas into 
THF, a mixture of 9, 10, TT24A, and '124B (4:4:1:1) was 
obtained. Compounds 9, 10, and TT24 were separated by 
column chromatography. TT24A and TT24B were 
inseparable, however, carbon-13 NMR spectrum indicates 4o 
two isomers. 
Likely, a small of amounts of methylamine is contami- 
nated in the dimethylamine gas, this methylamine then 
added to the unsubstituted quinone ring of triptycene bis- 
quinone to produce TT24. This mode of addition is different 
from the reaction of 1 with pure methylamine. It is suggested 
that dimethylamine acts as a base and remove the proton of 
methylamine to provide methylamine anion which is more 
reactive than methylamine itself, and in turn undergoes so 
addition reaction on the unactivated C=C of the quinone 
moiety. 
3s 
45 
1 
* 
(reagent from 
Aldrich) 
9 
10 
Me2NH (reagent 
from a gas cylinder, 
Linde Co.) 
THF, 0" C. 
- 9  + 10 + 
T 2 4 A  
Tl24B 
Anticancer testing of 7T24 show it has an IC,, value of 
55 48 nM (or 0.048 pM). The compound is as active as 
daunomycin. 
Anticancer and antimalarial activities of triptycene bis- 
quinones have been evaluated. Table 2 summarizes IC,, 
values (the concentrations of drugs required to inhibit by 
60 50% the viability of L1210 leukemic cells at day 4) of 
various triptycene bisquinones in the inhibition of L1210 
leukemic cell growth. In general, IC,, values are in the 
0.24-0.43 pM range with the exception of carboxylic acid 
13 and its sodium salt 14. Possibly, the passage ability of 
65 sodium salt 14 through cell membrane decreases as water 
solubility increases; in turn, ability in destroying cancer cells 
decreases. The IC,, value of daunomycin, a known antican- 
US 6,828,450 B2 
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cer drug, under similar treatment conditions is 0.041 pM. and the combined extract was washed twice with water, and 
Triptycene bisquinones induce DNA cleavage and inhibit brine, dried (MgSO,), concentrated to give 1.07 g (94% 
nucleoside transport. In contrast, daunomycin, inhibits yield) of compound 2. Recrystallization from ether:hexane 
topoisomerases I and 11, does not block nucleoside transport. (1:l) gave 0.89 g (78% yield) of yellow solids: mp 132-133" 
Moreover, triptycene bisquinones 7, 8 ,  9, and ritonavir 5 C. (Lit.6 134-136" C.); MS, FAB, miz 239 (M+1), 238 
inhibit Plasmodium falciparum 3D7 (a malaria strain) with (M+); 'H NMR d 8.70 (S22H, C9,10H), 7,97 (dd, J=6.1,3.6 
IC,, values of 8,4.7,5.6, and 9.7 pM, respectively. Malaria Hz, 2H, C5,8H), 7.40 (dd, J=6.6, 3.2 Hz, 2H, C697H 1 3  6.55 
protease plasmepsin I1 was also inhibited by compounds 8,9, 
and ritonavir and IC,, values of these compounds are 9.7, C8a,10a), 131.5 C4a,9a), 128.5 (d, c9,10>, 125.5 (d, 
23.6, and 0.10 pM, respectively. Presumably, these reactive 10 c538)3 120.7 (d, c637)3 
triptycene bisquinones undergo addition reactions with 
lysine, tryptophan, histidine, and cysteine residues of pro- 
teins to produce cross-linked proteins. 
2H, C233H)3 3.97 ( s 2  6H, OCH3); 13c NMR 149.5 
(d, c233)3 55.6 ('3 OCH3). 
2 2 - T r i m  e t  h o  y -  2 - d i  h y d r  - 2 l o - [  2 1 
benzenoanthracene-l,4-dione (4). 
A mix tu re  of 2 .00  g ( 8 . 4 0  mmol )  of 1 , 4 -  
dimethoxyanthracene (2), 1.411 g (10.1 mmol) of methoxy- 
hydroquinone (3), 3.90 g (16.8 mmol) of silver oxide, and 
0.536 g (1.68 mmol) of zinc iodide in 30 mL of toluene 
(1.79 mmol) of 3 and 1.30 g (5.60 mmol) of silver oxide 
were added and the reaction mixture was refluxed for 
Compound 1 7 8 9 11 12 13 14 another day. The reaction mixture was cooled, diluted with 
20 200 mL of dichloromethane, filtered through Celite, and the 
filtrate was washed with aqueous NH,C1, and brine, dried 
(MgSO,), concentrated, and column chromatographed on 
General Methods. Nuclear magnetic resonance spectra silica gel using a gradient mixture of hexane and ethyl 
were obtained at 400 MHz for 'H and 100 MHz for I3C in acetate as solvent gave 2.21 g (70% yield) of 4: mp. 
deuteriochloroform, unless otherwise indicated. Infrared 2s 108-110" C.; 'H NMR d 7.43 (dd, J=5.5, 3 Hz, 2H), 7.00 
spectra are reported in wavenumbers (cm-I). Mass spectra (dd, J=5.5, 3 Hz, 2H), 6.52 (s,  2H, C6,7 Hs), 6.25 (s,  lH), 
were taken from a Hewlett Packard 5890A Series 11, 6.23 (s,  lH), 5.71 (s,  lH,  C3H), 3.79 (s,  6H, OMe), 3.72 (s,  
GC-MS. FAB spectra were taken by using Xe beam (8 KV) 3H, OMe). I3C NMR d 183.5 (C=O), 178.2 (C=O), 158.4, 
and m-nitrobenzyl alcohol as matrix. Methoxyhydroquinone 153.8, 150.9, 150.5, 149.6, 149.5, 144.3, 144.1, 133.6, 
(3), quinizarin, silver oxide, zinc iodide, sodium borohy- 30 133.5, 125.2 (2C), 124.5, 124.4, 109.5, 105.6, 56.4, 56.38, 
dride methylamine in THF, dimethylamine in THF, ethyl 56.3, 41.5, 41.2. Anal. Calcd for C,,CH,,O,: C, 73.79; H, 
3-aminopropanoate hydrochloric acid salt, and t-butyl 4.85. Found: C, 73.51; H, 5.07. 
3-aminopropanoate hydrochloric acid salt were purchased 2,5,8-Trime t hoxy-4a,9,9a,  10-  tetra hydro -9,lO-[ 1 ,2]  
from Aldrich Chem. Co. Davisil silica gel, grade 643 benzenoanthracene-l,4-dione (5) 
(200-425 mesh), was used for the flash column 35 A mixture of 1.00 g (7.10 mmol) of methoxyhydro- 
chromatographic-separation. quinone (3), 2.50 g (10.7 mmol) of silver oxide, and 1.20 g 
1,4-Dimethoxyanthracene (2). (8.50 mmol) of K,C03 in 50 mL of benzene was stirred 
To a cold (0' C.) methanol (20 mL) solution of 1.00 g under argon at 25" C. for 3 h, the mixture was filtered 
(0.0042 mol) of quinizarin under argon was added 0.638 g through Celite, and washed with 5 mL of dichloromethane. 
(0.0168 mol) of sodium borohydride. The resulting mixture 40 The filtrate was concentrated to give 0.970 g (99% yield) of 
was stirred at 0" C. for 1 h. To it, 11 mL of 6 N HC1 was methoxybenzoquinone (6): 'H NMR d 6.72 (s,  2H), 5.95 (s,  
added dropwise at 0" C. over a period of 10 min. The lH), 3.84 (s,  3H). I3CNMR d 187.4, 181.6, 137.1, 134.4, 
precipitated orange solids were collected, washed several 111.5, 107.6, 56.2. This material was used in the next step 
times with distilled water, dried under vacuum, and recrys- without purification. 
tallized from acetone-ether to give 0.83 g (95% yield) of 45 A solution of 0.70 g (2.90 mmol) of 2 and 1.00 g (7.20 
anthra~ene-l,4-dione'~ as yellow crystals, mp 204-206" C. mmol) of 6 in 10 mL of toluene in a sealed tube was heated 
'H NMR d 8.60 (s,  2H, C 9,lO Hs), 8.10 (dd, J=6.4,3.2 Hz, at 150" C. for 1 day, cooled to 25" C., concentrated to 
2H, C 5,8 Hs), 7.70 (dd, J=6.4, 3.2 Hz, 2H, C 6,7 Hs), 7.10 dryness, and column chromatographed on silica gel using a 
(s,  2H, C 2,3 Hs); I3C NMR d 184.7 (s,  C=O), 140.1 (d), gradient mixture of hexane and ethyl acetate as solvent gave 
134.8 (s) ,  130.2 (d), 129.6 (d), 128.9 (d), 128.4 (d), 128.4 (s) .  SO 0.52 g (48% yield) of compounds 5 as a mixture of exo- and 
To 2.00 g (1.00 mmol) of 1,4-anthracenedione, a solution endo-(1:l) isomers along with 0.62 g of 6. The exo- and 
of 6.68 g (38.0 mmol) of sodium hydrosulfite in 50 mL of endo-isomers were partially separated by silica gel column 
water and 50 mL of 1,4-dioxane was added. The resulting and the stereochemistry have not assigned. Compound 5, 
mixture was stirred at 25" C. for 3 h, and added 100 mL of less polar isomer: MS, miz 376 (M+), 375. 'H NMR d 
water. The mixture was cooled over an ice-water bath, and ss 7.24-7.18 (m, 2H), 7.08-7.04 (m, 2H), 6.65 (s,  2H, C6,7 
the precipitated dark green solids were collected by Hs), 5.61 (s,  lH), 5.33 (bs, 2H), 3.82 (s,  6H, OMe), 3.48 (s,  
filtration, washed twice with water, and dried under vacuum 3H, OMe), 3.12 (ABd, J=9 Hz, lH), 3.06 (ABd, J=9 Hz, 
to give 1.75 g (87% yield) of 1,4-dihydroxyanthracene, mp 1H). More polar isomer: MS, miz 376 (M+), 375. 'H NMR 
167-169" C.; 'H NMR d 8.70 (s,  2H, C 9,lO Hs), 8.05 (m, d 7.40 (m, 2H), 7.16 (m, 2H), 6.60 (ABd, J=8.8 Hz, lH), 
To a 0.275 g (11.0 mmol) of pre-washed (with distilled C9,lO Hs), 3.76 (s,  3H, OMe), 3.73 (s,  3H, OMe), 3.51 (s,  
diethyl ether) sodium hydride under argon were added 1.00 3H, OMe), 3.13 (Abd, J=9 Hz, lH), 3.08 (Abd, J=9 Hz, 1H). 
g (4.80 mmol) of 1,4-dihydroxyanthracene, 0.75 mL (12.0 This mixture of compounds was used in the next step. 
mmol) of iodomethane, and 10 mL of DMF (distilled over 1,4-Dihydroxy-2,5,8-trimethoxy-9,lO-dihydro-9,10-[1,2] 
CaH,). The solution was stirred at 25" C. for 1.5 h, diluted 65 benzenoanthracene. 
with 20 mL of water, and acidified with 6 N HC1 (PH -2). To a solution of 0.77 g (2.0 mmol) of 5 in 30 mL of 
The mixture was extracted three times with ethyl acetate, 1,4-dioxane and 30 mLof water was added 1.12 g (20 mmol) 
TABLE 2 
Cytotoxicities of triptycene bisquinone analogs in L1210 leukemic cell under argon was refluxed for days' To the mixture' 0'25 
system in vitro. 
IC,, @M) 0.291 0.270 0.430 0.300 0.240 0.310 1.48 4.00 
2H, C 5,8 Hs), 7.50 (s, 2H, C 6,7 Hs), 6.60 (s, 2H, C 2,3 Hs). 60 6.56 (Abd, J=8.8 Hz, lH), 5.65 (s, lH, =CH), 5.33 (bs, 2H, 
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of KOH. The solution was stirred at 25" C. for 1 h, acidified 8-trimethoxy-9,10-dihydro-9,10-[ 1,2]benzenoanthracene-1, 
with 1 N HC1, and extracted three times with dichlo- 4-dione: 'H NMR d 7.44 (dd, J=5.5, 3 Hz, 2H), 7.01 (dd, 
romethane. The combined extract was washed with brine, J=5.5, 3 Hz, 2H), 6.54 (s,  2H, C6,7 Hs), 6.29 (s,  lH), 6.22 
dried (MgSO,), and concentrated to give 0.77 g (100% (s,  lH), 4.14 (s,  3H, OMe), 3.81 (s,  3H, OMe), 3.79 (s,  3H, 
yield) of 1,4-dihydroxy-2,5,8-trimethoxy-9,lO-dihydro-9, s OMe). This material was used in next step without purifi- 
10-[1,2]benzenoanthracene: MS, miz 376 (M+). 'H NMR d cation. 
7.43 (dd, J=5.5, ~ H z ,  lH), 7.38 (dd, J=5.5, 3 Hz, lH), 6.96 To a solution of 0.109 g (0.240 mmol) of 2-bromo-3,5, 
(dd, J=5.5, 3Hz, 2H), 6.51 (s,  2H, C6,7 Hs), 6.29 (s,  lH,  8-trimethoxy-9,10-dihydro-9,10-[1,2]benzenoanthracene-l, 
C3H), 6.09 (s,  lH), 5.98 (s,  lH), 5.3 (s,  lH, OH), 4.96 (bs, 4-dione in 5 mL of acetonitrile, 6 mL of 1,4-dioxane, and 2 
lH,  OH), 3.81 (s,  3H, OMe), 3.805 (s,  3H, OMe), 3.66 (s,  i o  mL of water, was added 0.660 g (1.20 mmol) of ceric 
3H, OMe). This compound was used in the next step. ammonium nitrate. The solution was stirred at 25" C. for 6 
Oxidation of 1,4-Dihydroxy-2,5,8-trimethoxy-9,10dihydro- h, diluted with ether, washed with water, and brine, dried 
9,lO-[1,2]benzenoanthracene to 4. (MgSO,), concentrated, and column chromatographed on 
To a mixture of 0.77 g (2.0 mmol) of 1,4-dihydroxy-2,5, silica gel using a gradient mixture of hexane and ether as 
8-trimethoxy-9,10-dihydro-9,10-[1,2]benzenoanthracene is eluant to give 60 mg (59% yield) of 1. 
and 0.60 g (4.2 mmol) of sodium sulfate (anhydrous) in 15 2-Bromo-3-(methylamino)-9,10-dihydro-9,10-[1,2] 
mL of dried acetone under argon at 25" C. was added 0.56 benzenoanthracene-l,4,5,8-tetraone (8). 
g (4.0 mmol) of silver oxide. The mixture was heated under A solution of 0.200 g (0.473 mmol) of 1 and 0.47 mL 
reflux for 6 h, cooled to 25" C.,  diluted with (0.946 mmol) of methylamine (2.0 M in THF) in 1 mL of 
dichloromethane, and filtered through Celite. The filtrate 20 THF was stirred under argon at 0" C. for 1 h. The solution 
was concentrated to give 0.77 g of the crude product. was concentrated to dryness, and column chromatographed 
Column chromatography on silica gel using a gradient on silica gel using a gradient mixture of hexane and ethyl 
mixture of hexane and ethyl acetate as solvent gave 0.73 g acetate as solvent to give 0.132 g (66% yield) of 8: mp. O C.; 
(95% yield) of 4. MS, CI miz 424,422 (-1:l; M+1); 'H NMR d 7.48 (dd, J=5, 
2-Methoxy-9,10-dihydro-9,10-[1,2]benzenoanthracene-l,4, zs 3Hz, lH), 7.45 (dd, J=5,3 Hz, lH), 7.07 (dd, J=5 ,3  Hz, 2H), 
5,8-tetraone (7). 6.64 (s,  2H, C6,7 Hs), 6.28 (s,  lH), 6.10 (s,  lH), 5.88 (bs, 
To a solution of 0.77 g (2.0 mmol) of 4 in 16 mL of lH,  NH), 3.33 (d, J=5.6 Hz, 3H, MeN); I3C NMR (acetone- 
acetonitrile, 26 mL of 1,4-dioxane and 10 mL of water was d6) d 183.33, 183.3, 178.2, 170.9, 154.4, 152.3, 152.0, 
added 2.0 g (3.6 mmol) of ceric ammonium nitrate at 25" C. 148.0, 147.0, 143.7, 143.5, 136.4, 136.3, 126.5 (2C), 126.0, 
The solution was stirred for 1 2  h, diluted with 30 125.7,  125.0,  44.3, 42.9, 33.2.  Anal. Calcd for 
dichloromethane, and washed with water. The organic layer C,,H,,BrNO,: C, 59.74; H, 2.86. Found: C, 59.74; H, 2.76. 
was dried (MgSO,), concentrated to give the crude product. 2-Bromo-3-methoxy-6-(dimethylamino)-9,lO-dihydro-9, 
Recrystallization from ether gave 0.65 g (95% yield) of 7: 10-[1,2]benzenoanthracene-1,4,5,8-tetraone (9) and 
MS, CI, miz 345 (M+l), 317 (-CO); 'H NMR d 7.48 (dd, 2-Bromo-3-methoxy-7-(dimethylamino)-9,lO-dihydro-9, 
J=5.5, 3 Hz, 2H), 7.07 (dd, J=5.5, 3 Hz, 2H), 6.65 (s,  2H, 3s 10-[1,2]benzenoanthracene-1,4,5,8-tetraone (10). 
C6,7 Hs), 6.2 (s,  lH), 6.18 (s,  lH), 5.78 (s,  lH,  C3H), 3.78 To a solution of 0.200 g (0.473 mmol) of 1 in 2 mL of THF 
(s,  3H, OMe). I3C NMR d 182.2, 182.17, 182.0, 176.9, under argon at 0" C., was added 0.24 mL (0.473 mmol) of 
158.5, 152.5, 151.6, 151.5, 149.6, 142.2, 142.0, 135.4, dimethylamine (2.0 M in THF). After stirring at 0" C. for 2 
135.3, 125.8 (2C), 125.4, 125.3, 105.7, 56.6(OMe), 42.2, h, the reaction solution was concentrated to dryness, and 
41.9. Anal. Calcd for C,,H,,O,: C, 73.25; H, 3.51. Found: 40 column chromatographed on silica gel using a mixture of 
C, 73.01; H, 3.80. benzene and ethyl acetate (1O:l) as solvent to give 0.099 g 
2-Bromo-3-methoxy-9,10-dihydro-9,10-[1,2] (48% yield) of 9 (less polar isomer; the regiochemistry has 
benzenoanthracene-l,4,5,8-tetraone (1). not been determined) and 0.098 g (48% yield) of 10 (more 
To a solution of 0.30 g (0.87 mmol) of 7 in 20 mL of DMF polar). 
under argon at 25" C. was added 0.16 g (0.87 mmol) of 4s Less polar isomer: MS, CI, miz 468,466 (-1:l; M+1); 'H 
N-bromosuccinimide. After the solution was stirred for 10 h, NMR d 7.47-7.43 (m, 2H, Ar-H), 7.05-7.02 (m, 2H, 
it was diluted with water, and extracted twice with ethyl Ar-H), 6.22 (s,  lH), 6.14 (s,  lH), 5.38 (s,  lH,  C7H), 3.80 
acetate. The combined extract was washed with brine, dried (s,  3H, OMe), 3.11 (s,  6H, Me,N). I3C NMR d 181.4 (2C), 
(MgSO,), concentrated, and column chromatographed on 181.2 (2C), 153.7, 150.4, 149.3, 144.1, 143.9, 142.2, 141.8, 
silica gel using a gradient mixture of hexane and ether as SO 139.1, 127.1, 125.5, 125.3, 124.7, 124.2, 102.5, 61.1, 42.8, 
solvent gave 0.29 g (45% yield) of 1: mp 207-210" C.; MS 42.7, 42.0, 41.4. 
EI, mi2424 & 422 ( l : l ,  M+), 344 (M-Br), 300, 287, 232, More polar isomer: MS, CI, miz 468, 466 (-1:l; M+1); 
152, 126; 'H NMR d 7.48 (dd, J=5.5, 3 Hz, 2H), 7.09 (dd, 'H NMR d 7.48-7.42 (m, 2H, Ar-H), 7.04-7.01 (m, 2H, 
(s,  lH), 4.17 (s,  3H, OMe); I3C NMR d 182.2 (s,  CO), 182.0 ss (s,  3H, OMe), 3.10 (s,  6H, Me,N). I3C NMR d 181.6 (2C), 
(s,  CO), 176.2 (s,  CO), 175.5 (s,  CO), 156.2, 151.6, 151.4, 181.4 (2C), 154.0, 150.7, 149.6, 144.9, 144.0, 142.6, 141.5, 
150.2, 141.8, 135.5, 135.4, 126.2, 126.1, 126.07, 126.0, 139.8, 127.2, 125.6 (2C), 125.0, 124.3, 102.4, 61.2, 43.0 
125.6, 125.4,117.2, 61.7 (OMe), 43.0,42.1.Anal. Calcd for (2C), 42.0, 41.9. HRMS miz 466.0285 (466.0290, calcd for 
C,,H,,BrO,: C, 59.60; H, 2.62. Found: C, 59.33; H, 2.87. C,,H,,Br NO,, M-H'). 
Synthesis of 1 from Bromination of 4 Followed by Oxida- 60 2-Bromo-3-[2-(ethoxycarbonyl)ethylamino]-9,lO-dihydro- 
tion. 9,10-[1,2]benzenoanthracene-1,4,5,8-tetraone (11). 
To a solution of 90 mg (0.24 mmol) of 4 in 5 mL of DMF To a mixture of 5.70 mg (0.236 mmol) of NaH (pre- 
under argon at 25" C. was added 52 mg (0.30 mmol) of washed with distilled ether) in 2 mL of DMF under argon at 
N-bromosuccinimide (NBS). The solution was stirred at 40" 0" C. was added 36.3 mg (0.236 mmol) of b-alanine ethyl 
C. for 12 h, diluted with diethyl ether, washed twice with 65 e s t e r  hydroch lo r ide  ( e thy l  3 -aminopropanoa te  
water, and once with brine, dried (MgSO,), and concen- hydrochloride). The solution was stirred at 0" C. for 30 min, 
trated to give 109 mg (quantitative yield) of 2-bromo-3,5, cooled to -46" C., and a solution of 100 mg (0.236 mmol) 
J=5.5, 3 Hz, 2H), 6.66 (s, 2H, C6,7 Hs), 6.23 (s, lH), 6.16 Ar-H), 6.24 (s, lH), 6.16 (s, lH), 5.39 (s, lH,  C7H), 3.79 
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of 1 in 1 mL of DMF was added via cannula. The solution 
was stirred at -46" C. for 6 h, diluted with a mixture of ethyl 
acetate and benzene ( l : l ) ,  washed twice with water, brine, 
dried (Na,SO,), concentrated, and column and benzene 
(1: l ) ,  washed twice with water, brine, dried (Na,SO,), 
concentrated, and column give 55 mg (46% yield) of 11 and 
30 mg (30% recovery) of 1. Compound 11: mp. 119-121" 
C.; MS, miz 510,508 (-1:l; M+1), 422,420 (1:l); 'H NMR 
d 7.45-7.42 (m, 2H, Ar-H), 7.08-7.04 (m, 2H, Ar-H), 
6.65 (s,  2H, C6,7 Hs), 6.3 (bs, lH, NH), 6.27 (s,  lH), 6.10 
(S lH), 4.16 (q, J=7 Hz, 2H, OCH,), 4.03 (q, J=6 Hz, 2H, 
CH,N), 2.64 (t, J=6 Hz, 2H, CH,CO), 1.26 (t, J=7 Hz, 3H, 
CH,); I3C NMR d 184.0, 183.6, 182.6, 182.3, 177.3, 171.7, 
154.5, 151.8, 151.7, 147.4, 144.3, 142.4, 142.2, 135.8, 
135.5, 126.2, 126.1, 125.9, 125.3, 61.3, 43.7, 42.2, 40.5, 
35.4, 14.4. Anal. Calcd. For C,,H,,BrNO,: C, 59.07; H, 
3.57. Found: C, 58.69; H, 3.72. 
2 -Bromo - 3 - [ 2 - (t - bu t o x y c arb on  y 1) e th y 1 amino ] - 9,lO - 
dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraone (12). 
To a mixture of 12.0 mg (0.496 mmol) of NaH (pre- 
washed with distilled ether) in 2 mL of DMF under argon at 
0" C. was added 90.0 mg (0.496 mmol) of b-alanine t-butyl 
ester hydrochloride. The solution was stirred at 0" C. for 30 
min, cooled to -46" C., and a solution of 201 mg (0.496 
mmol) of 1 in 1 mL of DMF was added via cannula. The 
solution was stirred at -46" C. for 8 h, diluted with a mixture 
of ethyl acetate and benzene ( l : l ) ,  washed twice with water, 
brine, dried (Na,SO,), concentrated, and column chromato- 
graphed on silica gel using a mixture of hexane and ethyl 
acetate (1O:l) as solvent to give 165 mg (62% yield) of 12: 
mp. 171-173" C.; MS, miz 538,536 (-1:l; M+1), 482,480 
(1:l); 'H NMR d 7.45-7.42 (m, 2H Ar-H), 7.08-7.04 (m, 
2H, Ar-H), 6.64 (s,  2H, C6,7 Hs), 6.27 (s,  lH), 6.22 (bs, 
lH,  NH), 6.22 (bs, lH, NH), 6.10 (s, lH), 4.00 (q, J=6.7 Hz, 
2H, CH,N), 2.55 (t, J=6.7 Hz, 2H, CH,CO), 1.44 (s, 9H, 
CH,); I3C NMR d 182.3, 182.0, 177.0, 173.5, 170.6, 154.1, 
151.4, 151.37, 147.0, 144.2, 142.1, 141.9, 135.4, 135.2, 
128.8, 125.8, 125.76, 125.5, 125.0, 81.5, 43.5, 41.9, 40.5, 
36.2,28.0 (3C). Anal. Calcd for C,,H,,BrNO,: C, 60.46; H, 
4.13. Found: C, 60.75; H, 4.39. 
N-(2-Bromo-9,10-dihydro-1,4,5,8-tetraoxo-9,10-[ 1,2] 
benzenoanthracene-3-yl)-3-aminopropanoic acid (13). 
A solution of 0.100 g (0.187 mmol) of 12 and 0.2 mL 
(2.60 mmol) of trifluoroacetic acid in 5 mL of dichlo- 
romethane was stirred at 0" C. for 1 h and then at 25" C. for 
2 h. The solution was concentrated to dryness, and recrys- 
tallized from benzene to give 0.090 g (100% yield) of purple 
solids: mp. 149-151" C.; MS, miz 482, 480 (-1:l; M+1), 
422, 420 (1:l); 'H NMR d 7.49-7.46 (m, 2 H), 7.08-7.06 
(m, 2H), 6.64 (s,  2H), 6.27 (s,  lH), 6.22 (bs, lH,  NH), 6.10 
(s, lH), 4.04 (q, J=6 Hz, 2H, CH,N), 3.40 (bs, lH,  OH), 2.73 
(t, J=6 Hz, 2H, CH,); I3C NMR (CD,OD) d 182.8, 182.77, 
177.2, 174.2, 174.1, 151.6, 151.4, 147.6, 145.6, 142.9, 
142.6, 137.9, 135.4, 129.0, 128.9, 128.2, 128.18, 126.1, 
125.2,43.8,42.4,42.3,34.8.Anal. Calcd for C,,H,,BrNO,: 
C, 57.52; H, 2.94. Found: C, 56.72; H, 2.88. 
Preparation of TT24: 
To 20 mL of THF solution, 1 g (0.022 mol) of dimethy- 
lamine gas (from a gas cylinder purchased from Linde 
Company) was added. A 1.1 M of dimethylamine in THF 
was resulted. To a cold (0' C.) solution of 0.081 g (0.19 
mmol) of triptycene bisquinone 1 in 2 mL of THF under 
argon was added 0.17 mL (0.19 mmol) of dimethylamine. 
The solution turn to purple immediately and was stirred at 0" 
C. for 10 min. The solvent was removed on a rotary 
evaporator and then under vacuum and the crude product 
was column chromatographed on silica gel using a gradient 
66 
mixture of hexane and ethyl acetate as the eluent to give 
compounds 1,2, and TT24. 
Compound TT24: 'H NMR (CDC1,) 6 7.44-7.40 (m, 2H), 
5 7.03 (m, 2H), 6.27 (s,  lH), 6.15 and 6.14 (2 s,  lH), 5.69 (q, 
J=5.6 Hz, NH), 5.26 (s,  lH), 3.80 & 3.79 (2s, 3H, OMe), 
2.79 (d, J=5.6 Hz, 3H, NMe); I3C NMR (CDC1,) 6 181.7, 
181.6, 179.5, 156.2, 147.8, 147.6, 143.9, 143.8, 143.6, 
142.3, 141.8, 141.3, 139.6, 139.1, 131.2, 126.9, 125.52, 
125.49, 125.46, 125.4, 124.8, 124.75, 124.3, 124.2, 102.3, 
95.8, 95.7, 61.1, 60.4, 42.2, 41.9, 41.3, 41.0, 29.3 (2C). 
10 
Synthesis of Other N Analogs and S Analogs 1s 
As illustrated in Scheme 17, nitrogen analog 1 has been 
prepared. Treatment of TT13 with 1 equivalent each of 
2o L-lysine hydrochloric acid and sodium hydride in a 1 : l  
mixture of THF and DMF under argon at room temperature 
gave amino acid analog 1 which is a water soluble drug. 
Scheme 19 outlines the synthetic route to prepare nitrogen 
2s analogs 2-4. Treatment (Kenani, A,; Bailly, C.; Helbecque, 
N.; Houssin, R.; Bernier, J. -L.; Henichart, J. -P. Eur: J.  Med. 
Chern. 1989, 24, 371-377.) of D-galactosamine hydrochlo- 
ride (commercially available) with sodium hydroxide and 
3o di-t-butylcarbonate in 1,4-dioxane and water, followed by 
protection of the hydroxyl function with excess of acetyl 
anhydride in pyridine, and removal of the Boc protecting 
group with hydrochloric acid in 1,4-dioxane produces amine 
6. Addition of 6 with 7T13 in THF at -40" C. followed by 
35 removal of the acetoxy protecting group affords nitrogen 
analog 2. 
Br 
0 
NaH 
THF-DMF. r.t. 
C02H 
* 
(L-lysine) 
1T13 
13 
Nitrogen analog 1 
65 Similarly, glucosamine hydrochloride car, be used to 
prepare glucosamine analog (of 2; instead of galactosamine 
analog). 
67 
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-continued 
Schrmrl9 
1. NaOH, (t-Bu0)ZCo 
dioxane-Hz0 
acetyl anhydride 
OH 2. pyridine 
NHz'HC1 3. dioxane 
* HO 
6 +  
5 
HC1 
5 (reference 1) 10 
OAc 
1s 
AcO 
NHZ 
AC = CH3CO 
6 
A 20 & l T H F  -40" C ~ 2s 
M e 0  
4 
0 0 
30 1T1 3 
I 
SEM 
SEM = CHzOCHzCHzSiMe3 
8 
1. THF - 
-40" C. 
2. n-BudNF 
THF 
1T13 
N N 
H 
I 
Nitrogen analog 3 
Nitrogen analog 2 
THF 
-40" C. 
7 + 1T13 
Syntheses of nitrogen analogs 3 and 4 are depicted in 4s 
Scheme 20. Protection of N-9 of adenine (7) with 
(trimethylsily1)ethyl chloromethyl ether (SEM-C1) and 
sodium hydride in DMF produces compound 8. Addition of 
8 with TT3 in THF at -40" C. followed by removal of the 
SEM protecting group with tetra-n-butylammonium fluoride so 
in THF furnishes nitrogen analog 3. Direct treatment of 
adenine and catalytic amount of sodium hydride in THF at 
-40" C. gives nitrogen analog 4. The N9 hydrogen of 
hence, N9 nitrogen should react with TT3. 
adenine (7) is more acidic than that of C6 amine group, M e 0  
5s 
Scheme 20 
[Tfj ClCHzOCHzCHzSiMe3 NaH 
I 
H 
7 
Nitrogen analog 4 
60 
Sulfur analogs: Uses of thiol containing amino acid such 
as N-protected L-cysteine provides sulfur analog (Scheme 
21). Hence, addition of N-Boc cysteine and sodium hydride 
6s in DMF-THF followed by trifluoroacetic acid (removal of 
the Boc protecting group) will afford sulfur analog. 
69 
1. NaH 
THF-DMF, r.t. 
b 
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1T13 
10 
13 
Sulfur analog 9 
The above four nitrogen analogs and the sulfur analog are 3o 5.  (a) Daub, J. ;  Jakob,  L.;  Salbeck, J .  Chirale 
water soluble materials. Other nitrogen and sulfur analogs elektronentransfer-aktive chinone mit triptycen- 
are prepared by methods known to one of ordinary skill in teilstrukturen: synthesekonzeption und eigenschaften. 
the art, In using substitutions which are known to one of Chem. Bev. 1988, 121, 2187-2194. (b) Siegfried, H.; 
ordinary skill in the art. Sinzger, K.; Bau, R.; Metzenthin, T.; Salbeck, J. 1,4,5,8- 
Compounds of this invention other than those particularly Te t r ao xo - 1,4,5,8 -tetra hydro t hi an t hr ene : synthesis , 
shown may be prepared without undue experimentation by 35 structure, and spectroelectrochemical properties. Chem. 
those skilled in the art of synthetic chemistry by methods Bev. 1993, 121, 465-471. 
analogous to, those specifically disclosed herein or in pub- 6. Criswell, T. R.; Klanderman, B. H. Studies related to the 
lications and patent applications incorporated by reference conversion of 9,lO-anthraquinones to anthracenes. J .  Org. 
or by methods known in the art. Chem. 1974, 39,77&774. 
Although the description above contains many specifici- 40 7. Hamon, D. P. G.; Spurr, P. R. Reductive elimination of 
ties these should not be construed as limiting the scope of the bromine from 2,3-disubstituted 1,4-dibromo-2-butenes by 
invention, but merely providing illustrations of some Of the iodide ion: a convenient route to 2,3-bis[iodomethyl]-1, 
presently preferred embodiments of the investion. Thus, the 3-butadiene and related compounds, Syntheses 1981, 
appended claims and their legal equivalents, rather than by 45 8 Hamon, D, P, G,; spur, P, R, J ,  Chem. sot, Chem, 
the examples given. All references cited herein are incor- 
porated by reference to the extent not inconsistent with the 
disclosure herein. 
Literature References in Synthesis Section: 
scope of the invention should be determined by the 873-874. 
' Commun, 1981, 873-4. 
What is claimed is: 
1. A triptycene analog comprising a compound of for- 
. Iwamura, H.; Maino, K. 5,8-Dihydroxy-9,10-dihydro-9, 5n 
I_ 
lo-[ 1,2]benzenoanthracene-1,4-dione. An intramolecular 
1978, 72Ck721. 
Lipczynska-Kochany, E.; Iwamura, H. Charge-transfer 
complexation with a new class of electron acceptors made 
of triptycenequinone unit. Chem. Lett. 1982, 1075-1078. 55 
(a) Quast, H.; Fuchsbauer, H. -L. ESR-spektrosckopischer 
nachweis intramolekularer wechselwirkungen in 
r adikalkationen von poly( a-methoxy)tripty cenen . Chem. 
Bev. 1986,119,1016-1038. (b) Quast, H.; Fuchsbauer, H. 
-L. Intramolekulare wechselwirkungen in radikalkationen 60 
von di-und tetra( a-me t hox y ) -9,lO-di hydro - 9,lO - 
ethanoanthracen. Chem. Bev. 1986, 119, 2414-2429. (c) 
Patney, H. K. A general and simple route to the synthesis 
of triptycenes. Synthesis 1991, 694-696. 
Russell, G. A,; Suleman, N. K. Radical Anions of Trip- 65 wherein 
tycene Bis- and Tris(quinones). J .  Am. Chem. SOC. 1981, 
triptycene quinhydrone. J .  Chem. SOC. Chem. Commun. R3 
R' 
X 
X is selected from the group consisting of  H, R, SR and 
103, 156Ck1561. NRs 
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Y is selected from the group consisting of  halogen, R, 
R and R1-’ are independently selected from the group 
R3.4 ’ , independently of one another, are selected from the 
group consisting of  H, bromine, R, SR, and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of: =0, =N-OH and =CHR; and 
reduced forms thereof, wherein in reduced forms, either 
5 .  A triptycene analog having the formula: 
NR,, SR and H; 
R4& R’ 
consisting of  H, halogen, OR, and hydrocarbyl; 5 
*’ R5 R2 R5 R5 ~ 2 2  
10 
ring A or ring C or both is replaced with X 
1s 
wherein 
X is selected from the group consisting of  H, R, SR and 
X* Y or R2 
2o Y is NR, selected from the group consisting of  halogen, NR,, 
R5 R5 R, SR and H; 
R and R1-’, are independently selected from the group 
consisting of  H, halogen, OR, and hydrocarbyl; 
R3.4 ’ , independently of one another, are selected from the 
group consisting of  H, bromine, R, SR, and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of  =0, =N-OH, and =CHR; 
RZ1 and RZ2 are independently selected from the group 
consisting of  H, R, and OR; and 
reduced forms thereof and pharmaceutically acceptable 
salts of the foregoing, as well as optical isomers 
thereof. 
and wherein reduced form, each R5 is 
independently H, Cl-C8 alkyl or -OR; 
and pharmaceutically acceptable salts of the forgoing, as 
wherein when all of R5 are =o, at least one of X, Y, 
2. The triptycene analog of claim 1 having the formula: 
2s 
well as optical isomers thereof; 
R1-R4 is not H. 
30 
6. A triptycene analog having the formula: 
3s R’8 
OMe & / /  0 0 40 
4s 
3. The triptycene analog of claim 1 having the formula: 
wherein 
R5 is selected from the group consisting of  R, halogen, 
R6 is selected from the group consisting o f  H, R, SR and 
R7 and Rs are independently selected from the group 
consisting of  H, halogen, and hydrocarbyl; 
R17 and RIs are independently are selected from the group 
consisting of  H, bromine, R, SR, and NR,; 
R19 and RZo are, independently of one another, H, R, or 
OR; 
(R9 and RIO) and (R1’ and R1’) and (R13 and R14) and 
(R1’ and R16) are independently together =O or are 
independently H or -OR; 
R is selected from the group consisting of  H, halogen, 
OR, and hydrocarbyl; and reduced forms thereof; 
and pharmaceutically acceptable salts of the foregoing, as 
well as optical isomers thereof. 
Br NR,, SR, and H; 
NR,; 
ss 
OMe 
0 
4. The triptycene analog of claim 1, wherein: 
X is selected from the group consisting of  H, OMe and 60 
Y is selected from the group consisting of  H, Br, and 
R1, R2, R3 and R4 are all H; and 
R5 is, independently of other R5s, selected from the group 
C0,Me; 
OMe; 
65 
consisting of  OH, OMe, =0, and H. 
74 
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7. A method of making a compound of claim 1, compris- 
ing: heating an optionally substituted anthracene with an 
optionally substituted quinone with silver oxide. 
5 
8. The method of claim 7, further comprising adding zinc 
iodide. Y R2 
R5 R5 
9. The method of claim 7, wherein the optionally substi- 
tuted anthracene has the formula: and wherein in reduced forms, each R5 is independently 
and pharmaceutically acceptable salts of the foregoing, as 
wherein when all of R5 are =0, at least one of X, Y, 
wherein either: 
H, Cl-C8 alkyl or -OR; 
well as optical isomers thereof; 
R1-R4 is not H; and 
(a) Y is a hydrogen and X is a methoxy group; 
(b) R1 is a hydrogen and R2 is a methoxy group; or 
(c) R2 is a hydrogen and R1 is a methoxy group, 
by reacting a triptycene derivative of formula (I) with 
N-bromosuccinimide, wherein the Y, R1 or R2 that is hydro- 
11. The method of claim 10, wherein the triptycene 
1s 
\ \  
OR 
20 
w
+OR 
and the optionally substituted quinone has the formula: 
2s gen is replaced with a bromine. 
derivative is: 
30 
OR 
3s where R is H or hydrocarbyl. 
10. A method of brominating a triptycene derivative of 
formula (I): 
(1) 0 
R3 40 
12. A triptycene analog of claim 1, 
wherein at least one of X, Y, R1 and R2 is selected from 
the group consisting of  a nitrogen containing group, a 
water soluble group, and a sulfur containing group. 
13. The compound of claim 12, wherein X is -NR,. 
14. The compound of claim 12, wherein R2 is -NR,. 
15. The compound of claim 14, wherein R2 is -NMe,. 
16. The compound of claim 12, wherein at least one of X, 
Y, R1 and R2 is selected from the group consisting of  amine, 
amino acid and amine sugar. 
17. The compound of claim 12, wherein X is -NH- 
(CH,),-CO,R, where n is an integer from 0 to 8 ,  and R is 
4s 
R' 
X 
SO 
wherein X is selected from the group consisting o f  H, R, 
SR and NR,; 
Y is selected from the group consisting of  halogen, R, 
NR,, SR and H; 
R and ~ 1 - 2  are independently selected from the group 
consisting of  H, halogen, OR, and hydrocarbyl; 
R3.4 ' 
group consisting of  H, bromine, R, SR, and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of: =0, =N-OH and =CHR; and 65 containing group. 
reduced forms thereof, wherein in reduced forms, either 
ring A or ring C or both is replaced with 
ss as defined in claim 12. 
18. The compound of claim 17 wherein R is H. 
19. The compound of claim 12, wherein one or more of 
X, Y, R1 and R2 contains an optionally substituted nitrogen 
20. The compound of claim 19, wherein the optionally 
' independently Of One are from the substituted nitrogen containing hydrocarbyl group is a fused 
21. The compound of claim 12, wherein X is a sulfur 
22. The compound of claim 21, wherein the sulfur con- 
6o containing hydrocarbyl group. 
ring structure. 
taining group also contains one or more N atoms. 
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23. The compound of claim 12 having the formula: 27. The compound of claim 12 having the formula: 
1s 
28. The compound of claim 12 having the formula: 
24. The compound of claim 12 having the formula: 
20 
2s 
OH 
OH 
N 
H 
0 
30 
29. The compound of claim 12 having the formula: 
HOzCCHzCHzNH 
0 
25. The compound of claim 12 having the formula: 
3s 
0 
40 
4s 
26. The compound of claim 12 having the formula: so 
30. The compound of claim 12 having the formula: 
65 
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31. The compound of claim 12 having the formula: synthesis, inhibits protein synthesis, decreases the prolifera- 
tion of cancer cells, or decreases the viability of cancer cells. 
37. The triptycene analog of claim 6, 
wherein at least one of R5, R6, R7 and Rs is selected from 
the group consisting of  a nitrogen containing group, a 
water soluble group, and a sulfur containing group. 
38. A method of making a nitrogen-containing compound 
of claim 12, comprising: reacting a triptycene derivative of 
formula: 
5 
Br 
/ I  10 
NH2 W S  C02H $+ 0 0 R3 
32. The triptycene analog of claim 12 having the formula: 1s 
R’ 20 
X 
NHMe. 
M e 0  2s wherein 
33. A triptycene analog comprising a compound of for- 
mula: 
30 
R3 
X &R’ 
’ \  
R5 R2 
3s 
40 
wherein X is -NW(CW,),Z, where the Ws are indepen- 45 
dently selected from the group consisting of  H, Cl-C8 
alkyl, and Cl-C8 alkenyl; n is an integer from 1 to 8; 
and Z is selected from the group consisting of  R, COR, 
COOR, CONR,, OOCR and NRCOR; 
Y is selected from the group consisting of  halogen, SO 
Cl-C8 alkyl, Cl-C8 alkenyl, OR, NR,, SR, H, COR, 
OCOR and NRCOR; 
R and R1-’, are independently selected from the group 
consisting of  H, OR, and hydrocarbyl; 
R3.4 ’ 
group consisting of  H, OR, SR, and NR,; 
R5, is =O; and reduced forms thereof and pharmaceuti- 
cally acceptable salts of the foregoing, as well as 
optical isomers thereof. 
, independently of one another, are selected from the ss 
34. The triptycene analog of claim 5,  60 
wherein at least one of X, Y, R1 and R2 is selected from 
the group consisting o f  a nitrogen containing group, a 
water soluble group, and a sulfur containing group. 
35. The compound of claim 34 wherein at least one of RZ1 
36. The compound of claim 12 which blocks nucleoside 
transport, induces DNA fragmentation, inhibits nucleic acid 
and RZ2 is -CO,R. 65 
R3.4 ’ , independently of one another, are selected from the 
group consisting of  H, bromine, R, SR and NR,; 
R5, independently of other R5s, is selected from the group 
consisting of  =0, and =N-OH, and =CHR; 
Y is Br, and X is -OR; 
R and R1-’ are independently selected from the group 
consisting of  H, OR, and hydrocarbyl; and reduced 
forms thereof; 
with a primary or secondary amine. 
39. A triptycene analog of formula: 
and the reduced forms thereof, wherein in said reduced 
forms, either ring A or ring C or both is reduced to 
R5 R5 
X+ Y or R2 
R5 R5 
wherein all but one of X, Y, R1 and R2 is independently 
H, Cl-C6 alkyl, Cl-C6 alkenyl, OR, SR or NR2 
wherein each R is independently H or Cl-C6 alkyl and 
the other R1 or R2 is a solubilizing group; and each R5 
is independently H, Cl-C6 alkyl or OR. 
US 6,828,450 B2 
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40. The triptycene analog of claim 39, wherein the soh-  
NR(CR,),X wherein X is a sugar, R, COR, COOR, 
selected from the group consisting of  H, Cl-C8 alkyl 
and Cl-C8 alkenyl; n is an integer from 1 to 8. bilizing group is of the formula: 
CONR,, OOCR and NRCOR; R is independently * * * * *  
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